Manual of HEMATOLOGY

Book · January 2012

DOI: 10.13140/2.1.1499.9681

1 author:

Gamal Abdul Hamid

Aden University

66 PUBLICATIONS **85** CITATIONS

SEE PROFILE

University of Aden

Faculty of Medicne & Health Sciences

Department of Medical Laboratory Sciences

Manual of

HEMATOLOGY

Prof Dr Gamal Abdul Hamid

Manual of

HEMATOLOGY

Dr Gamal Abdul Hamid
MB, BS, FAIM (Germany), PhD
Professor and Director National Oncology Center, Aden
Head, Clinical laboratory and Hematology unit,
Faculty of Medicine & Health Sciences
Consultant Hematologist Oncologist

Contents

	Preface to the edition	
1	Hemoglobin	9
2	The Spectrophotometer	18
3	Erythrocyte Sedimentation Rate	27
4	Microhematocrit	36
5	Preparation of a Blood Smear	43
6	Red Blood Cell Morphology	50
7	White Blood Cell Count And Differential Count	71
8	Iron Deficieny Anemia And Megaloblastic Anemia	94
9	Sickle Cell Hemoglobinopathies	106
10	Acute Leukemia	115
11	Chronic Leukemia	135
12	Coagulation Disorder Tests	147
13	Review Questions	160
14	Answers	190
15	Bibliography	191

Preface to the edition

These practical topics are designed to supply the basic knowledge of both the clinical and laboratory aspects of haematological diseases and blood transfusion.

At the end of each practice I have supplied a list of objectives in studying each practice. There are two main pruposes in these objectives. Fiiirst , they facilitate the learining process of acquisition, retention and recall of data is greatly helped if the facts and concepts are centered around a particular objective. Secondly, many objectives are closely related to the practical topics and the importance of these practices in diagnosis and treatment.

Dr Gamal Abdul Hamid

LESSON 1 : HEMOGLOBIN

HEMOGLOBIN *1*

OBJECTIVES

- List the two main components of hemoglobin
- State the function of hemoglobin
- List the manual and automated methods for determining hemoglobin and explain them
- List the normal hemoglobin values for children and adults
- Perform a hemoglobin determination using a cyanmethemoglobin method.
- List the precautions to be observed when performing the hemoglobin determination.
- Remember the cause which may increases or decreases the hemoglobin values.

GLOSSARY

- **Cyanmethemoglobin:** a stable compound formed when hemoglobin is combined with drabkin's reagent
- **Drabkin's reagent:** a diluting reagent used for hemoglobin determination which contains iron, potassium, cyanide, and sodium bicarbonate
- **Globin:** the portion of the hemoglobin molecule composed of protein
- **Heme:** the portion of the hemoglobin molecule containing iron
- **Hemoglobin:** a red blood cell constituent which is composed of heme and globin and which carries oxygen to the tissues of the body; abbreviated "Hb" or Hgb"
- **Sahli pipet:** a pipet with a volume of 0.02 ml which was formerly widely used for manual hemoglobin determination.

ABBREVIATIONS/ SYMBOLS

- **Hb:** Hemoglobin
- **HbO2 :** Oxyhemoglobin
- **HbCO:** Carboxyhemoglobin
- **Hi:** Hemiglobin (methemoglobin)
- **HiCN:** Hemiglobincyanide (cyanmet Hb)

Hemoglobin Synthesis

It occurs in the RBC precursors from the globin polypeptide chain and heme. This synthesis stops in the mature RBCs.
Hb is a tetramer, formed of 4 polypeptide chains with a heme group attached to each chain. These polypeptides are of different chemical types. Each chain is controlled by a different gene, which is activated and inactivated in a special sequence.
Alpha chain is controlled by two sets of gene (i.e. 4 genes), which are present on chromosome No. 6. Beta, Gamma and Delta chains are controlled by one set of genes (i.e 2 genes) for each chain, which are present on chromosome No. 11.

The most common Hbs are HbA ($\alpha 2\beta 2$, the major adult Hb), HbF ($\alpha 2\gamma 2$, the major fetal Hb), and HbA2, a minor adult Hb

TABLE 1: THE HUMAN HEMOGLOBINS

Hemoglobin	Composition	Representation
A	$\alpha 2\beta 2$	95-98% of adult Hb
A2	$\alpha 2\delta 2$	1.5-3.5% of adult Hb
F	$\alpha 2\gamma 2$	Fetal Hb, 0.5-1%
Gower 1	$\zeta 2\varepsilon 2$	Embryonic hemoglobin
Gower 2	$\alpha 2\varepsilon 2$	Embryonic hemoglobin
Portland	$\zeta 2\gamma 2$	Embryonic hemoglobin

At birth, Hbf forms about 70% of the total Hb, while Hb-A forms the rest.
By 6 months of age, only trace amounts of gamma chain are synthesised and very little amounts of residual Hb-F are present. At 6-12 months age, Hb-F forms 2% of the total Hb, while Hb-A forms the rest. Hb-A2 forms about 3% of the total Hb.
The release of oxygen from red cells into tissue is strictly regulated. Under normal condition, arterial blood enters tissues with an oxygen tension of 90 mmHg and hemoglobin saturation close to 97%. Venous blood returning from tissues is deoxygenated. The oxygen tension is about 40 mmHg; the oxyhemoglobin dissociation curve describes the relation between the oxygen tensions at equilibrium. The affinity of hemoglobin for oxygen and the deoxygenation in tissues is influences by temperature, by CO2 concentration, and by the level of 2,3-diphosphoglycerate in the red cells. In the case of tissue or systemic acidosis, the oxygen dissociation curve shifted to the right and more oxygen is released. The same effect results from the uptake of carbon dioxide, which raises the oxygen tension of carbon dioxide.
The oxygen supply to peripheral tissues is influenced by three mechanisms:

1. The blood flow, which controlled by the heart beat volume and the constriction or dilatation of peripheral vessels.
2. The oxygen transport capacity, which depends on the number of red blood cells and the hemoglobin concentration.
3. The oxygen affinity of hemoglobin

Clinical Significance

Hemoglobin concentrations below 12 gm/dl in men and 10.2gm/dl women indicate an anemic condition and produce symptoms progressing from weakness, tachycardia, and dizziness to dyspnea at rest, cardiac failure, and coma. Symptoms of anemia range from mild to severe and depend on the degree of Hemoglobin deficit, the extent of physiologic adaptation, and the intensity of physical exertion. Thus a moderately severe anemia of acute onset (hemorrhage) may produce severe symptoms, whereas the same degree of anemia developing very gradually can be asymptomatic due to compensatory changes.

Hemoglobin values may also be affected by other disease states as well as nonpathologic conditions such as age, sex, altitude, and the degree of fluid retention or dehydration. New-born infants normally exhibit hemoglobin concentrations higher than adults that sustain them during early life before active erythropoiesis begins. After puberty, male and female hemoglobin values differ due to the greater body mass and higher oxygen requirements of men.

Normal Values

Age	RBC/ million	Hb gm/dl	Hematocrit
Cord blood	5+-1	16.5 +- 3	55+-10
3 months	4+- 0,8	11.5 +- 2	36+-6
6 months	4.8 +-0,7		
7 Y-12Years	4.7 +-0.7	13+- 1	38+-4
Adult M	5.5+- 1	15.5 +- 2.5	47+-7
Adult –Female	4.8+-1	14+- 2.5	45+-5

Variations

Elevated hemoglobin may occur with the following:

- Dehydration as a result of prolonged vomiting or severe diarrhea
- Hemoconcentration such as in shock or immediately after hemorrhage
- High altitude
- Polycythemia or erythrocytosis
- Severe burns

Decreased hemoglobin may occur with the following

- Anemia resulting from increased blood destruction or decreased blood production
- Cirrhosis
- Hemorrhage as a result of trauma or childbirth
- Hyderemia of pregnancy or fluid retention
- Hypothyroidism
- Idiopathic steatorrhea
- Intravenous overload
- Leukemia

Determining the Concentration of Hemoglobin

The cyanmethemoglobin (hemiglobincyanide; HiCN) method has the advantage of convenience and a readily available, stable standard solution.

Hemiglobincyanide (HiCN) Method

Principle
Blood is diluted in a solution of potassium ferricyanide and potassium cyanide. The potassium ferricyanide oxidizes hemoglobins to hemiglobin (Hi; methemoglobin), and potassium cyanide provides cyanide ions (CN^-) to form HiCN, which has a broad absorption maximum, at a wavelength of 540 nm and compared with that of a standard HiCN solution.

Reagent

The diluent is detergent-modified Drabkin reagent

Potassium ferricyanide (K3Fe(CN6)	0.20 g
Potassium cyanide (KCN)	0.05 g
Dihydrgen potassium phosphate (anhydrous (KH2PO4)	0.14 g
Non-ionic detergent-e.g, Sterox S.E.	0.5 ml
(Harleco) or Triton X-100 (Rohm and Haas)	1.0 ml
Distilled water to	1000 ml

The solution should be clear and pale yellow, have a pH of 7.0 to 7.4, and give a reading of zero when measured in the photometer at 540 nm against water blank.
Substituting dihydrogen potassium phosphate, KHP2PO4, in this reagent for sodium bicarbonate, NaHCO3, in the original Drabkin reagent shortens the time needed for complete conversion of Hb to HiCN from 10 minutes to 3 minutes. The detergent enhances lysis of erythrocytes and decreases turbidity from protein precipitation.
Care must be taken with KCN in the preparation of the Drabkin solution, as salt or solutions of cyanide are poisonous. The diluent itself contains only 50 mg KCN per liter, less than the lethal dose for a 70-kg person. However, because HCN is released by acidification, exposure of the diluent to acid must be avoided. Disposal of reagents and samples in running water in the sink is advised. The diluent keeps well in a dark bottle at room temperature, but should be prepared fresh once a month.

Method

Twenty microliter of blood is added to 5.0 ml of diluent (1:251) or 20μl of blood in 4 ml of blood (dilution 1:201), mixed well, and allowed to stand at room temperature for at least three minutes. The absorbance is measured at 540 nm or with an appropriate filter. A vial of HiCN standard is then opened and the absorbance measured, at room temperature, in the same instrument in a similar fashion. The test sample must be analyzed within a few hours of dilution. The standard must be kept in the dark when not in use and discarded at the end of the day.
The assay value of the standard is present in the vial and commonly is expressed in milligram equivalents. To convert this value to hemoglobin in grams per decilitre, the assay value is multiplied by the dilution of blood used in the test (i.e 1:251). Consequently, an 80-mg standard is equivalent to 20.08 g/dl ($\frac{80 \times 251}{1000}$) or according to the formula.
Claculation of hemoglobin concentration

$$\text{Hb (g/dl)} = \frac{A^{540}\ \text{test sample}}{A^{540}\ \text{standard}} \times \text{Concentration of standard (mg/dl)} \times \frac{251}{1000}$$

If the concentration of the standard is known in grams, read the concentration of unknown hemoglobin according to this formula:

$$\frac{A^{(\text{unknown})}}{A^{(\text{Stand})}} \times \text{Conc}^{(\text{Standard})} = \text{Conc}^{(\text{unknown})}\ (\text{g/dl})$$

It is usually convenient to calibrate the photometer to be used for hemoglobinometry by preparing a standard curve or table that will relate absorbance to Hb concentration in grams per decilitre.
The absorbance of fresh HiCN standard is measured against a reagent blank. Absorbance readings are made of fresh HiCN standard and of dilutions of this standard in the reagent (I in 2, 1 in 3, 1 in 4) against a reagent blank. Hb values in grams per decilitre are calculated for each solution as described previously. When the absorbance readings are plotted on linear graph paper as the ordinates against Hb concentration as the abscissae, the points should describe as straight line that passes through the origin.
An advantage of the HiCN method is that most forms of hemoglobin (Hb, HbO2, Hi, and HbCO, but not SHB) are measured.
The test sample can be directly compared with the HiCN standard, and the readings can be made at the convenience of the operator because of the stability of the diluted samples.

Increased absorbance not due to hemoglobin may be caused by turbidity due to abnormal plasma proteins, hyperlipemia, large number of leukocytes (counts >30000/μl) or fatty droplets, any of which may lead to increased light scattering apparent absorbance.

ERRORS IN HEMOGLOBINOMETRY

The source of error may be those of the sample, the method, the equipment, or the operator.

Errors Inherent in the Sample

Improper venipuncture technique may introduce Hemoconcentration, which will make hemoglobin concentration and cell counts too high. Improper technique in fingerstick or capillary sampling can produce errors in either direction.

Errors Inherent in the Method

The HiCN method is the method of choice. The use of HiCN standard for calibration of the instrument and for the test itself eliminates a major source of error. The broad absorption band of HiCN in the region of 540 nm makes it convenient to use it both in filter-type photometers and in narrow-band spectrophotometers. With the exception of SHb, all other varieties of hemoglobin are converted to HiCN.

Errors Inherent in the Equipment

The accuracy of equipment is not uniform. A good grade of pipette with a graduated accuracy of greater than 99% is desirable. Calibration of pipettes will lessen errors. Significant error can be introduced by the use of unmatched cuvettes, therefore, flow-through cuvettes are preferred.
The wavelength settings, the filters, and the meter readings require checking. The photometer must be calibrated in the laboratory before its initial use and must be rechecked frequently to reduce the method's error to 2%.

Operator's Errors

Human errors can be reduced by good training, understanding the clinical significance of the test and the necessity for a dependable method, adherence to oral and written instructions, and familiarity with the equipment and with the sources of error.

STUDENT PERFORMANCE GUIDE

HEMOGLOBIN DETERMINATION USING THE SAHLI PIPET

Name:
Date:

Instructions

1. Practice the procedure for determining hemoglobin concentration.
2. Demonstrate the procedure for hemoglobin determination satisfactory for the instructor. All steps must be completed as listed on the instructor's Performance Check Sheet.
3. Complete a written examination successfully. .

Material and Equipments

- Gloves
- Hand disinfection
- Spectrophotometer
- Graduated pipet, 5 ml
- Cuvette
- Blood sample
- Sahli pipet
- Drabkin's reagent
- Test tubes
- Pipet filler
- Surface disinfectant
- Standard hemoglobin solution (20g/dl)
- Safety bulb for pipet or automatic pipetter
- Parafilm
- Biohazard container

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant and put gloves			
2. Assemble equipment and material			
3. Turn on spectrophotometer			
4. Set wavelength at 540 nm			
5. Label 2 test tubes: blank and unknown			
6. Dispense 5.0 ml of Drabkin's reagent into each test tube using a safety bulb and a 5 ml pipet.			
7. Attach pipet filler to Sahli pipet			
8. Draw blood up to 0.02 ml(20μl) mark on the pipet			
9. Wipe excess blood sample into the unknown tube			
10. Dispense blood sample into the unknown tube.			
11. Rinse the pipet at least 3 times with the solution in the tube by alternately aspirating the solution into the pipet and gently dispensing it.			
12. Mix contents of the tube thoroughly and let it stand for at least ten minutes (tubes can be mixed by inverting after placing parafilm over the top of the tube).			

13. Put Drabkin's solution to a cuvette; place Cuvette in the well of spectrophotometer; set absorbance to zero following manufacturers' instructions.			
14. Transfer content of unknown tube to a Cuvette; place Cuvette in the well of spectrophotometer			
15. Read the absorbance and record result			
16. Pipet 5.0 ml of 20 g/dl hemoglobin standard into a Cuvette; read the absorbance and record.			
17. Use the following formula to calculate hemoglobin concentration and record results $\frac{A^{(uuk)}}{A^{(stand)}} \quad X \quad conc^{(stand)} = conc^{(unk)}$ (g/dl)			
18. Discard all specimens into biohazard container			
19. Clean equipment and return to proper storage			
20. Clean work area surface disinfectant			
Remove and discard gloves into appropriate container and wash hands with disinfectant			
Comments: Student/Instructor			

Date:----------Instructor

LESSON 2 : **THE SPECTROPHOTOMETER**



THE SPECTROPHOTOMETER *2*

OBJECTIVES

- Explain the principle of the spectrophotometer
- List the parts of the spectrophotometer
- Use the spectrophotometer
- Construct a standard curve
- List precautions that should be observed when using a spectrophotometer

---

GLOSSARY

- **Absorbance**: the light absorbed by a substance containing colored molecules, designated in formulas by "A" ; also called optical density (O.D)
- **Beer's Law**: a mathematical relationship upon which the basis of analysis by spectrophotometry is formed and which the basis shows that absorbance is related linearly to concentration
- **Cuvette**: a tube manufactured to strict standards for clarity and lack of distortion in the glass and used to hold liquids to be examined in the spectrophotometer
- **Diffraction grating**: a device which disperses light into a spectrum
- **Galvanometer:** instrument which measures electrical current
- **Monochromatic light**: light consisting of one color; light that is of one wavelength
- **Monochromator:** device which isolates a narrow portion of the light spectrum.
- **Percent transmittance**: the percentage of light which passes through a substance; %T
- **Photoelectric cell**: a device which detects light and converts it into electricity.
- **Reagent blank**: a solution which contains some or all of the reagents used in the test but does not contain the substance being tested.
- **Spectrophotometer**: an instrument which measures intensities of light in different parts of the spectrum.
- **Standard curve**: in spectrophotometry, a graph which shows the relationship between the concentrations and absorbance (or percent transmittances) of a series of standard solutions.

PRINCIPLES OF SPECTROPHOTOMETRY

Spectrophotometers are used to determine the concentrations of colored solutions. This determination is made by passing a narrow beam of light through the solution. The portion of light which passes through the colored solution is the **percent transmittance**. The light which does not pass through is absorbed by the solution and is measured as **absorbance**. Concentrated solutions allow less light to pass through than dilute solutions. Thus, it can be said that the more concentrated the solution, the greater its absorbance or the percent transmittance can be read from most spectrophotometers. For most colored solutions, the absorbance increases with the concentration. These solutions are said to follow Beer's Law, a mathematical relationship which shows that the absorbance of a colored solution is directly proportional to its concentration. This relationship is linear. For most colored solutions the percent transmittance decreases as the concentration increases; this relationship is geometric (nonlinear).

Transmittance: This is the ratio of the inensity of the transmitted light over the intensity of the incient light. This is usually multiplied by 100 to give percentage Trantmission

Percentage transmission

$$\%T = \frac{I_T}{I_o} \times 100$$

Where I_T is the intensity of the transmitted light and I_o is the intensity of the incident light.

Optical density (also extinction or absorbance).
Without dealing with the mathmatics we can say that optical density (OD) is related to transmittance in the following way:

$$OD = 2 - \log_{10} \%T$$

Thus if there is 100% transmission, then OD=0, that is to say the absorbance is nil. Many photoelectric instruments are caliberated in both ways. For manual procedures we normally use OD since if Beer's law is obeyed, a plot of concentration against OD is a straight line and therefore much easier to handle than the exponential curve given by plotting %T against concentration. In automated procedures, however, %T is often used.
We can drive the basic equation for photoelectric absorptiometry.
According to Beer's and Lambert's laws that

$$OD \alpha C.L$$

Where C= concentration and L= light path
Therefore $OD = K.C.L$
Where K is a constant
If we consider two solutions, one a standard(S) and the other an unknown test (T) we can write :

$(OD)_S = K_S C_S L_S$

and $(OD)_T = K_T C_T L_T$

therefore $\frac{(OD)_S = K_S C_S L_S}{(OD)_T = K_T C_T L_T}$

By treating both solutions in the same way we can make $K_S = K_T C_S$ and $L_S = L_T$, and our equation becomes:

$$\frac{(OD)_S}{(OD)_T} = \frac{C_S}{C_T}$$

then $C_T = \frac{(OD)_T}{(OD)_S} \cdot C_S$

i.e Concentration of test

= $\frac{\text{OD of test}}{\text{OD of standard}}$ X Concentration of standard

PARTS OF SPECTROPHOTOMETR

A light source in the spectrophotometer provides a beam of light which passes to a **monochromator.** This monochromator has a diffraction grating which disperses the light into a spectrum. It also contains a slit which isolates a narrow beam of **monochromatic light**, light of one wavelength. This monochromic light is directed toward the sample well in which a Cuvette holding the colored solution is placed. The **Cuvette** is a special tube manufactured to precise specifications. A portion of the light will be absorbed by the molecules in the solution. The light which passes through is detected by a **photoelectric cell** which converts it to electrical current. This current is measured and recorded by a **galvanometer**. The information can be presented as either absorbance (A) units or percent transmittance (%T) on the readout display of the spectrophotometer.



STANDARD CURVE

A standard curve can be used to determine the concentrations of colored solutions which follow Beer's Law. Dilutions of a standard of known concentration are reacted with a reagent which forms a color whose intensity is proportional to the concentration of the standard substance. The absorbances or percent transmittances, of the solutions are then determined using the spectrophotometer. The results (A or %) are plotted against the concentrations of the diluted standards, and a line is drawn through the points (figure 2). Absorbance is plotted using linear graph paper. If percent transmittance is measured, semilog paper must be used to obtain a straight line. This graph, the standard curve, may then be used to find the concentration of unknowns of the same substance. A standard curve must be prepared for each test method and each spectrophotometer.

Example of Preparation of a Standard Curve Using Hemoglobin

A standard curve can be prepared easily using hemoglobin as the standard solution.. Hemoglobin, when mixed with Drabkin's reagent, is converted to cyanmethemoglobin, a pigment which absorbs light at 540 nm. A standard curve for hemoglobin can be made using dilutions of a 20g/dl hemoglobin standard.
Standard are available in various concentrations and manufacturer's instructions should be followed in preparing the dilutions should be followed in preparing the dilutions and calculating concentrations. Hemoglobin standards may be purchased as a dry powder to be reconstituted with Drabkin's reagent or in a ready-to-use solution. Drabkin's reagent contains cyanide, must be handled with caution, and must not be mouth pipetted.



Determining the Absorbances of the Standards

Dilutions of the hemoglobin standard are made with Drabkin's reagent, the reagent used in the hemoglobin test. Four tubes consisting of 5, 10, 15, and 20 g/dl hemoglobin are set up. The spectrophotometer wavelength is set to 540 nm and the absorbance is set to zero using Drabkin's reagent as the **reagent blank**. A reagent blank is a solution that contains the reagents of the test but none of the substance being measured. The standard dilutions are transferred to a Cuvette and the absorbance of each is determined and recorded.

Plotting the Standard Curve

Using graph paper, the absorbances are plotted on the "Y" axis (coordinate), and the concentrations on the "X" axis (abscissa).. A line is drawn through the four points on the graph. If the dilution were made correctly and the absorbances were measured correctly, a line draw through the points of the standards should be straight and should pass through the origin (0,0). If all the points do not fall in a straight line, a ruler can be used to draw a line of "best fit" which connects most of the points. The standard curve is then ready to be used to determine the hemoglobin concentration in a blood sample. The absorbance of the unknown solution is read the value is matched with an absorbance on the graph.

The concentration of the unknown can then be read directly from the graph. This method of measurement is valid only when the substance follows Beer's Law. (If % T is read for the standards, the standard curve must be plotted on semi-log graph paper to obtain a straight line.)

If only one standard is used, the concentration of an unknown may be found by using the formula:

$$C_u = \frac{A_u}{A_s} \times C_s$$

Where

C_u= concentration of unknown
C_s= concentration of standard
A_u= Absorbance of unknown
A_s= Absorbance of standard

Again, this formula may only be used for solutions which are known to follow Beer's Law. A sample calculation using this formula is shown in the example:

Example: given the following values, use the absorbance formula to find the hemoglobin concentration of the unknown:

$A_s = 0.600$ $A_u = 0.300$ $C_s = 20$ g/dl

Use the absorbance formula: $\frac{C_u \text{ (g/dl)}}{C_s \text{ (g/dl)}} = \frac{A_u}{A_s}$

Substitute the value given: $\frac{C_u \text{ (g/dl)}}{20 \text{ g/dl}} = \frac{0.300}{0.600}$

C_u = 10.0 g/dl. Therefore, the unknown hemoglobin = 10.0 g/dl

STUDENT PERFORMANCE GUIDE

STANDARD CURVE

Name:
Date:

Instructions

1. Practice the procedure for using the spectrophotometer to prepare a standard curve.
2. Demonstrate the procedure for using the spectrophotometer to prepare a standard curve satisfactory for the instructor. All steps must be completed as listed on the instructor's performance check list..
3. Complete a written examination successfully. .

Material and Equipments

a. Gloves
b. Blood sample
c. Surface disinfectant
d. Hand disinfection
e. Spectrophotometer
f. Graduated pipet, 5 ml
g. Cuvette
h. Sahli pipet
i. Drabkin's reagent
j. Test tubes
k. 5 and 10 graduated pipettes
l. Graph paper
l. Standard hemoglobin solution (20g/dl)
m. Safety bulb for pipet or automatic pipettes
n. Parafilm
o. Biohazard container
p. Pen or pencil

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant and put gloves			
2. Assemble equipment and material			
3. Turn on spectrophotometer to warm up			
4. Set wavelength to 540 nm			
5. Assemble materials			
6. Label five test tubes 0(blank), 5, 10, 15 and 20			
7. Reconstitute the hemoglobin standard according to manufacturer's instructions			
8. make dilutions of the hemoglobin standard as follows: a. Pipet Drabkin's reagent into the tubes using a 5 or 10 ml pipet with safety bulb (or automatic pipet): **Tube** 0 = 6.0 ml 5= 4.5 ml 10= 3.0 ml 15= 1.5 ml 20= 0.0 ml			

b. Pipet the hemoglobin standard solution into the same tubes as follows, using a clean 5 ml pipet: **Tube** 0= 0.0ml 5= 1,5 ml 10= 3.0 ml 15= 4.5 ml 20= 6.0 ml			
9. Observe the tubes to see that each contains the same volume (6.0 ml) and mix each tube using parafilm to cover top of tube.			
10. Transfer contents of the “0” tube to a clean Cuvette and place in Cuvette well of the spectrophotometer.			
11. Place the cap over the top of the Cuvette well and set absorbance to zero using control knob			
12. Remove the “0” Cuvette from the well			
13. Transfer contents of “5” tube to a clean Cuvette and place it in Cuvette well			
14. Record absorbance			
15. Remove the Cuvette from the sample well			
16. Repeat steps 12-14 for tubes 10, 15, 20			
17. Record the results on the worksheet			
18. Draw the “X” axis and “Y” axis as show in figure			
19. Label the “X” axis in units of hemoglobin concentration: 0, 5, 10, 15, 20 g/dl			
20. Label the “Y” axis in absorbance (A) units from 0-1.0 using intervals of 0.100			
21. Plot the absorbance of tubes 5, 10, 15, 20			
22. Draw the best straight line through the points, being sure it passes through the origin 0,0)			
23. Save this graph for use in determining the hemoglobin concentration of a blood sample.			
24. Dispose of used reagents and contaminated materials properly			
25. Disinfect of used reagents and contaminated materials properly.			
26. Remove and discard gloves appropriately and wash hands with hand disinfectant			
Comments Student/Instructor:			

LESSON 3
ERYTHROCYTE SEDIMENTATION RATE

ERYTHROCYTE SEDIMENTATION RATE 3

OBJECTIVES

- List properties of blood which affect the erythrocyte sedimentation rate and explain how the rate is affected by each factor
- Perform a test to measure the erythrocyte sedimentation rate.
- State the normal values for the erythrocyte sedimentation rate.
- List technical factors which may affect the erythrocyte sedimentation rate.
- Remember the cause which may increases or decreases the erythrocyte sedimentation rate.

GLOSSARY

- **Aggregate**: total substance making up a mass; a clustering of particles.
- **Inflammation**: A tissue reaction to injury
- **Rouleaux**: a group of red cells arranged like a roll of coins
- **Sedimentation**: The process of solid particles settling at the bottom of a liquid

---

Erythrocyte Sedimentation rate (ESR), more commonly referred to as sedimentation rate is a measure of the speed with which red cells in anticoagulated tube. The test measures the distance the upper part of a red cell column descends in a specified amount of time and is usually reported as the number of millimetres per hour. Sedimentation normally takes place slowly, but the rate increases in numerous conditions involving an inflammatory process or tissue necrosis, frequently in proportion to the severity of the disease.

ESR is non-specific indicator of the physiologic responses associated with connective tissue diseases, dysproteinemia, malignancy, and infectious diseases, although it is not directed at any particular organ or disorder. When used as a general screening test, a normal ESR significantly reduces the probability of unsuspected disease processes, whereas elevated results indicate the need for further testing. A gradually increasing sedimentation rate is indicative of continuing or increasing problem, whereas a gradually diminishing ESR reflects clinical improvement and is a favourable sign of an abating inflammatory condition. Laboratory determinations of ESR may be used to detect occult organic disease and to follow the course of inflammatory conditions such as rheumatic fever, tuberculosis, rheumatoid arthritis, and myocardial infarction.

FACTORS AFFECTING THE RATE OF SEDIMENTATION

Three factors which affect the ESR

1. Properties of the erythrocytes
2. Properties of the plasma
3. Mechanical or technical factors.

Properties of Erythrocytes

The rate of sedimentation is affected by the size, shape and number of erythrocytes. In normal blood, erythrocytes suspended in the plasma form few, if any aggregates. The mass of the falling erythrocytes is small and the ESR tends to be low. In abnormal blood, the erythrocytes sometimes aggregate to form what is called **rouleau.** This phenomenon is called rouleau because the cells form aggregates that look like rolls or stacks of coins. This causes an increase in the mass and an increased rate of sedimentation.

The sedimentation rate is directly proportional to the weight of the cell aggregate and inversely proportional to the surface area. Changes in the shape of the erythrocytes can also affect the ESR. For example, in sickle cell anemia the irregularly shaped erythrocytes cannot form rouleau and the ESR may be slow. The sedimentation rate may be rapid in other anemias because there are fewer erythrocytes to interfere with settling. When erythrocytes are increased, as in polycythemia, the erythrocytes settle slowly.

Properties of Plasma

An accelerated ESR is favoured by elevated levels of fibrinogen and, to a lesser extent, $\alpha 2$, $\beta 2$ and γ-globulins. These asymmetric protein molecules have a greater effect than other proteins in decreasing the negative charge of erythrocytes (zeta potential) that tends to keep them apart. The decreased zeta potential promotes the formation of rouleaux, which sediment more rapidly than single cells. Removal of fibrinogen by defibrination lowers the ESR.

There is no absolute correlation between the ESR and any of the plasma protein fractions. Albumin and lecithin retard sedimentation, and cholesterol accelerate the ESR.

Mechanical or technical factors

Mechanical and technical factors such as temperature, time, size of tube, and tilting or vibration of tube during incubation will affect the sedimentation rate. The points listed below should be heeded if the test results are to be correct:

1. The sedimentation tube must be kept exactly vertical; even minor degrees of tilting may greatly increase the ESR
2. The test should be set up on a counter free from vibration, such as that from a centrifuge, to avoid a falsely increased rate of settling.
3. The temperature in the room should be kept constant while the test is being performed. Low temperature cause erythrocytes to settle more slowly.

4. The test should be set up within two hours after the blood sample is collected.
5. The length and diameter of the sedimentation tube affect the rate of sedimentation. Therefore, standard tubes should be used in the test.
6. The test must be timed carefully. The ESR increases with time.

Stages in the ESR

Three stages can be observed:

1. In the initial 10 minutes, there is little sedimentation as rouleaux form
2. For about 40 minutes, setting occurs at a constant rate.
3. Sedimentation slows in the final 10 minutes as cells pack at the bottom of the tube

METHODS

Westergren Method

Because of its simplicity, the Westergren method is widely used. The ICSH (1993) has recommended it as the reference method utilizing undiluted whole blood. The ICSH states that the patient's hematocrit should not exceed 35% because reproducibility of sedimentation may be poorer in narrow tubes. A formula to convert between diluted blood ESR and undiluted is: diluted blood ESR= (undiluted ESRX0.86)-12

Equipment

The Westergren tube is a straight pipette 30 cm long, 2.55 mm in internal diameter, and calibrated in millimetres from 0 to 200. It holds about 1 ml. The Westergren rack is also used, with leveller as needed for a vertical tube position.

Reagent

A 0.105 molar solution (range, 0.10 to 0.136) of sodium citrate is used as the anticoagulant-diluent solution (31 g of $Na_3C_6H_5O_7 \cdot H_2O$ added to 1 L of distilled water in a sterile glass bottle). This is filtered and kept refrigerated without preservatives.

Procedure

1. Two ml of whole blood added to 0.5 ml of sodium citrate and mix by inversion
2. A Westergren pipette is filled to the 0 mark and placed exactly vertical in the rack at room temperature without vibration or exposure to direct sunlight.
3. After exactly 60 minutes, the distance from the 0 mark to the top of the column of red cells is recorded in millimetres as the ESR value. If the demarcation between plasma and red cell column is hazy, the level is taken where the full density is first apparent.

Modified Westergren Method

A modification of the Westergren method produces the same results but employs blood anticoagulated with EDTA rather than with citrate. This is more convenient, since it allows the ESR to be performed from the same tube of blood as is used for other hematologic studies. Two millilitres of well-mixed EDTA-blood is diluted either with 0.5 ml of 3.8% sodium citrate or with 0.5 ml of 0.85% sodium chloride. Undiluted blood anticoagulated with EDTA gives poor precision (ICSH 1977).

Wintrobe Method

The Wintrobe method is one of the common methods of measuring the ESR. A Wintrobe tube graduated from 0-100 millimetres and with a capacity of one millimetre of blood is used for this method. The use of disposable Wintrobe tubes is recommended because of the difficulty in disinfecting and cleaning the reusable type. A special rack which holds the tube vertically is also required. The sample tested is venous blood with the anticoagulant, EDTA, added.
A long-tipped Pasteur pipet is used to fill the Wintrobe tube to the zero mark with blood. The tube is then placed in the sedimentation rack for one hour. At the end of the hour, the total distance which the erythrocytes have fallen is measured. The rate is recorded in mm/hour.

Normal Values

Normal values for sedimentation rate is vary according to the particular method used, since tube diameters and column heights vary with method. However regardless of the method used, the rest requires a minimum of 1 hour to complete. The normal range for ESR is expressed in millimetres per hour (mm/h).

Method	Men	Women	Children
Westergren <50 years age >50 years age > 85 years age	15 mm/h 20 mm/h 30 mm/h	20 mm/h 30mm/h 42 mm/h	0-20 mm/h
Wintrobe Adult > 70 years	0-9 mm/h 0-50 mm/h	0-20 mm/h 0-50 mm/h	0-15 mm/h
Culter	0-8 mm/h	0-10 mm/h	4-13 mm/h
Landau (micromethod)	0-6 mm/h	0-9 mm/h	< 2 years =1-6 2-14 years= 1-9
Smith (micromethod)			3-13 mm/h

Interpretation and Clinical Significance

ESR is one of the oldest laboratory tests and of greatest value when used to indicate an active, although obscure, disease process and to differentiate between certain conditions with similar clinical findings and symptoms. For example, ESR rises in myocardial infarction but remains normal in angina pectoris; increases during rheumatic fever, rheumatoid arthritis, and pyogenic arthritis but not osteoarthritis; and is elevated with hepatic carcinoma but is generally normal with cirrhosis. The sedimentation rate also helps differentiate advanced cancer of the stomach from peptic ulcer, since sedimentation is usually rapid when metastases and tumor inflammation are present.
The speed of red cell settling is affected by many factors, including the concentration of various plasma protein fractions, mainly fibrinogen and globulin, as well as the size, shape, and number of erythrocytes. The ESR is accelerated by the increased quantities of fibrinogen associated with tissue necrosis, infection, and the abnormal globulins are globulin fractions seen in multiple myeloma and other gammopathies. Active antibody formation, along with loss of albumin from kidney disease, enteritis, or faulty synthesis, also alters the sedimentation rate by increasing the ratio of globulins to albumin.
In pregnancy, the ESR increases moderately, beginning at the tenth to twelfth week, and returns to normal about one month postpartum.

The ESR has been reported to be of clinical significance in:

- ✓ Sickle cell disease: low value in absence of painful crisis, moderately increased one week into crisis
- ✓ Osteomyelitis; elevated, helpful in following therapy
- ✓ Stroke: ESR of ≥28 has poorer prognosis
- ✓ Prostate cancer: ESR≥ 37 mm/h has higher incidence of disease progression and death.
- ✓ Coronary artery disease: ESR ≥22 mm/h in white men had high risk of CAD.

ALWAYS REMEMBER THESE VARIATIONS

Elevated erythrocyte sedimentation rate may occur with the following:
Marked Elevation

- ✓ Acute severe bacterial infection
- ✓ Carcinoma
- ✓ Collagen diseases
- ✓ Leukemias
- ✓ Malignant lymphoma
- ✓ Multiple myeloma
- ✓ Portal or biliary cirrhosis
- ✓ Sarcoma
- ✓ Severe renal disease
- ✓ Ulcerative colitis
- ✓ Viral pneumonia
- ✓ Waldenström macroglobulinemia

Decreased (Zero) erythrocyte sedimentation rate may occur with the following:

- ☻ Cryoglobulinemia
- ☻ Hemoglobin C disease
- ☻ Polycythemia vera
- ☻ Sickle cell anemia

Moderate elevation of ESR may occur with the following:

- ✓ Acute and chronic infections
- ✓ Acute glomerulonephritis
- ✓ Advanced age
- ✓ Agranulocytosis
- ✓ Anaphylactoid purpura
- ✓ Coronary thrombosis
- ✓ Ectopic pregnancy
- ✓ Hyperthyroidism, hypothyroidism
- ✓ Internal hemorrhage
- ✓ Intravenous dextran
- ✓ Lead and arsenic intoxication
- ✓ Malignant tumors with necrosis
- ✓ Menstruation
- ✓ Myocardial infarction
- ✓ Nephritis, nephrosis
- ✓ Normal pregnancy
- ✓ Oral contraceptive
- ✓ Rheumatic fever
- ✓ Syphilis
- ✓ Tuberculosis

STUDENT PERFORMANCE GUIDE
ERYTHROCYTE SEDIMENTATION RATE
WESTERGREN METHOD

Name:
Date:

Instructions

1. Practice performing the procedure to measure the erythrocyte sedimentation rate.
2. Demonstrate the procedure for measuring the erythrocyte sedimentation rate satisfactory for the instructor. All steps must be completed as listed on the instructor's Performance Check Sheet.
3. Complete a written examination successfully. .

Material and Equipment

- Gloves
- Hand disinfection
- Sample of venous, anticoagulated blood
- Westergren tube
- Westergren rack
- Timer
- Surface disinfectant
- Biohazard container

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant and put gloves			
2. Assemble equipment and material			
3. Check the levelling bubble to insure that the rack is level			
4. Obtain anticoagulated blood sample			
5. Mix blood well			
6. Fill Westergren tube to the "0" mark. Tube must be filled from bottom and avoid getting bubbles in the tube.			
7. Place tube in sedimentation rack and set timer for one hour. Be certain the tube is vertical			
8. Measure the distance the erythrocytes have fallen (in mm) after one hour;			
9. Record the sedimentation rate in mm/h			
10. Disinfect and clean equipment and return to storage.			
11. Clean work area with surface disinfectant			
12. Remove and discard gloves appropriately			
13. Wash hands with disinfectant			
Comments			

Date:----------Instructor----------

Please draw and write down the result of the procedure

LESSON 4: MICROHEMATOCRIT

MICROHEMATOCRIT *4*

OBJECTIVES

- Perform a microhematocrit sample
- Centrifuge a hematocrit sample
- Determine the hematocrit value
- Explain what the microhematocrit measures
- List the normal values for a microhematocrit
- List conditions that affect the microhematocrit value
- List precautions that should be observed in performing the microhematocrit

---

GLOSSARY

- **Buffy coat**: a light-colored layer of leukocytes and platelets which forms on the top of the red cell layer when a sample of blood is centrifuged or allowed to stand.
- **EDTA**: ethylene diamine tetraacetic acid; commonly used anticoagulant for hematological studies.
- **Hematocrit**: the volume of erythrocytes packed by centrifugation in a given volume of blood and expressed as a percentage; abbreviated “crit” or Hct”
- **Microhematocrit**: a hematocrit performed on a small sample of blood
- **Microhematocrit centrifuge**: a machine which spins capillary tubes at a high speed to cause rapid separation of liquid from solid components
- **Plasma**: the liquid part of the blood in which the cellular elements are suspended

---

The hematocrit (Hct), or packed cell volume, measures the percentage of a given volume of whole blood that is occupied by erythrocytes. Thus a hematocrit value of 45% indicates that 45 ml of each 100 ml of peripheral blood is composed of red blood cells. Hematocrit values may be determined directly from a centrifuged microhematocrit tube or calculated from other measurements in a CBC profile performed by electronic cell counters.

The hematocrit procedure divides the blood specimen into three distinct layers, with packed erythrocytes on the bottom, leukocytes and platelets (called the buffy coat) in the middle, and the plasma on the top. An examination of the microhematocrit tube in the laboratory allows a rough estimation of the white cell count as well as an inspection of plasma color and clarity to detect abnormalities. Laboratory determination of the hematocrit aids in the diagnosis and evaluation of anemia and may also be used to calculate erythrocyte indices, total mass, and blood volume

PERFORMING THE MICROHEMATOCRIT

The blood sample may be obtained from a capillary puncture or from a tube of venous blood which has had the anticoagulant EDTA or heparin is added.
The blood is drawn by capillary action into capillary tubes of very small diameter which are sealed. To do this, the clean end of the tube is placed in sealing clay. This makes a tight seal and prevents contamination of the clay with blood. Tubes may also be sealed using disposable plastic sealing caps.
The tube is then placed in a special microhematocrit centrifuge. The sealed ends of the tubes are placed against the rubber gasket and the open ends toward the center. After being centrifuge for the prescribed time (usually 3-5 minutes) at 10,000 to 12000g, the hematocrit percentage is read by placing the tube on a special microhematocrit reader.

Factors that Influence Microhematocrit Values

The values obtained for microhematocrits can be influenced by physiological or pathological factors and by the handling of the specimen during the test procedure. Improper blood collection or the use of inadequately mixed blood can cause unreliable results.

Clinical Significance

Hematocrit Values generally directly parallel both the hemoglobin and erythrocyte count, since any variation of one value produces an equal change in the others when red cells are a normal size.

Hemoglobin and erythrocyte counts may be estimated from the microhematocrit reading of normal blood according to the following formula:

1 hematocrit point = 0.34 g hemoglobin /dl of blood
1 hematocrit point = 107,000 erythrocyte/μl of blood

The accuracy of hemoglobin and hematocrit relationship according to the following formula:
Hematocrit reading = Hemoglobin value X 3 +- 3%

For example, a hemoglobin value of 13.0 g/dl should be accompanied by a hematocrit value between 36% and 42% (13.0X3= 39% +- 3%=36% to 42%).

Any consistent deviation of laboratory results from this relationship indicates the presence of many red cells of abnormal size or hemoglobin content.
The normal relationship between hematocrit and hemoglobin or erythrocyte count does not exist in certain pathologic conditions in which the red cells are larger or smaller than normal. Thus, patients with Macrocytic red cells, which usually contain a larger amount of hemoglobin than normal, demonstrate a hematocrit value higher than the corresponding erythrocyte count would indicate.
Conversely, microcytic red cells, which generally contain less hemoglobin than normal, produce a decreased hematocrit in spite of a normal erythrocyte count, since smaller cells pack into a smaller volume.

Normal Values

Children

Newborns	42%-62%
3 months	29%-54%
1 year	29%-41%
10 years	36%-40%

Adults

Males	40% - 52%
Females	37%-47%

Variations

Elevation hematocrit may occur with the following:	Decreased hematocrit may occur with the following :
✓ Dehydration due to prolonged vomiting or severe diarrhea ✓ Hemoconcentration resulting from shock, surgery, or hemorrhage ✓ Polycythemia ✓ Severe burns	✓ Anemia resulting from decreased blood production or increased blood destruction ✓ Hemorrhage or prolonged blood loss ✓ Hydremia as a result of pregnancy, cardiac decompensation, or excessive fluid administration. ✓ Hypothyroidism ✓ Idiopathic steatorrhea ✓ Leukemia

STUDENT PERFORMANCE GUIDE

MICROHEMATOCRIT

Name:
Date:

Instructions

1. Practice the microhematocrit procedure
2. Demonstrate the microhematocrit procedure satisfactorily for the instructor. All steps must be completed as listed on the instructor's Performance Check Sheet.
3. Complete a written examination successfully. .

Material and Equipments

a. Gloves
b. Hand disinfection
c. Capillary tubes, plain and with heparin
d. Sealing clay Microhematocrit centrifuge and reader
f. Blood lancet, sterile, disposable
g. Puncture-proof container for sharp objects
h. Tube of anticoagulated venous blood
i. Soft tissues
j. 70% alcohol
k. Gauze or cotton, sterile
l. Biohazard container

Procedure s=satisfactory U= unsatisfactory			
You must	S	U	Comments
1. Wash hands with disinfectant and put gloves			
2. Assemble equipment and material			
3. Fill two capillary tubes using a tube of EDTA anticoagulant blood: a. Mix the tube of blood thoroughly by rocking tube from end to end gently 20-30 times b. Remove cap from tube, avoiding contamination of hands with blood. c. Tilt the tube so that blood is very near the top edge of the tube. d. Insert a plain capillary tube beneath the surface of the blood and fill to two thirds by capillary action (if using pre-capillary tubes, fill to the line. Note: Wipe the outside of the filled capillary tube with tissue, if necessary, to remove excess blood. e. Seal the tube by placing the clean end into the tray of the sealing clay or using plastic sealing cap. f. fill a second tube in the same manner			

4. (OR) Fill two capillary tubes from a capillary puncture: a. Wash hands with disinfectant and put on gloves b. Perform a capillary puncture c. Wipe away the first drop of blood d. Place one end of a heparinized capillary tube into the second drop of blood e. Allow the tube to fill two thirds by capillary action. f. Fill a second tube in the same manner g. Wipe the outside of the filled capillary tube with tissue, if necessary, to remove excess blood h. Seal the tube by placing the clean end into the tray of the sealing clay /			
5. Check to see the interior sealing clay edge appears level in tube			
6. Place tube into the microhematocrit centrifuge with sealed ends securely against the gasket (balance the centrifuge by placing the tubes opposite each other			
7. Fasten both lids securely			
8. Set the timer and adjust the speed if necessary			
9. Centrifuge for the prescribed time			
10.Allow centrifuge to come to a complete stop and unblock lid			
11. Determine the microhematocrit values using one of the following methods: A. A centrifuge which requires calibrated tubes and has a built-in scale 1. Position the tubes as directed by the manufacturer's instructions to obtain the microhematocrit value. B. A centrifuge which can accept any microhematocrit tubes: 1. Remove capillary tubes from centrifuge capillary 2. Place tube on the microhematocrit reader provided 3. Follow instructions on the reader to obtain the hematocrit value			
12. Average the values from the two tubes and record the hematocrit			
13. Discard capillary tubes and used lancets into a puncture-proof container for sharp objects			
14. Clean equipment and return to storage			
15. Clean work area with surface disinfectant			
16. Remove and discard gloves appropriately and wash hands with disinfectant			
Comments Student/Instructor			

Date:----------Instructor

LESSON 5

PREPARATION OF A BLOOD SMEAR

PREPARATION OF A BLOOD SMEAR 5

OBJECTIVES

- Discuss the purpose and importance of the blood smear
- List the components that may normally be observed in a blood smear.
- Prepare a blood smear
- Preserve a blood smear
- List precautions to observe when preparing a blood smear
- Stain a blood smear
- List precautions to be observed for proper staining of a blood smear.

GLOSSARY

- **CBC**: complete blood count; a commonly performed group of haematological tests
- **Fixative**: preservative; chemical which prevents deterioration of cells or tissues.
- **Morphology**: study of form and structure od cells, tissues, organs

The peripheral blood smear is the most practical diagnostic tool for the hematologist. A drop of blood is applied against slide that is subsequently stained with polychrome stains
(Wright-Giemsa) to permits identification of the various cell types. These stains are mixtures of basic dyes (methylene blue) that are blue and acidic dyes (eosin) that are red. As such, acid components of the cell (nucleus, cytoplasmic RNA, basophilic granules) stain blue or purple, and basic components of the cell (hemoglobin, eosinophilic granules) stain red or orange. In addition to the polychrome stains, monochrome stains are sometimes used to visualize young red cells (reticulocyte stain), denatured hemoglobin (Heinz body stain) or cellular iron (Prussian blue stain).
The blood smear is used to assess red cell size/shape; white cell appearance and differential; abnormal cells; platelet size and morphology; detection of parasites, e.g malaria. The smear may suggest a diagnosis, e.g. type of anemia, presence of malaria, leukemia and myelodysplasia.

Specimen Requirements

Whole unclotted is required for preparing the peripheral blood film. Fresh peripheral blood from a skin puncture is the specimen of choice for manual differential count, but blood anticoagulated with an EDTA salt is used most often. EDTA is preferred since it prevents formation of artefacts and acceptably preserves blood for up to 3 hours. Use of an anticoagulant introduces certain morphologic changes in the leukocytes, which become increasingly exaggerated with storage time. Examples of these changes include vacuoles in the cytoplasm of granulocytes and karyorrhexis (nuclear disintegration). When final evaluation of blood films are made, the amount of time the cells were allowed to interact with EDTA before the films were prepared and stained should be taken into consideration.

Peripheral Blood (slide method)
Materials
a. Slide glass: the slide glass must be clean and free of grease, lint, and dust. If precleaned slides are not available, slides may be prepared by washing in detergent, rinsing in hot water and drying. Slide glasses with a 1 to 2 cm length of frosted area at one end are convenient for labelling with a pencil.
b. Spreading slide: If a glass slide for spreading blood is not available, one may be made by affixing a cover glass for hemocytometer to one end of a slide glass with adhesive tape. The spreader should have a smooth, clean head that is narrowed than the slide glass.
c. a dryer (cold air) or a fan.

Technique

a. Hold a spreader with the thumb and index or middle fingers of your dominant hand
b. Use finger of your other hand to hold the slide glass on a flat surface.
c. Place a small drop of blood at the lower end of the head of the spreader
d. Place the head of the spreader on the unfrosted area of the slide near the frosted area at an angle of about 30 degrees, and allow blood to spread by capillary action evenly along the interface between the spreader and the slide.
e. Using the thumb and the index or middle finger of the hand holding the spreader, push the spreader forward with a rapid, even motion. The pressure should be as light as possible.
f. Air-dry the blood film promptly with a dryer or a fan. Do not blow on it.
g. Write the name of the patient and the date on the frosted area with a pencil.



Conditions for making the perfect slide smears are as follows:
a. To minimize the disadvantage of the slide method-less uniform distribution of leukocytes and platelets

b. Length and thickness of the blood film should be from 3 to 4 cm to provide a sufficiently large area of adequate cells separation. Conditions relating to cell separation are as follows:

1. The greater the volume of blood, the longer and thicker the film.
2. The more obtuse the angle between slide and spreader, the shorter and thicker the film.
3. The stronger the pressure of spreading, the longer and thinner the film.
4. The faster the speed of spreading, the shorter and thicker the film.

c. The line of tail end of the film should be almost straight and vertical to the long line of the slide.

d. The film should not be striped; to prevent striping, move the spreader forward with a steady, even speed.

STAINING OF SMEAR

Both blood smear and marrow smears should be stained immediately. If this is not possible, however, the slide may be immersed in the methanol in a coplin jar for thirty to sixty seconds and allowed to air dry. It them may stained at a later date. The methanol is a fixative or preservative that prevents changes or deterioration of cellular component.

Example

Leishman's Stain

Use commercially available stain or prepare stain as follows:

1. Add glass beads to 500 ml of methanol
2. Add 1.5 gm of Leishman's powder
3. shake well, leave on a rotary shaker during the day, then incubate at 37 ^{0}C overnight

   There is no need for filter

Method

1. Make a thin film and air dry rapidly
2. Place the film on a staining rack, flood with Leishman's stain and leave for 1 minute to fix
3. Add twice as much buffered distilled water (preferably fro, a plastic wash bottle as this permits better mixing for the solution), pH 7.2
4. Leave to stain for 10 minutes
5. Wash off with tap water



STUDENT PERFORMANCE GUIDE

PERIPHERAL BLOOD SMEAR AND STAINING

Name:
Date:

Instructions

1. Practice preparing a blood smear.
2. Demonstrate the procedure for preparation of a blood smear satisfactory for the instructor. All steps must be completed as listed on the instructor's Performance Check Sheet.
3. Complete a written examination successfully. .

Material and Equipments

- Gloves
- Hand disinfection
- Microscopic slides
- 95% ethyl alcohol
- Laboratory tissue
- Material for capillary puncture
- Puncture-proof container for sharp objects
- Blood sample (in DTA)
- Capillary tubes
- Slide rack
- Hot water
- Detergent
- Distilled water
- Methanol
- Staining rack
- Surface disinfectant
- Immersion oil
- Microscope
- Lab coat
- Stains
- Biohazard container

Procedure	S=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Assemble equipment and materials			
2. Prepare several clean slides A. Use pre-cleaned slides, or B. Clean slides with soap, rinse with hot water followed by distilled water, dip in 95% ethyl alcohol, and polish dry with clean lint-free cloth			
3. Place a clean slide on a flat surface (be sure to touch only the edges of the slide with fingers			
4. Wash hands with disinfectant and put on gloves			
5. Obtain an anticoagulated blood sample (provided by the instructor)			
6. Mix blood well and fill a plain capillary tube with blood			
7. Dispense a small drop of blood from the capillary tube onto the slide about one-half to three-fourths inch from the right end (if left-handed, reverse instructions)			

8. Place the edge of a clean, polished unchipped spreader slide in front of the drop of blood at a 30-35^0 angle. Spreader should be lightly balanced with fingertips			
9. Pull the spreader slide back into the drop of blood by sliding gently along the slide until the blood spreads along three-fourths of the width of the spreader			
10. Push the spreader slide forward with a quick steady motion (use other hand to keep slide from moving while spreader is pushed			
11. Examine the smear to see if it is satisfactory			
12. Repeat the procedure until two satisfactory smears are obtained			
13. Allow the smear to air dry quickly (slide may be waved gently to accelerate drying) and label the slide.			
14. Place the dried smear in absolute methanol for thirty to sixty seconds to preserve the smear			
15. Remove the slide from methanol and allow to air dry			
16. store for staining (stain with Wright / or Leishman stain)			
17. Leishman Stain: Flood the slide with Leishman's stain. And leave for I minute to fix. Add double the volume of water and stain the film for 7-10 minutes. Then wash it in a stream of buffered water until it has acquired a pinkish tinge (up to 2 minutes). After the back of the slide has been wiped clean, set it upright to dry.			
18. Place thoroughly-dried slide on microscope stage, stain side up			
19. focus with low power (10X) objective			
20. Scan slide to find area where cells are barely touching each other			
21. Place a drop of oil immersion on the slide			
22. Rotate oil immersion lens carefully into position			
23. Focus with fine adjustment knob only			
24. Observe color of the cells			
25. Remove slide from stage			
26. Wipe oil from slide gently and clean the lens with soft tissue and return other equipment to proper storage			
27. The smear is ready for interpretation			
Comments: Student/Instructor			

LESSON 6

RED BLOOD CELL MORPHOLOGY

RED BLOOD CELL MORPHOLOGY 6

OBJECTIVES

- List the RBCs that may normally be observed in a blood smear.
- Describe and draw Poikilocytosis and list the causes
- Describe and draw Anisocytosis (change in size) and list the causes
- Describe and draw change in color and list the causes
- List the red cell inclusion and mention the causes.

GLOSSARY

- **Anisocytosis**: Presence of red cells with increased variability (heterogenous in size) as measured by red cell distribution
- **Poikilocytosis**: Variation in shapes. It is helpful in the differentiation of anemias. Examples of poikilocytes characteristic of certain anemias include; Elliptical, sickle, fragmented, and spherical forms.
- **Anisochromia-** Variation of the color of erythrocytes due to unequal hemoglobin concentration
-

All of the cells in the peripheral blood have finite life spans and thus must be renewed continuously. The mechanisms responsible for regulating steady-state hematopoiesis and the capacity to modulate blood cell production in response to stresses such as anemia or infection consist of a series of progenitor cells in the bone marrow and a complex array of regulatory factors. It is the process of blood cell production, differentiation, and development. The hematopoietic system consists of the bone marrow, liver, spleen, lymphnodes, and thymus.
It starts as early as the 3rd week of gestation in the yolk sac. By the 2nd month, hematopoiesis is established in the liver and continuous through the 2nd trimester. During the 3rd trimester it shifts gradually to bone marrow cavities. During infancy: all marrow cavities are active in erythropoiesis “Red Marrow”. During childhood: erythropoiesis becomes gradually restricted to flat bones as; skull, vertebrae, sternum, ribs and pelvic bones, in addition to ends of long bones. The shafts of long bones become populated by fat “yellow marrow”.

Developmental and maturation of erythrocytes

Erythrocytes are rapidly maturing cells that undergo several mitotic divisions during the maturation process. The Pronormoblast" is the first identifiable cell of this line followed by the “Basophilic normoblast ", polychromatic normoblast ", orthochromatic normocyte” and reticulocyte stages in the bone marrow. Reticulocytes enter the circulating blood and fully mature into functioned erythrocytes.
Reticulocytes represent the first nonnucleated stage in erythrocytic development. Although the nucleus has been lost from the cell by this stage, as long as RNA is present, synthesis of both protein and heme continues. The ultimate catabolism of RNA, ribosome disintegration, and loss of mitochondria mark the transition from the reticulocyte stage to full maturation of the erythrocyte. If erythropoietin stimulation produces increased numbers of immature reticulocytes in the blood circulation, these Reticulocytes are referred to as stress or shift Reticulocytes. Supravital stains such as new methylene blue are used to perform quantitative determination of blood Reticulocytes.
Red number of RBCs per cubic millimeter gives an indirect estimate of the Hb content of the blood. Manual blood cell counting chamber (hematocytometer) methods give errors of 7%-14% or even more, depending on the experience of the technician. Automatic counting machines reduce this error to about 4%. However, many smaller laboratories do not have these machines. Reference values are 4.5-6.0 million/mm^3 (4.5-6.0 $X10^6$ /L) for men and 4.0-5.5 million/cu mm (4.0-5.5 X 10^6/L) for women.

Examination of Wright-stained peripheral blood smear gives a vast amount of information. It allows visual estimation of the amount of hemoglobin in the RBCs. In addition, alterations in size, shape, and structures of individual RBCs or WBCs are visible, which may have diagnostic significance in certain diseases. Pathologic early forms of the blood cells are also visible.

FIGURE 1: DEVELOPMENTAL CHARACTERISTICS OF ERYTHROCYTES

Pronormoblast
Size 12- 19 μm in diameter
N:C ratio 4:1
Nucleus Large, round nucleus
Chromatin has a fine pattern 0-2 nucleoli'
Cytoplasm: distinctive basophilic colour without granules

Basophilic Normoblast
Size 12- 17 μm in diameter
N:C ratio 4: 1
Nucleus:
Nuclear chromatin more clumped
Nucleoli usually not apparent
Cytoplasm: Distinctive basophilic colour



Polychromatic Normoblast
Size 11-15 μm in diameter
N:C ratio 1:1
Nucleus:
Increased clumping of the chromatin
Cytoplasm: Colour: Variable, with pink staining
Mixed with basophilia

Reticulocyte (Supravital stain)
Size 7-10 μm
Cell is anuclear polychromatic erythrocyte
Diffuse reticulum (Wright stain)
Cytoplasm: Overall blue appearance

Orthochromic Normoblast or nucleated RBC
Size: 8-12 μm
Nucleus:
Chromatin pattern is tightly condensed.
Cytoplasm:
Colour: reddish-pink (acidophilic)

Erythrocyte
Average diameter 6-8 μm



FIGURE 2: DEVELOPMENTAL SERIES OF ERYTHROCYTE

IDENTIFICATION OF CELLS

In identifying a cell, the technologist should think in the following terms:

1. What is the size of the cells?
    a. Small
    b. Medium
    c. Large
2. What are the characteristics of the nucleus?
3. What are the characteristics of the cytoplasm?

When attempting to identify cells, it is important to note the degree to which the cells take up the stain.

Shape: A normal RBC is a biconcave disc.

Size: The mean corpuscular diameter is 6.7 - 7.9 microns (average 7.2).

Other characteristics include an average thickness of 2.5μm, an average volume of 90 fL and an average surface area of 169 μm.

The variation from normal can be classified as:

1. Alteration in RBC distribution.
2. Variation in size- Anisocytosis
3. Variation in shape- Poikilocytosis
4. Alteration in color
5. Inclusions in the erythrocytes

1. ALTERATION IN RED BLOOD CELLS DISTRIBUTION

NORMAL DISTRIBUTION

An ideal normal blood film has an even distribution of erythrocytes in the thin portion adjacent to the feather end of the film. In this thin area red cells should be slightly separated from one another or barely touching without overlapping. The thin area should represent at least one third of the entire film.

Normal red cells should be circular with a smooth edge and a central pale area that gradually fades into reddish-pink cytoplasm.

In the thicker portions of the film, red cells may overlap or lie on top of one another, making them unsuitable for evaluation.



ABNORMAL DISTRIBUTION
ROULEAUX

Formation of rouleaux is reflected in the usual observation area by erythrocytes that are not separated from one another; they appear in short or long stacks (rouleaux) resembling coins or flat plates. The entire outline of each cell is not visible. Rouleaux are the arrangement of red cells with their biconcave surfaces in apposition.



Rouleaux are characteristic of hyerproteinemia and multiple myeloma because of an increased amount of plasma globulin. In macroglobulinemia, rouleaux formation is often pronounced and creates lengthy chains. The first clue to the presence of a paraprotein or protein abnormality is rouleaux along with an increased erythrocyte sedimentation rate.
When fibrinogen is significantly increased (e.g in infections tissue necrosis, or pregnancy) rouleaux forms long stacks.

AGGLUTINATION

Clumping of cells together in clusters. It is caused by the presence of surface immunoglobulin on erythrocytes and expression of surface adhesion molecules on leukocytes and platelets. Thus, the outline of each individual cell is not seen.



Autoagglutination occurs when an individual's red cells agglutinate in his or her own plasma or serum that contains no known specific agglutinins. A common form of autagglutination is seen in cold agglutinin disease. Here clumps of red cells may be noted on a blood film when the temperature is below 31^0C and particularly below 31^0C, which enhances autoantibody activity. Blood film preparation and red cell description are almost impossible without warming of the blood and glass slide prior to preparation

2. VARIATION IN SIZE- ANISOCYTOSIS

Automated complete blood counts usually include measurement of the mean corpuscular volume (MCV), which is important because this value indicates the average size of erythrocytes. Observation of red cell morphology on the blood film provides a quality control checks on the electronic MCV, as well as the other two red cell indices, mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC).

MACROCYTIC



Macrocytic are cells with a diameter of approximately 9 μm or larger, having a mean cell volume (MCV) of greater than 100 μm. Macrocytes may arrive in the peripheral circulation by several mechanisms. Three of the most distinct are (1) impaired deoxyribonucleic acid (DNA) synthesis leading to a decreased number of cellular divisions consequently a large cell
(megaloblastic erythropoiesis,
(2) Accelerated erythropoiesis yielding a reticulocytosis which in the Wright

stained smear is manifested as polychromatophilic macrocytes.
(3) increased membrane cholesterol and lecithin, although this mechanism may not be reflective of a true macrocytosis (obstructive liver disease.



Macrocytes canbe found in

- Deficiency of Vitamins B12 or Folate.
- Hypothyroidism
- Liver disease, alcohol,
- Smoking

Megaloblasts are extremely large (12 to 25 micron)

- Vitamin B12 deficiency
- Folate deficiency
- Drugs interfere with folate metabolism: Methotrexate, Cyclophosphamide, Nitrous oxide, Arsenic

MICROCYTES

A microcyte is a small having a diameter of less than 6.7μm and an MCV of less than 80μm. The RDW is high in the heterogenous microcytic population. Any defect that results in impaired hemoglobin synthesis causes a microcytic hypochromic blood picture.



Only three clinical conditions produce a microcytosis: iron-deficiency anemia, thalassemia syndrome, and anemia of chronic disease. A significant number of microcytes may be seen in patients with lead poisoning and iron-loading anemias. However the number of microcytes in these conditions is not in large enough numbers to cause microcytic blood indices.

3. VARIATION IN SHAPE- POIKILOCYTOSIS

Normal erythrocyte shows little or no shape variation. Variation only on the edges of films primarily is an artifact of preparation. Recognition of various shapes or poikilocytes on the film is helpful in the differentiation of anemias. Examples of poikilocytes characteristic of certain anemias include elliptical, sickled, fragmented, and spherical forms.

TARGET CELLS "CODOCYTES"

Target cells appear in the peripheral blood as a result of increase in RBC surface membrane. Their true circulating form is a bell-shaped cell. In air dried smears, however, they appear as "targets," with a large portion of hemoglobin displayed at the rim of the cell and another portion of hemoglobin shown as central, eccentric, or banded. Target cells are always hypochromic.
The mechanism of targeting is related to excess membrane cholesterol and phospholipids and decreased cellular hemoglobin. This is well documented in patients with liver disease, whose cholesterol-to phospholipids ratio is altered. As cholesterol accumulates in the plasma, as is the case with liver dysfunction, the RBC membrane is expanded by increased lipid, resulting in increased surface area. Consequently, the osmotic fragility is also decreased.

The presence of target cells is a common clinical finding in any of the conditions in which hemoglobin synthesis is abnormal: sickle cell anemia, and homozygous and heterozygous hemoglobin C disease. Target cells may also be observed in patients with iron deficiency or liver disease, and following splenectomy



SPHEROCYTES

Spherocytes have several distinctive properties and, in contrast to the target cell, they have the lowest surface area- to volume ratio. They are smaller in diameter than normal red cells, and their hemoglobin content is relatively concentrated. Because these cells have no visible central pallor, they are easily distinguished in a peripheral blood smear.
There are several mechanisms for the production of spherocytes, each sharing the mutual defect of loss of membrane. In the normal aging process of Rubs, spherocytes are produced as a final stage before senescent RBCs are detained in the spleen and trapped by the reticuloendothelial system (RES).

Erythrocyte from patients with hereditary spherocytosis has a mean influx of sodium twice that of normal cells. It is thought that this increased permeability to sodium results from some sort of membrane lesion.



Because spherocytes have 35 times the ability of normal cell to metabolize glucose, these cells can handle their increased sodium content as they travel through plasma, by producing enough energy to pump sodium from the cell.

Spherocytes may be seen in immune hemolytic anemias, in the hemoglobinopathies, in hereditary spherocytosis, and in severe burns, physical RBC injury and toxins. They may also be observed in any of the splenic states-hypersplenism or postsplenectomy

OVALOCYTES AND ELLIPTOCYTES

The ovalocyte is a cell of many capabilities. It can appear normochromic or hypochromic; normocytic or macrocytic. Its exact physiologic mechanism is not well defined. When ovalocytes are incubated in vitro, they reduce adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG) more rapidly than do normal cells.

Ovalocytes are egg-shaped and have a greater tendency to vary in their hemoglobin content. Elliptocytes, on the other hand, are pencil-shaped and invariably not hypochromic



Ovalocytes may be found in patients with megaloblastic anemias, and in this condition they appear as oval macrocytes. They may be seen in patients with sickle-cell anemia, myelodysplasia, and thalassemia major, as well as following postsplenectomy. Elliptocytes are seen in those patients with hereditary elliptocytosis, iron deficiency anemia, and myelofibrosis.

ECHINOCYTES AND BURR CELLS

Echinocytes have evenly distributed uniform-size blunt spicules or bumps on their surfaces. Echinocytes or crenated red cells may be seen on films made from anticoagulated blood that is several hours old, but such cells are artifacts not normally present in vivo.

Bessis states that crenation is caused by release of basic substances from glass slides that change the pH and transform the cells into echinocytes.

In anemia associated with renal insufficiency, some red cells acquire a membrane abnormality with irregularly sized and unevenly spaced spicules. Such red cell celled *burr cell*

Crenated cells may be minimal and not always recognizable. Crenated cells with uniform blunt spicules represent an artifact that is evident in particularly every cell in the thin portion of the film and should not be reported.

Crenated erythrocyte (Echinocytes) may be produced in

- Blood smear which dries slowly
- They are often found in various portions of the blood smear

The number of *burr* cells often increases as blood urea nitrogen (BUN) increases. This membrane alteration is probably related to plasma chemical abnormalities The spicules of burr cells are usually reversible. As the cells can be induced to revert to normal shape.

Burr cells are increased in:

- Anemia
- Bleeding gastric ulcers
- Gastric carcinoma
- Peptic ulcer
- Renal insufficiency, uremia
- Pyruvate kinase insufficiency





ACANTHOCYTES

Acanthocytes (thorn or spike) are small, densely stained red cells that are no longer disc shaped and have a few irregularly spaced, pointed spicules or thornlike projections of various lengths and widths over their surfaces.

Acanthocytes have observed in:



- Liver cirrhosis
- Hepatic hemangioma
- Neonatal hepatitis
- Postsplenectomy
- Retinitis pigmentosa
- Alcoholic cirrhosis with hemolysis
- Pyruvate kinase deficiency
- Lipid metabolism disorder Abetaliporoteinemia

STOMATOCYES

The stomatocyte is a normal-sized red cell that, in wet preparation, appears bowl-shaped. This peculiar shape is manifested in air dried smears as a slitlike area of central pallor. The exact physiologic mechanism of stomatocytosis in vivo has yet to be clarified. Many chemical agents may induce stomatocytosis in vitro (phenothiazine and chloropromazine), but these changes are reversible. Stomatocytes are more often artifactual than a true manifestation of a particular pathophysiologic process.

The artifactual stomatocyte will have a distinct slitlike area of central pallor in the genuine stomatocyte will appear shaded.



stomatocytes may be found in patients with:

- Acute alcoholism
- Alcoholic cirrhosis
- Hereditary sepherocytosis
- Infection mononucleosis
- Lead poisoning
- Malignancies

POIKILOCYTES SECONDARY TO TRAUMA

Ertythrocytes may fragment and lyse when subjected to excessive physical trauma in the cardiovascular system. Intravascular hemolysis and shortened red cell survival may result from severe trauma. The hallmark of hemolytic anemia secondary to red cell fragmentation is the schistocyte, which takes several forms. Two mechanisms for fragmentation are recognized. First, alteration of normal fluid circulation occurs, which may predispose to fragmentation. Examples of this include viscidities, malignant hypertension, thrombotic thrombocytopenic purpura, and heart valve replacement.

Second, intrinsic defects of the RBC make it less deformable and therefore more likely to be fragmented as it traverses the microvasculature of the spleen.

Spherocytes, antibody-altered red cells, and red cells containing inclusions have significant alterations that decrease their RBC survival; these severe as examples of the second mechanism

Helmet cells are recognized by their distinctive projections- usually two – surrounding an empty area of the RBC membrane that looks as if it has been bitten off. In hematologic conditions in which large inclusion bodies (Heinz bodies) are formed, helmet cells are visible in the peripheral blood smear. Fragmentation occurs by the pitting mechanism of the spleen. Helmet cells may also be seen in pulmonary emboli, myeloid metaplasia, and disseminating intravascular coagulation (DIC)

Schistocytes represent the extreme form of RBC fragmentation. Whole pieces of RBC membrane seem to be missing, and very bizarre RBCs are apparent. Schistocytes may be seen in patients with microangiopathic hemolytic anemia, DIC, heart valve surgery, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, severe burns, and Zeive's syndrome.



TEARDROPS "DACROCYTES"

Dacrocytes have been so labeled because of their shape. They may also be pear shaped with a blunt pointed projection and may be normal size, small, or large. If a red cell contains a rigid inclusion cannot pass through small openings of splenic sinuses and thus remains behind. As the red cell squeezes through the small opening, it is stretched beyond its ability to regain its original shape. Thus, a tear drop or pear shape is created.

Teardrop cells typically are observed in myelofibrosis with myeloid metaplasia because of the large size of the spleen. Other conditions with dacrocytes include myelophthistic anemia, pernicious anemia, β-thalassemia, drug-induced Heinz body formation, tuberculosis, and tumor metastasized to the marrow.



POIKILOCYTOSIS SECONDARY TO ABNORMAL HEMOGLOBIN CONTENT

Poikilocytes can be diagnostic of a chronic hereditary hemolytic anemia. Three types of poikilocytes are characteristic of three abnormal hemoglobins: drepanocytes (from Hb S), Hb CC crystals, and Hb SC crystals.

DREPANOCYTES (SICKLE CELLS)

Sickle cells are red cells that have been transformed by hemoglobin polymerization into rigid, inflexible cells with at least one pointed projection. These patients may be homozygous or heterozygous for the presence of the abnormal hemoglobin known as hemoglobin S. Conditions of low oxygen tension cause the abnormal hemoglobin to polymerize, forming tubules that line up in bundles to deform the cell. The surface area of the transformed cell is much greater, and the normal elasticity of the cell is severely restricted. Most sickle cells posses the ability to revert to discocyte shape when oxygenated, but approximately 10% of these cells are incapable of reverting to their normal shape. These irreversibly sickled cells (ISC) are the result of repeated sickling episodes. In the peripheral blood smear, they appear as crescent – shaped cells with long projections. When reoxygenated, ISCs may undergo fragmentation.



Blood smear of patient with sickle cell anemia.

Classically sickle cells are best seen in wet preparations. Many of the cells observed in the Wright Giemsa stain are oat cells, or the boat-shaped form of the sickle cell.Sickle cells are naturally seen in patients homozygous for hemoglobin S and are rarely seen in the heterozygous states. Several other hemoglobinopathies may exhibit sickling (for example, hemoglobin C Harlem and hemoglobin I). Hemoglobin O Arab does not sickle, but it facilitates the sickling process and therefore increases the severity of the S heterozygous state.



Sickling test of patient with sickle cell anemia

4. RED CELL INCLUSIONS

HOWELL-JOLLY BODIES

Howell-Jolly bodies are nuclear remnants containing DNA. They are 1 to 2 μm in size and may appear singly or doubly in an eccentric position on the periphery of the cell membrane. They are thought to develop in periods of accelerated or abnormal erythropoiesis. A fragment of chromosome becomes detached and is left floating in the cytoplasm after the nucleus has been extruded

Howell-jolly bodies may be seen following splenectomy and in thalassemic syndromes, hemolytic anemias, megaloblastic anemias, and functional hyposplenia



BASOPHILIC STIPPLING

Red cells that contain ribosomes can potentially form stippled cells; however, it is believed that the actual stippling is the result of the drying of cells in preparation for microscope examination. Coarse, diffuse, or punctuate basophilic stippling may occur and consist of ribonucleoprotein and mitochondrial remnants. Diffuse basophilic stippling appears as a fine blue dusting, whereas coarse stippling is much more outlined and easily distinguished.

Punctate basophilic stippling is a coalescing of smaller forms and is very prominent and easily identifiable. Stippling may be found in any condition showing defective or accelerated heme synthesis, in lead intoxication, and in thalassemia syndrome.



SIDEROBLASTIC GRANULES
PAPPENHEIMER BODIES

Sideroblastic granules are small, irregular inclusions seen along the periphery of RBCs. They usually appear in clusters, as if they have been gently placed upon the red cell membrane. Their presence is presumptive evidence for the presence of iron. However, the Prussian blue stain is the confirmatory test for determining the presence of these inclusions.



These granules in red blood cells consist of nonheme iron caused by an excess of available iron throughout the body. They are designated “pappenheimer bodies” when seen in a Wright-stained smear and “siderotic granules” when seen in Prussian blue stain. Siderotic granules are found in siderblastic anemias and in any condition leading to hemochromatosis. They may also be seen in the hemoglobinopathies, such as sickle-cell anemia and thalassemia, as well as following splenectomy and hyposplenemia

CABOT’S RINGS

The exact physiologic mechanism in Cabot’s ring formation has yet to be elucidated. It is known that they appear in a “figure-eight” confirmation like the beads of a necklace.



They are not composed of DNA but do contain arginine-rich histone and nonhemoglobin iron.
Cabot’s rings are rare morphologically but may be found in megaloblastic anemias, in homozygous thalassemia syndromes, and following splenectomy

5. ALTERATION IN ERYTHROCYTE COLOUR: ANISOCHROMIA

HYPOCHROMIA



With decreasing Hb concentration, there is increased central pallor and the cells are then described as hypochromic. Hypochromia is caused by impaired Hb synthesis and ranges from slight pallor to marked pallor, in which there may be only a thin rim of Hb. The changes in Hb content in severe iron deficiency anemia are evident in the MCH and MCHC. Hypochromia is associated most often with microcytosis. Example of hypochromic, microcytic anemias include iron deficiency anemia, thalassemia, and sideroblastic anemia. Hypochromia is sometimes associated with normocytic (normal-size) red cells in disorders such as rheumatoid arthritis, chronic infection, or inflammation. These conditions result from defective macrophage iron release, which prevents iron from reaching the normoblasts for proper red cell maturation.

Polychromatophilia is used if a nonnucleated erythrocyte has a faintly blue orange color when stained with Wright stain. This cell blue colour is due to diffusely distributed residual RNA in the cytoplasm. The polychromatophilic erythrocyte is larger than a mature erythrocyte. If stained with a supravital stain, a polychromatophilic erythrocyte would appear to have a threadlike netting within it and would be called a reticulocyte.



Three types of RBC inclusions can not be seen with Wright's or Giemsa stain. All three require supravital staining techniques or other special procedures.

Reticulocyte is the stage in RBC maturation just before full maturity. Their number serves as an index of bone marrow RBC production.

Hemogglobin H inclusions can some times be seen on a reticulocyte preparation as uniformly distributed small round dots somewhat resembling basophilc stippling but of slightly differing sizes. If a reticulocyte is affected, the HbH inclusions coexist with the more irregular and more linear reticulum structures.

Heinz bodies also require a special staining procedure and may need RBC pretreatment with a strong oxidizing agent such as phenylhydrazine.

TABLE 1 RED BLOOD CELL MORPHOLOGY GRADING CHART

Morphology	Grade As
Polychromatophilia Tear drop RBC Acanthocytes Schistocytes Spherocytes	1+ = 1 to 5/field 2+ = 6 to 10/field 3+ = > 10/field
Poikilocytosis Ovalocytes Elliptocytes Burr cells Bizarr-shaped RBC Target cells Stomatocytes	1+ = 3 to 10/field 2+ = 11 to 20/field 3+ = > 20/field
Rouleaux	1+ = aggregate of 3 to 4 RBCs 2+ = aggregate of 5 to 10 RBCs 3+ = Numerrous aggregates with only a few free RBCs
Sickle Cells Basophilic stippling Pappenheimer bodies Howell-Jolly bodies	Grade as positive only

STUDENT PERFORMANCE GUIDE

RBCs MORPHOLOGY

Name:
Date:

Instructions

1. Practice identifying erythrocytes from a stained blood smear.
2. Identifying erythrocytes morphology changes in distribution, shape, size inclusions and change in color.
4. Complete a written examination successfully. .

Material and Equipments

- Stained blood smear
- Microscope
- Lens paper
- Oil immersion
- Soft laboratory tissue
- Drawings and descriptions of stained blood smear

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant			
2. Assemble equipment and material			
3. Place stained smear on microscope stage and secure it with clips			
4. Bring cells into focus using low power (10x)			
5. Scan slide to find area of slide where cells are barely touching each other			
6. Place one drop of immersion oil on slide			
7. Rotate oil immersion objective carefully into position			
8. Focus with fine adjustment knob until cells can be seen clearly			
9. Raise the condenser and open the diaphragm to allow maximum light into objective			
10. Scan slide to observe RBCs changes in color, size, shape, distribution and inclusions.			
11. Report what you see			
12. Rotate low power objective into position			
13. Remove slide from the microscope stage			
14. Clean oil objective thoroughly			
15. Clean oil from slide gently			
Comments			

Date:----------Instructor----------



LESSON 7-8

WHITE BLOOD CELL COUNT AND DIFFERENTIAL

WHITE BLOOD CELL COUNT AND DIFFERENTIAL

7-8

OBJECTIVES

- List the normal white cell count for adults, children and newborn infants
- Name a condition that causes Leukocytosis and one that causes leukopenia
- Perform a manual white cell count
- Calculate the results of a white blood cell count
- List the precautions to observe when performing a white blood cell count
- List the white cell diluting fluids and state the function of each.
- List and draw the different types of white cells

GLOSSARY

- **Leukocytosis**: increase above normal in the number of leukocytes in the blood
- **Leukopenia**: Decrease below normal in the number of leukocytes in the blood
- **Granulocytes** - These are leukocytes which have specific granules. The three different types of granulocytes have different types of specific granules. Granulocytes are spherical in shape, contain nuclei and include neutrophils, eosinophils, and basophils. These cells are part of the formed elements of whole blood.

INTRODUCTION

The myeloblast is the first identifiable cell in the granulocytic series. Myeloblast constitutes approximately 1% of the total nucleated bone marrow cells. This stage lasts about 15 hours. The next stage, the promyelocyte, constitutes approximately 3% of the nucleated bone marrow; this stage lasts about 24 hours. The myelocyte is the next maturational stage, with approximately 12% of the proliferative cells existing in this stage. The stage from myelocyte to metamyelocyte lasts an average 4.3 days. The time required for the division and maturation of a myeloblast to a mature granulocyte is 5-12 days.

Two stages of granulocytes are observed in the circulating blood: the band form of neutrophils, eosinophils and basophils and in end stage of maturation.

The normal number of neutrophilic granulocytes in the peripheral blood is about 2500-7500/μl. Neutrophilic granulocytes have a dense nucleus split into two to five lobes and a pale cytoplasm. The cytoplasm contains numerous pink blue or gray blue granules. Two types of granules can be distinguished morphologically; primary or azurophilic granules which appear at the promyelocyte stage and secondary granules, which appear later. The primary granules contain myeloperoxidase, and acid hydrolase, whereas lyszymes, lactoferrin, and collagenase are found in the secondary granules.

It has been estimated that $1.5X10^9$ granulocytes/kg are produced daily in the healthy organism. Most of these cells stay at various stages of maturation in the bone marrow from where they can be mobilized in case of lymphopoietic stress. Following their release from the bone marrow, granulocytes circulate for no longer than 12 h in the blood. About half of the granulocytes present in the blood stream are found in the circulating pool, whereas the other half is kept in a marginated pool attached to blood vessel walls. After granulocytes move from the circulation into tissues, they survive for about 5 days before they die while fighting infection or as a result of senescence.

The major function of granulocytes (neutrophils) is the uptake and killing of bacterial pathogens. The first step involves the process of chemotaxis by which the granulocyte is attracted to the pathogen. Chemotaxis is initiated by chemotactic factors released from damaged tissues or complement components. The next step is phagocytosis or the actual ingestion of the bacteria, fungi, or other particles by the granulocyte. The recognition and uptake of a foreign particle is made easier if the particle is opsonized. This is done by coating them with antibody or complement. The coated particles then bind to Fc or C3b receptors on the granulocytes. Opsonization is also involved in the phagocytosis of bacteria or other pathogens by monocytes. During phagocytosis a vesicle is formed in the phagocytic cell into which enzymes are released. These enzymes, including collagenase, amino peptidase, and lysozyme, derive from the secondary granules of the granulocyte.

The final step in the phagocytic process is the killing and digestion of the pathogen. This is achieved by both oxygen dependent and independent pathways. In the oxygen-dependent reactions, superoxide, hydrogen peroxide, and OH radicals are generated from oxygen and NADPH. The reactive oxygen species are toxic not

only to the bacteria but also to surrounding tissue causing the damage observed during infections and inflammation.

Eosinophil: Eosinophils, phagocytic cells arising from the bone marrow, are segmented granulocytes that circulate in such small numbers that their function is not fully understood. Eosinophils are closely associated with allergic conditions, although their exact role in the etiology and manifestation of allergic reaction is unclear.

Eosinophils make up 1-4% of the peripheral blood leukocytes, are similar to neutrophil but with some what more intensely stained reddish granules. In absolute terms, eosinophils number upto 400/μl. Eosinophil cells can first be recognised at the myelocyte stage.

Basophils: Basophils are seen less frequently than eosinophils; under normal conditions, less than 100/μl are found in the peripheral blood. Basophils have receptors for immunoglobulin E (IgE) and in the cytoplasm; characteristic dark granules overlie the nucleus. Degranulation of Basophils results from the binding of IgE and allergic or anaphylactic reactions are associated with release of histamine (activate role of allergy), heparin and hydroxytryptamine, which causes these cells to be closely associated with fibrinolysis, prevention of stasis and coagulation, and lipid metabolism

A monocyte is influenced by hematopoietic growth factors to transform into a macrophage in the tissue. Functionally, monocytes and macrophages have phagocytosis their major role, although they also have regulatory and secretory functions.

In contrast to the granulocytic leukocytes, the promonocytic will undergo two or three mitotic divisions in approximately 2 to 2.5 days. Monocytes are released into the circulating blood within 12 to 24 hours after precursors have their last mitotic division.

Histiocytes are the terminally differentiated cells of the monocyte macrophage system and are widely distributed throughout all tissues. Langerhans' cells are macrophages present in epidermis, spleen, thymus, bone, lymph nodes and mucosal surfaces. Langerhans' cell histiocytosis is a single organ/system or multisystem disease occurring principally in childhood.

Malignant histiocyte disorders include monocytic variants of leukemia and some types of Non-Hodgkin's lymphoma.

Lymphocytes: Hematopoietic growth factors play an important role in differentiation into the pathway of the pre-B cell or prothymocyte. The majority of cells differentiate into T lymphocyte or B-lymphocytes. The plasma cell is the fully differentiated B cell.

The stages of lymphocyte development are the lymphoblast, the prolymphocyte, and the mature lymphocyte. Mature lymphocytes can be classified as either large or small types.

Lymphocytosis occurs in viral infection, some bacterial infections (e.g pertusis) and in lymphoid neoplasia.

Lymphopenia occurs in viral infection (e.g HIV), lymphoma, connective tissue disease, and severe bone marrow failure.

Platelets: Two classes of progenitors have been identified: The BFU-M and The CFU-M. The BFU-M is the most primitive progenitor cells committed to Megakaryocyte lineage.

The next stage of Megakaryocyte development is a small, mononuclear marrow cell that expresses platelet specific phenotype markers.

The final stage of Megakaryocyte development is recognised in bone marrow, because of their large size and lobulated nuclei. These stages are polypoid.

Megakaryocyte is largest bone marrow cells, ranging up to 160um in size. The N: C ratio is 1:12. Nucleoli are no longer visible. A distinctive feature of the Megakaryocyte is that it is a multilobular, not multinucleated. The fully mature lobes of the Megakaryocyte shed platelets from the cytoplasm on completion of maturation.

FIGURE 3: WHITE BLOOD CELLS

TABLE 1: CHARACTERISTICS OF NEUTROPHILIC GRANULOCYTES

	MYELOBLAST	PROMYELOCYTE	MYELOCYTE	METAMYELOCYTE	BAND	SEGMENTED
Size (μm)	10 – 18	14 – 20	12 – 18	10 - 18	10 -16	10 16
N:C ratio	4:1	3:1	2:1	1:1	1:1	1:1
Nucleus Shape	Oval/round	Oval/round	Oval/round	Intended	Enlarged	Distinct lobes 2-5
Nucleoli	1-5	1-5	Variable	None	None	None
Cytoplasm Inclusion:	Auer rods	None	None	None	None	None
Granules	None	Heavy	Fine	Fine	Fine	Fine
Amount	Scanty	Slightly increased	Moderate	Moderate	Abundant	Abundant
Colour	Medium blue	Moderate blue	Blue-pink	Pink	Pink	Pink



FIGURE 4: MATURE LEUKOCYTES: (A) NEUTROPHIL, (B) EOSINOPHIL. (C) BASOPHIL, (D) MONOCYTE AND (E) LYMPHOCYTE

TABLE 2. CHARACTERISTICS OF MONOCYTES

	Monoblast	Promonocyte	Mature monocyte
Size (μm)	12-20	12-20	12-18
N:C ratio	4:1	3:1-2:1	2:1-1:1
Nucleus shape	Oval/folded	Elongated/folded	Horseshoe
Nucleus	1-2 or more	0-2	None
Chromatin	Fine	Lace-like	Lace-like
Cytoplasm	Vacuoles	Vacuoles	Vacuoles
Inclusion	Variable	Variable	Common
Granules	None	None or fine	Fine dispersed
Amount	Moderate	Abundant	Abundant
Colour	Blue	Blue-grey	Blue-grey

LEUKOCYTE COUNT

The white blood cell count (WBC) is a determination of the number of circulating leukocytes present in 1 μl or 1 ml^3 of whole blood. White blood cells are produced in the bone marrow and lymphatic tissues and enter the blood for transportation to the extravascular location where they function. Leukocytes have the blood when they reach their destination and enter body tissues to help defend against invading microorganisms through phsgocytosis and antibody formation.
Laboratory determination of the total WBC count, accompanied by a different count of cell distribution and morphology, is a vital aid to the diagnosis and evaluation of many pathologic disorders. The leukocyte count may be performed accurately by manual techniques, although most clinical laboratories currently use electronic cell counters to speed testing time.

TECHNIQUE

Reagent and Equipment

1. Pipettes, one of the following:
a. WBC Unopette (1:20 dilution) is recommended because of ease of use and technologist safety.
b. 20 μl pipette (also 10 * 75 mm test tubes with caps, and plain microhematocrit tube if this pipet (is used).
c. Thoma white count pipette (also used)

2. White count diluting fluid. Any one of the following diluting fluids may be used:
a. Acetic acid, 2% v/v, in distilled water.
b. Hydrochloric acid, 1% v/v, in distilled water
c. Turk's distilling fluid

Glacial acetic acid	3 ml
Aqueous gentian violet 1%W/v	1 ml
Distilled water	100 ml

Note: If the WBC Unopette is used, diluting fluid is unnecessary since it is contained in the Unopette

3. Microscope
4. Clean gauze or kimwipes
5. Improved Neubauer hemocytometer (counting chamber) with cover glass.

a. The hemocytometer with Neubauer ruling consist of two identically ruled platforms with a raised ridge on both sides of the two platforms on which a cover glass is placed. The space between the top of the platform and the cover glass over it is 0.1 mm



b. Each of the two platforms contains a ruled area composed of nine large squares of equal size. Each large square is 1 mm wide and 1 mm long. Therefore, the entire ruled area is 9 square mm (mm^3) 3 mm wide and 3 mm long.

c.The volume of the entire ruled area on one platform is 0.9 μl (width * length * depth, or, 3 mm *3mm *0.1 mm).
The volume of one large square is o.1 μl.

d.The four large corner squares, each of which is subdivided into 16 smaller squares, are labelled " W" and are the four squares used for counting white blood cells.

All hemocytometers used in the clinical laboratory must meet the specifications of the National Bureau of Standard (NBS) and are identified by those initials.

Specimen

Whole blood, using EDTA as the anticoagulant. Capillary blood may also be used.
Whole blood is mixed with a weak acid solution to dilute the blood and hemlyze the red blood cells.

1. **DILUTION OF BLOOD**. Mix the specimen of whole blood for approximately 1 minute. Proceed with testing according to the blood dilution method used. Prepare duplicate dilutions on each specimen to be tested.
a. WBC Unopette. Follow the procedure outlined in the Unopette section.
b. 20 μl pipette (1:20 dilution).

1. Place exactly 0.4 ml of diluting fluid into a 10*75 mm test tube. Remove exactly 0.02 ml (20μl) of diluting fluid from the tube so that 0.38 ml remains.

2. Add 0.02 ml of well-mixed whole blood to the tube. Cap tube and mix.

3. A 1:21 dilution of blood may be used by adding 0.02 ml whole blood to 0.4 ml diluting fluid

2. CLEAN THE COUNTING CHAMBER AND COVER GLASS with a lint free cloth. The use of 95% (v/v) ethanol also facilitates the cleaning process. Carefully place the cover glass on top of the ruled area of the counting chamber.

3. MIX THE DILUTED WHITE BLOOD CELL COUNTS.

I. If the WBC Unopette is used, follow the instructions outlined in that section for mixing the Unopette dilution.
II. If 0.02 ml of blood was diluted in a test tube, cap the tube and mix well for 2 minutes.
III. Mix the Thoma pipet for approximately 3 minutes to ensure hemolysis of the red blood cells and adequate mixing. This may be done with a mechanical shaker or mix by hand: place the thumb over the tip of the pipet and the middle finger over the other end of the pipet.

4. FILL THE COUNTING CHAMBER.

a. If the WBC Unopette is used, refer to the corresponding section of the Unopette procedure and proceed as outlined below.

1. Place the tip of the pipet on the edge of the ruled area of the counting chamber.

Allow the mixture to seep under the cover glass gradually and exactly fill this area. Care should be taken not to move the cover glass.

2. Fill the opposite side of the counting chamber with the second white count dilution.

3. When the counting chamber is filled, care should be taken that it is not jarred or the cover glass moved. The filled counting chamber should be allowed to stand for approximately 1 minute prior to performing the count to give the white blood cells time to settle.

b. If the 0.02 ml pipet was used and the diluted blood is in a test tube:

1. Half-fill a plain microhematocrit tube with the well-mixed dilution.

2. Hold the microhematocrit in a vertical position with the index finger covering the top of the microhematocrit tube.

3. Remove any excess liquid from the outside of the hematocrit tube with a piece of gauze

4. Use the index finger to control the rate of flow. Follow the procedure as described above, steps 4 a 1, 2, 3

5. COUNT THE WHITE BLOOD CELLS

a. Carefully, keeping the counting chamber horizontal at all times, place the hemocytometer on the stage of the microscope.
b. Using the low power (10*) objective, make certain the microscope light is adjusted correctly. In proper focus, the white blood cells should look like small dark or black dots.
c. Scan the four large corners squares marked 'W'. For accurate white counts, there should be an even distribution of cells in all four large squares, with no more than a ten-cell variation between the four squares.
d. Beginning with the upper left square, count all white blood cells in the four large corner squares and add the results together to obtain the total number of cells. In counting the cells that touch the outside lines of the large square, count only those that those that touch the left square (or right) and upper (or lower) outside lines (in counting chamber with double lines), disregarding those that touch the right (or left) and lower (or upper) outside margin. If the chamber has triple lines, count those cells that touch the midline of the three outside lines on two sides and disregard those touching the corresponding lines on the other two sides. (That is, count the cell touching either the right margin or the left margin and the cells on the upper margin or lower margin. It is irrelevant which sides are chosen, but it is important to be consistent and count the cells touching the same two lines every time.)
e. Count the cells on the opposite side of the counting chamber and record the number of cells counted in these four large squares. The total number of the cell counted on each side of the counting chamber should agree within 10% of each other. If the counts do not agree the procedure should be repeated.

6. Calculation of the WBC

a. For each of the two white counts performed, calculate the number of WBCs/μl, as shown below:

Number of white blood cells counted	X	Correction for volume	X	Correction for dilution

Number of white blood cells counted. Add the total number of WBC counted in chamber. For example table 3:

Square 1	25 white cells	25
Square 2	34 white cells	34
Square 3	32 white cells	32
Square 4	31 white cells	31
	Number of cells counted	122

Correction for volume. Obtain the WBC as the number of white blood cells in 1 μl of blood. Therefore, if the cells are counted in four large squares, the total

volume counted is 4 (1.0*1.0 *0.1) μl, or 0.4 μl. to obtain a volume of 1.0 μl, 0.4 is multiplied by 2.5 (1.0÷0.4). The correction factor for volume is then 2.5.

Correction for dilution. Since the blood was initially diluted 1:20, the correction factor for dilution is 20 (21 if using a 1:21 dilution).

b. Therefore:

WBC/μl= 122X2.5X20= 6,100 WBC/μl

c. WBC = $6{,}100X10^6 = 6.1X10^9$/L

d. Calculate the WBC for the second white count and average the two numbers for the final result.

SPECIAL CONDITIONS:

1. In certain conditions, such as leukemia, the WBC may be extremely high. If the white count is above $30.0X10^9$/L, it is advisable to employ a larger dilution of blood.
2. Whenever the WBC drops below $3.0X10^9$/L, a smaller dilution of the blood should be used to achieve a more accurate count. In this situation, the blood may be diluted 1:11 (0.02 ml whole blood + 0.2 ml diluting fluid) or drawn up to the 1.0 mark in a Thoma white cell pipet and diluted to the 11 mark with the white count diluting fluid for a dilution of 1:10. The white count then proceeds as previously outlined, with the appropriate correction factor used for the dilution.
3. It is important that the diluting fluid remain free from contamination. Often, small amounts of blood collect in the diluting fluid, causing inaccuracies and difficulties in distinguishing and counting the white blood cells.
4. It is imperative that the counting chamber and cover glass be free from dirt and lint. Again, contamination may cause inaccuracies and difficulties in counting white blood cells (The counting chamber and cover glass should be cleaned off immediately after completion of the count).
5. Pipet must be free of dirt and dried blood. Never leave undiluted blood in a Thoma pipet. It quickly hardens and plugs up the pipet Draw water or diluting fluid into the pipet and place it in a container of 10% aqueous water solution.
6. There is an approximate 15% error for a manual WBC that falls within the normal range. It is advisable to count at least 100 WBC on each side of the counting chamber. Generally, the more cells counted, the lower the percentage of error.
7. The diluting fluids used for the white blood cell count destroy or hemolyze all non-nucleated red blood cells. In certain disease states, nucleated red blood cells (NRBC) are present in the peripheral blood. These cells, because they contain a nucleus, cannot be distinguished from the white blood cells. Therefore, any time there are five or more nucleated red blood cells per 100 white blood cells in a differential, the white blood cell should be corrected as follows:

$$\text{Corrected WBC} = \frac{\text{Uncorrected WBC}}{100 + \#\text{ of NRBC/100 WBC}} \times 100$$

The white count is then reported as the corrected WBC.

8. Once the hemocytometer is filled, the counting of cells must proceed without delay. If too much time elapsed, the fluid in the chamber begins to evaporate, causing inaccuracies in the count.

CLINICAL SIGNIFICANCE

Significance changes in the number and distribution of white cells in the peripheral blood are extremely valuable indicators of the presence and cause of disease. Any rise above normal leukocyte values results from stimulation of the bone marrow by bacteria or invading organisms, whereas decreased WBC levels follow bone marrow depression due to viruses or toxic chemicals. Minor variations from normal values are not significant when accompanied by normal differential smears, although this does not rule out some early infections or myeloproliferative disorders.

Pathologic leukocyte values can be defined only after assessing the effect of physiologic factors such as age, stress, exercise, and other deviations from basal conditions. Physiologic factors including bathing, eating, and physical or emotional activity may cause slightly increased leukocyte counts, but the level of maximum elevation usually does not exceed twice the normal minimum level.

Physiologic leukocyte elevations generally subside to normal levels within several hours; therefore WBC counts should be repeated under more relaxed circumstances if the elevation is of doubtful significance. Leukocyte value for men and women are equally affected by a diurnal rhythm that increases WBC levels as much as 2000/μl between morning and evening, independent of food intake.

NORMAL VALUES

Leukocyte values less than 20,000 are considered slightly elevated, levels of 30,000 are considered moderately elevated, and those of 50,000 and over are considered greatly elevated. WBC counts less than 3000 are considered mildly decreased, levels between 1500 and 3000 are considered moderately depressed, and those under 1500 are considered severely depressed. The normal range for the leukocyte count is as follows;

TABLE 4:SOME NORMAL HEMATOLOGICAL VALUES ACCORDING TO AGE

Age	RBC/ million	WBC/1000/μl
Cord blood	5+-1	18+-8
3 months	4+- 0,8	12+-6
6 months	4.8 +-0,7	
7 Y-12Years	4.7 +-0.7	9+-4.5
Adult Male	5.5+- 1	7+-3.5
Adult –Female	4.8+-1	7.5+-3.5

TABLE 5: CAUSES OF LEUKOCYTOSIS AND LEUKOPENIA

Elevation leukocyte count (Leukocytosis) may occur in ***physiologic conditions*** such as the following:	Decreased leukocyte count (leukopenia) occur with the following:
✓ Adrenaline injections ✓ Anesthesia, Anorexia ✓ Anoxia ✓ Convulsive seizures ✓ Emotional stress (pain, anger) ✓ Exposure to cold ✓ Following trauma or hemorrhage ✓ Menstruation ✓ Paroxysmal tachycardia ✓ Pregnancy and childbirth ✓ Strenuous exercise or work ✓ Ultraviolet irradiation or sunlight An elevation count may also occur in ***pathologic conditions*** such as the following: ✓ Abscess ✓ Acute and chronic bacterial infection ✓ Anemia ✓ Appendicitis ✓ Chickenpox ✓ Cushing disease ✓ Diphtheria ✓ Erythroblastosis fetalis ✓ Infectious mononucleosis ✓ Leukemia ✓ Leukemoid reactions ✓ Meningitis ✓ Parasitic infestation ✓ Peritonitis ✓ Pneumonia ✓ Polycythemia vera ✓ Rheumatic fever ✓ Smallpox ✓ Tonsillitis ✓ Transfusion reaction ✓ Uremia	✓ Agranulocuyosis ✓ Anemia ✓ Bacterial infections that are overwhelming ✓ Brucellosis ✓ Drug and chemical toxicity ✓ Gaucher disease ✓ Hypersplenism ✓ Infectious hepatitis and cirrhosis ✓ Influenza ✓ Leukemia (some forms) ✓ Lupus erythematosus ✓ Measles ✓ Myxedema ✓ Protein therapy ✓ Psittacosis ✓ Radiation therapy ✓ Rheumatic fever ✓ Typhoid fever and paratyphoid fever ✓ Viral infections

DIFFERENTIAL WHITE CELL COUNT

The differential white cell count (Diff) is an enumeration of individual leukocyte distribution on a stained slide of peripheral blood. A differential is performed by microscopically identifying 100 or more white cells, classifying them according to morphology, and calculating the relative percentage of each cell type present. Reliable white cell classifications help to direct attention toward particular diseases, since characteristic abnormal cell distribution patterns are generally consistent with certain disorders.

TECHNIQUE

Performing differential cell counts is an art form. Skill is acquired only through practice based on a solid background of technical knowledge (Table 6) provides a summary of the steps required to perform a complete differential. These steps also discussed in details

TABLE 6: STEPS REQUIRED TO PERFORM THE COMPLETE DIFFERENTIAL CELL COUNT

- ✓ Check slide identification
- ✓ Perform patient specimen orientation
- ✓ Perform low-Power (10X) Scan of the blood film
  - ➢ Check feather edge or fibrin threads
  - ➢ Verify acceptable number of leukocytes
  - ➢ Verify stain quality
  - ➢ Examine erythrocyte distribution patterns and shapes
- ✓ Perform oil examination (100X0 of the blood film
  - ➢ Prepare blood film with oil
  - ➢ Estimate platelet count
  - ➢ Estimate leukocyte count
  - ➢ Perform leukocyte differential
    - ➢ Classify 100 leukocytes
    - ➢ Report results as percentage of all leukocytes counted
    - ➢ Keep separate count of NRBCs
    - ➢ Note and report abnormal leukocyte morphology
    - ➢ Grade abnormal erythrocyte morphology
    - ➢ Identify miscellaneous abnormal cells

Principle

An appropriately prepared and stained blood film is systematically scanned microscopically to estimate leukocyte count, identify morphologic erythrocyte abnormalities, estimate platelet number, and classify leukocytes into group types.

Microscopic Preparation

Procedure

1. Check slide identification
2. Perform patient specimen orientation:

Total WBC, Platelets, MCV and MCHC

3. Perform low-power scan to review blood film adequacy

a. Check feather edge for fibrin threads. Fibrin threads may be present even in films made from specimens that do not contain gross clots. Fibrin threads tend to entrap large leukocytes and are accompanied by platelet clumping. Neither a differential count nor a platelet estimate should be attempted on blood films that exhibit fibrin threads.

b. Examine film edges for excessive leukocytes. The edges of even the best-prepared blood film have accumulations of granulocytes and monocytes, but in films that are spread too thin, most of the large cells are pushed to the film edges, leaving relatively more lymphocytes in the centre. Blood film edges should contain less than 2 to 3 times more leukocytes than the number present in the body of the film

c. Verify acceptable number of leukocytes. In a total leukocyte count of no less than $4.0X10^9$/L, the acceptable working area should contain at least 300 leukocytes. This may be quickly ascertained by someone experienced in scanning blood films.

d. Verify stain quality. The stain should clearly distinguish between dark purple nuclear material and bright red-orange erythrocytes.

e. Examine erythrocyte distribution patterns and shapes.

f. Perform oil-immersion examination of the blood film

1. Prepare blood film with oil
2. calculate ratio of electronic platelet count to platelets per oil immersion field
3. Estimate platelet count
4. Estimate leukocyte count.
5. Perform differential leukocyte count.

PERFORM DIFFERENTIAL LEUKOCYTE COUNT

1. Classify 100 leukocytes. Leukocyte differentiation involves the counting and morphologic classification of 100 leukocytes reviewed while using a specific search pattern in the appropriate examination area of a blood film.

2. Report results of the 100 cells classified as a percentage. These results are considered relative cell counts. For example, if 60 neutrophils were found among 100 leukocytes counted, this would be reported as 60% neutrophils. When manual differential counters are used, the technologist must verify that the sum of the percentages equals 100%.

3. Keep separate count of nucleated red blood cells (NRBCs). NRBCs are counted separately while classifying the 100 leukocytes. They should be reported as the number per 100 leukocytes counted. If more than 5 NRBCs are found per 100 leukocytes, the automated leukocytes count must be corrected, because NRBCs, being as large as small leukocytes erroneously elevate the automated leukocyte count. The calculation for correction of the leukocyte count when NRBCs are present is discussed below in the section on Calculations.

4. Note and report abnormal leukocyte morphology. Leukocytes may appear abnormal or demonstrate inclusions, which must be noted on the differential count report. For example, toxic granulation in neutrophils is an indication of infection or chemical toxicity.

5. Identify and grade abnormal erythrocyte morphology

6. Identify and report in the differential comments any miscellaneous nonleukocyte abnormal cells, such as endothelial cells, basket cells, or NRBCs, that are found during the differential

CALCULATION FOR CORRECTION OF LEUKOCYTE COUNT IN THE PRESENCE OF NUCLEATED ERYTHROCYTES

When more than five nucleated red cells are found during a 100-leukocyte differential count, correction of the automated leukocyte count is necessary. The correction calculation is as follows:

$$\frac{\text{WBC X10}^9\text{/L X100}}{\text{NRBC per 100 leukocytes + 100}} = \text{Corrected WBC count}$$

For example, given a WBC count of 24.0 X 10^9/L and an NRBC count of 20/100 WBC

NORMAL VALUES

Newborn tends to have a white cell differential that resembles adult patterns. However by the fourth week of life levels begin to vary, with neutrophil values dropping to 40% or less and lymphocytes rising to 45% or greater. This initial neutrophil-lymphocyte inversion is followed by a gradual return to the adult ratio by 19-21 years of age. The normal values or average distribution of the six leukocyte categories generally reported on a differential are as follows:

TABLE 8: NORMAL VALUE

Cell Type	Relative value (%)	Absolute value (cells /μl
Polymorphonuclear Cells (polys)	35-80%	3000-7500
Immature Polys (bands)	0-10%	150-700
Lymphocytes (lymp)	20-50%	1500-4500
Monocytes (mono)	2-12%	100-500
Eosinophils (eos)	0-4%	50-400
Basophils (bas)	0-2%	25-100

TABLE 9: CAUSES OF NEUTROPHILIA & NEUTROPENIA

CAUSES OF NEUTROPHILIA

Bacterial infection
Inflammation e.g collagen disease, Crohn's disease
Trauma/surgery
Tissue necrosis/infarction
Hemorrhage and hemolysis
Metabolic, e.g diabetic ketoacidosis
Myeloproliferative disorders
Pregnancy
Drugs e.g steroids, G-CSF

CAUSES OF NEUTROPENIA

A. Decreased Production

1. General bone marrow failure, e.g aplastic anemia, megaloblastic anemia, myelodysplasia, acute leukemia, chemotherapy, replacement by tumor

2. Specific failure of neutrophil production
   Congenital, e.g Kostman's syndrome
   Cyclical
   Drug induced, e.g sulphonamides, chloropromazine, clorazil, diuretics, neomercazole, gold

B.Increased destruction

1.General, e.g hypersplenism

2. specific e.g autoimmune- alone or in association with connective tissue disorder, rheumatoid arthritis "Felty's syndrome"

TABLE 10: CAUSES OF EOSINOPHILIA

Allergic diseases e.g asthma, hay fever, eczema, pulmonary hypersensitivity reaction " e.g Loeffler's syndrome'
Parasitic disease; Ancylostoma, Ascaris, Filarial, Hookworm, Malaria, Schistosoma etc.
Skin diseases, e.g psoriasis, drug rash, eczema, leprosy pruritus of jaundice
Drug sensitiviry
Connective tissue disease
Hematological malignancy e.g Hodgkin's lymphoma, Eosinophilic leukemia, Eosinophilic leukemic reaction, Pernicious anemia, Polycythemia vera, Postsplenectomy, Sarcoidosis
Idiopathic hypereosinophilia

TABLE 11: CAUSES OF LYMPHOCYTOSIS

Bacterial or viral infections: brucellosis, chickenpox, IM, influenza, measles, mumps, paratyphoid fever, pertusis, syphilis, TB, typhoid fever, typhus, viral hepatitis, viral pneumonia.
Hemorrhagic disorders: Agranulocytosis, Aplastic anemia, banti disease, felty syndrome, Leukosarcoma, Lymphocytic leukemia, Multiple myeloma, NHL.
Miscellaneous: Addison disease, Carcinoma, hyperthyroidism, Malnutrition, Rickets, Waldenstrom macroglobulinemia.

CAUSES OF LYMPHOPENIA

Cardiac failure
Cushing disease
DiGuglielmo syndrome
Hodgkin's disease, Leukemias : e.g CML
SLE
Radiation of lymphoatics
Uremia
Thymic hypoplasia in children
Nitrogen mustard

TABLE 12: CAUSES OF MONOCYTOSIS

Agranulocytosis
Amoebic abscess
Banti disease
Brucellosis, Chickenpox, Chronic TB, I Mononucleosis, mumps, paratyphoid F, Rickettsial infection, typhoid fever, Typhus, Weil disease
Kala azar, Leishmaniasis, trypanosomiasis
Cirrhosis,Collagen disease
Gaucher disease
Malignant tumors, Hodgkin's disease, NHL, Monocytic leukemia. Myeloma
Subacute bacterial endocarditis

CAUSES OF BASOPHILIA

CML,Erythroleukemia Myelofibrosis, Polycythemia vera, Hodgkin's disease
Hemolytic anemia, Splenectomy
Hypothyroidism or myxedema
Infections especially during recovery phase
Irradiation
Ulcerative colitis
Uremia

PROBLEMS:

11. A 1:20 dilution is made in Unopette, with glacial acetic acid as the diluent. One hundred WBCs are counted in the four corner squares. What is the total WBC count?		11. $\frac{100X10X20}{4} = 5.0 \times 10^9/L$
12. The total WBC count is $20.0X10^9/L$ Twenty-five NRBCs are seen on the peripheral blood smear. What is the corrected WBC count?		12. $\frac{20 \times 10^9/L \times 100}{25+100} = 16.0 \times 10^9/L$
13. 250 WBCs were counted on a hemocytometer in four WBC squares (each 1 mm^2) on side A and 265 were counted in the same area on side B. A WBC pipet was used to dilute the patient blood. (0.5 part blood and diluents drawn to the 11 mark. What is the final leukocyte count?		13. (250+265)/2=257.5= Average no. cells counted $\frac{257.5 X20X10}{4} = 12875$

14. Calculate leukocytes ($X10^6/L$) for the following:

Dilution of blood	Squares	Depth of chamber	Total cells counted
A. 1:10	4	0.1 mm	194
B. 1:20	4	0.1 mm	383
C. 1:10	8	0.1 mm	273
D. 1:200	8	0.1 mm	207

Answers: A= $4.9X10^6/L$, B= $19.2X10^6/L$, C= $3.4 X10^6/L$, and D $51.8X10^6/L$

15. A differential count showed 8 Eosinophil in 100 leukocytes. Given a leukocyte count of $8.4 \times 10^6/L$. what is the indirect absolute number of eosinophils per liter? Show calculation. Is this result within the usual reference range?		15. ($0.08 \times 8.4 \times 10^9/L = 0.7\ 10^9/L$. this result is not within the usual reference range: it indicates Eosinophilia

STUDENT PERFORMANCE GUIDE

WHITE BLOOD CELL COUNT
"UNOPETTE METHOD"

Name:
Date:

Instructions

1. Practice performing and calculating a white cell count.
2. Demonstrate the white cell count satisfactorily for the instructor. All steps must be completed as listed on the instructor's Performance Check Sheet.
3. Complete a written examination successfully. .

Material and Equipments

- Gloves
- Hand disinfectant
- 70% alcohol
- soft tissue
- Sample of EDTA anticoagulated blood
- Microscope
- Test tube rack
- Hand counter
- lens paper
- WBC work shaker
- WBC worksheet
- Surface disinfectant
- WBC diluting fluid
- WBC diluting pipet
- Hemocytometer with coverglass
- Biohazard container

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Assemble equipment and materials			
2. Place a clean hemocytometer coverglass over a clean hemacytometer			
Wash hands with disinfectant and put on gloves			
4. Place exactly 0.38 ml of diluting fluid into a 10*75 mm test tube			
Add 0.02 ml of well-mixed whole blood to the tube.			
6. Cap tube and mix well for two minutes			
7. Draw the WBC diluting fluid with the pipet			
8. Place the index finger over the top of the pipet to control the flow of the fluid			
9. discard the first 3-4 drops of fluid from the pipet			
10.Touch the tip of the pipet to the edge of the coverglass and counting chamber			
11. Allow the fluid to flow under the coverglass until one sid of the chamber is completely full (usually one-half to one drop)			
12. Fill the opposite side of the chamber in the same manner			
13.Allow the cells to settle about two minutes			

14. Place hemocytometer on the microscope stage and secure			
15. Locate the ruled area of the chamber using the low power (10X) objective			
16. Locate the correct area for counting WBC (four large corner square)			
17. Count all the WBCs lying within the four large corner squares (1,2,3 and 4) using the boundary rule)			
18. Record results on worksheet			
19. Repeat steps 16-17 using side 2			
20. Record results from side 2 on the worksheet			
21. Average the total cells counted on the two sides of the chamber			
22. Use the formula to calculate the WBC count and record on worksheet			
23. Disinfect pipet, hemocytometer and coverglass with chlorine bleach			
24. Clean WBC pipet, Hemocytometer and coverglass carefully			
25. Return equipment to proper storage			
26. Remove and discard gloves and wash hands with hand disinfectant.			
Comments: Student/instructor			

Date:----------

IRON DEFICIENCY ANEMIA MEGALOBLASTIC ANEMIA 9

OBJECTIVES

- Describe peripheral blood and bone marrow morphology characteristic of iron deficiency anemia
- Describe peripheral blood and bone marrow morphology characteristic of megaloblastic anemia
- Describe causes iron deficiency anemia
- Describe causes of megaloblastic anemia
- Utilize morphology and iron values to distinguish among (a) iron deficiency anemia (sideroblastic anemia (c) thalassemia (d) anemia of chronic disease
- Utilize morphology and vitamin B12 and folate values to distinguish among (a) Vitamin B12 deficiency and (b) Folic acid deficiency

GLOSSARY

- **Ferritin**: Water-soluble storage form of iron. Serum ferritin concentration has a positive correlation to total body iron store.
- **TIBC:** Total iron binding capacity correlates relatively with transferring concentration
- **Transferrin**: Major iron transport protein in plasma
- **Folic acid deficiency** –A deficiency in a B vitamin known as folic acid, which can cause megaloblastic anemia.
- **Megaloblastic (pernicious) anemia** - A rare blood disorder in which the body does not absorb enough vitamin B-12 from the digestive tract, resulting in an inadequate amount of red blood cells (RBCs) produced.
-

IRON DEFICIENCY ANEMIA

Iron deficiency anemia is the most common nutritional deficiency in the world. In order to understand the symptoms, etiology and treatment of this anemia, it is necessary to review normal iron and heme metabolism.

Table 1: Causes of Iron Deficiency

Iron store depletion	**Iron-Deficient Erythropoiesis**	**Iron-Deficient Anemia**
Inadequate diet Rapid growth Infancy Adolescence Normal menses Blood duration	Excessive menses Pregnancy Acute Hemorrhage Malabsorption Gasterectomy Regional enteritis Inflammation Acute infections Chronic inflammatory states Polycythemia Vera treated with phlebotomy	Chronic blood loss Varices Peptic ulcer disease Large bowel tumors Diverticultis Angiodysplasia Intravascular hemolysi Hookworm infestation Sever malabsorption Postgasterectomy Sprue Regional enteritis

Pathophysiology

Iron deficiency develops in sequential stages over a period of negative balance (loss exceeds absorption).
Since Fe is absorbed with difficulty, most people barely meet their daily requirements added losses due to menstruation (mean 0.5 mg/day), pregnancy (0.5 to 0.8 mg/day), lactation (0.4 mg/day) and blood loss due to disease or accident readily lead to Fe deficiency. Fe depletion results in sequential changes or stages.
Stage I (Depletion of iron stores): Fe loss exceeds intake: with this negative Fe balance, storage Fe (represented by bone marrow Fe content) is progressively depleted. Although the Hb and serum Fe remain normal, the serum ferritin concentration falls to <20 ng/ml. As storage Fe decreases, there is a compensatory increase in absorption of dietary Fe and in the concentration of transferrin (represented by a rise in Fe-binding capacity.
Stage II (Impaired erythropoiesis: Exhausted Fe stores cannot meet the needs of the erythroid marrow, while the plasma-transferrin level increases, the serum-Fe concentration declines, leading to a progressive decrease in Fe available for RBC

formation. When serum falls to < 50 μg/dl, and transferrin saturation to <16%, erythropoisis is impaired. The serum ferritin receptor concentration rises (>8.5mg/l)
Stage III (Anemic stage): The anemia with normal appearing RBCs and indices is defined.
Stage IV: Microcytosis and then hypochromia are present. The most significant finding is the classic microcytic hypochromic anemia.
Stage V: Fe deficiency affects tissue, resulting in symptoms and signs.

Clinical and Laboratory Features

The onset is insidious. In early stage, there is no clinical manifestation. But with complete depletion of iron stores, anemia develops and clinical symptoms appear. Symptoms such as weakness and lethargy are considered to be related to hypoxia cause by the decrease in hemoglobin.
A variety of other abnormalities may occur from an absence of tissue iron in iron-containing enzymes. These include koilonychia (concavity of nail) glossitis, pharyngeal webs, muscle dysfunction, impaired thermogenesis and gastritis.
The most common dysphagia described in patients with IDA includes ice-eating (phagophagia), dirt eating (geophagia), and starch eating (amylophagia).
Peripheral blood Picture: The blood picture is well-developed iron deficiency is microcytic (MCV 55 to 74 fl), hypochromic (MCHC 22 to 31 g/dl, MCH 14 to 26 pg). When the anemia is mild, the morphologic aspects of the red blood cells are little affected. Microcytosis and anisocytosis are usually the first morphologic signs to develop even before anemia develops.
The blood film demonstrates progressive poikilocytosis.The most frequent poikilocytes are target cells and elliptocytes. Nucleated red cells may be seen if hemorrhage has occurred.
Both the relative and absolute number of reticulocytes may be normal or even slightly increased.
WBC is usually normal but some times eosinophilia may be present. Platelets may be normal, increased or decreased. Thrombocytopenia may occur in severe or long-standing anemia especially if associated with folate deficiency. It has proposed that thrombocytosis is related to iron deficiency caused by chronic blood loss.
Iron studies: The serum iron is decreased. It is usually less than 30μg/dl and the TIBC is increased with less than 15% transferrin saturation.
Serum ferritin levels are decreased in all stages of IDA and may be the first indication of a developing iron deficiency. Serum ferritin is an important test to differentiate iron deficiency anemia from other microcytic hypochromic anemia.
Serum ferritin levels are normal in the anemia of chronic disease, and increased in sideroblastic anemia and thalassemia.

Table 2: Laboratory studies in Iron deficiency

	Iron-store depletion	Iron-Deficient Erythropoiesis	Iron-deficiency Anemia
Hemoglobin	Normal	Slight decrease	Marked decrease (microcytic/hypochromic
Iron stores	< 100 mg (0-1+)	0	0
Serum Iron (μg/dl)	Normal	<50	<40
TIBC (μg/dl)	250-410	>410	>470
Percent saturation	20-30	<15	<10
Ferritin (μg/dl)	<20	<12	<
Percent sideroblast	40-60	<10	<10
Red blood cell protoporphyrin (μg/dl RBC)	30	>100	>200

Bone marrow characterized by decreased M:E ratio, moderate increased of cellularity and mild to moderate erythroid hyperplasia. In erythroid series there is poorly hemoglobinized normoblasts with scanty ragged cytoplasm and erythroid nuclear abnormalities (nuclear fragmentation, multinuclearity). The stains for iron shows absence of hemosiderin in the macrophage and the sideroblasts are markedly reduced or absent.



FIGURE 1: **IRON DEFICIENCY ANEMIA**. The RBC's are smaller than normal and have an increased zone of central pallor. This is indicative of a hypochromic microcytic anemia. There is increased anisocytosis and poikilocytosis.

Hemoglobin (g/dl)	MCV/MCH (fl) (pg)	Morphology	
Normal ↓ 11 ↓ 9 ↓ 7 ↓ 5	90/32		Uniformly Normocytic Normochromic
	80-90/30-32		Slightly microcytic Normo-hypochromic +/- anisocytosis
	70-80/26-30		Microcytic, Hypochromic +anisocytosis Pencil-shaped cells
	<70/<26		Microcytic ,hypochromic + aniso-and poikilocytosis

TABLE 3. DIFFERENTIAL DIAGNOSIS OF MICROCYTIC ANEMIA

	Thalassemia	Iron deficiency	Chronic inflammation
Serum iron	Normal/increase	Low	Low
TIBC	Normal	High	Low
Percent saturation	>20%	<10%	10-20%
Ferritin (μg/L)	>50	<10	20-200
Iron store	3-4+	0	1-4+
Transferrin-receptor	Normal/increased	Increased	Normal

MEGALOBLASTIC ANEMIA

The pathophysiology of the megaloblastic anemias is associated with two primary abnormalities: (1) ineffective erythropoiesis and (2) a moderate hemolysis of circulating erythrocytes.
The etiological classification can be divided into three main groups (1) those due to vitamin B12 deficiency (2) those due to folic acid deficiency; and (3) those that are unresponsive treatment with either of these essential nutrients and result from a variety of causes.

Classification

1. Vitamin B12 Deficiency
2. Folate Deficiency
3. Megaloblastic anemia unresponsive to vitamin B12 and Folate therapy

Vitamin B12 Deficiency

1. Decreased in intake
   A. Dietary, usually seen only in true vegetarians
   B. Impaired absorption, such as in pernicious anemia
   C. Malabsorption (Familial, drug induced, sprue, celiac disease, gastrectomy)
   D. Competition from parasites (Fish tapeworm and bacteria)
2. Increased requirements
   A. Pregnancy
   B. Increased cellular proliferation (tumors)
   C. Hyperthyroidism
3. Impaired utilization
   A. Red cell enzymopathy
   B. Abnormal vitamin B12 binding protein (transcobalamin II)
   C. Nitrous oxide administration
   D. Lack of transport protein (TcII)

Folate Deficiency

1. Decreased in intake
   A. Dietary, usually a lack of green vegetables B. Alcoholism
   C.Impaired absorption due to sprue and celiac disease
2. Increased requirements
   A. Pregnancy B. Increased cellular proliferation (tumors)
   C.Miscellaneous states (Homocystinuria, hyperthyroidism)
3. Impaired utilization
   A. Folic acid antagonists (methotrexate, dilantin, trimethoprim, pyrimethamine)

Megaloblastic anemia unresponsive to vitamin B12 and Folate therapy

1. Metabolic inhibitors

A. Drug-induced disorders: Purine antagonists (6 mercaptopurine), pyrimidine antagonists (5-Fluorouracil) alkalating agents (cyclophosphamide).

2. Unknown causes
   A. Pyridoxine-responsive megaloblastic anemia
   B. Erythemic myelosis (Erythroleukemia or DiGuglielmo syndrome).

VITAMIN B12 DEFICIENCY

Megaloblastic anemia is associated with an abnormal appearance of the bone marrow erythroblasts in which nuclear development is delayed and nuclear chromatin has a lacy open appearance. There is a defect in DNA synthesis usually caused by deficiency of vitamin B12 (B12,cobalamin) or folate

Clinical Manifestation

There are three cardinal manifestations of vitamin B12 deficiency of whatever cause:

- Macrocytic megaloblastic anemia
- Glossitis
- Peripheral neuropathy and subacute combined degeneration of the spinal cord. Optic neuropathy, depression, and impaired memory.

On examination: Sensory loss in the legs and positive Romberg sign.
Neurological abnormalities appear to occur more frequently in pernicious anemia due to vitamin B12 deficiency.

Special Tests in Diagnosis

The main test for the detection of vitamin B12 deficiency is the serum vitamin B12 assay. To establish the cause of the deficiency, a radioactive vitamin B12 absorption test is performed.
Serum vitamin B12 assay:
1. Microbiological assay
2. Radio-isotop assay
Radioactive vitamin B12 absorption test (eg Schilling Test):
The ability of the body to absorb vitamin B12 can be assessed by measuring the absorption of a small oral dose of ^{57}C-labelled vitamin B12 orally if simultaneous administration of intrinsic factor, it implies lack of intrinsic factor.

The Schilling Test

An oral dose of 1μg radioactive vitamin B12 (^{57}C-vit.B12) is administered to the fasting subject followed two hours later by a large parenteral injection of unlabelled B12 (1000μg). The injection flushes out about 1/3 of the absorbed radioactive B12 into the next 24 hours.

- Normal subjects excrete 10% or more of the 1μg dose in their urine.

- Patients with pernicious anemia excrete less than 5% but occasionally upto 7% of the dose.
- Borderline results of upto 10% may occur in atrophic gastritis.
- If the patients absorb normal amounts of vitamin B12, no further testing is necessary.
- If absorption is subnormal, a second parenteral injection of unlabelled B12 is given 24 hours later, followed by a further test dose of radioactive B12 with intrinsic factor, and the B12 absorption is again estimated. If absorption returns to normal, a diagnosis of pernicious anemia may be made.
- If absorption is again subnormal, a lesion of the small intestine is likely.

Source of error:

1. Incomplete urine collection
2. Inactive intrinsic factor
3. Presence of another diagnostic isotope in the urine

Measurement of the unsaturated B12 binding capacity (UBBC), which in the normal subject reflects the amount of TC II and to a lesser extent TC I and TC II and TC III available in the serum for binding with added B12. The normal range for serum UBBC is 500-1200 ng/l. The UBBC is usually elevated due to an increase in TC I in CML, acute promyelocytic leukemia.

FOLATE DEFICIENCY

Causes of Folate Deficiency

1. Inadequate intake
2. Intestinal malabsorption (e.g celiac disease, tropical sprue)
3. Increased demand: Pregnancy, hemolytic anemia, leukemia, lymphoma, sideroblastic anemia, carcinoma, inflammatory disorder, hyperthyroidism and skin disease.
4. Inability to utilize folate due to the action of folate antagonist (anticonvulsant, contraceptives).

Manifestations

The most typical manifestation of folate deficiency is megaloblastic anemia, a hematopoietic disorder whose features have already been discussed. The salient molecular abnormality in folate deficiency is a marked slowing of DNA synthesis, a defect expressed not only in the characteristic morphological abnormalities of the megaloblastic cells, but also in a marked prolongation of the S (DNA synthesis) phase in replicating cells and in a disruption in chromatin structure detectable as chromosomal tangles and breaks. Despite extensive study, a biochemical explanation for the slowing of DNA synthesis in folate deficiency is not yet available, although it appears to be somehow related to the defect in dTMP formation seen in folate-deficient cells.

OTHER MANIFESTATIONS: Folate deficiency affects other rapidly dividing tissues. A stomatitis characterized by a sore mouth and a smooth, beefy red

tongue occurs frequently. It probably results from impaired proliferation of the oral mucosa, which is worn away during eating and must be constantly renewed.
Special Tests in Diagnosis: There are two main laboratory tests used to detect folate deficiency
Serum Folate Assay: Microbiological (Lactobacillus) and radioisotope method are available for measuring serum folate concentration.
Red Cell Folate Assay
Red cell contains 20-50 times as much folate as serum. The red cell folate level is usually a more reliable indicator of tissue folate stores than the serum folate, which fluctuates widely according to dietary intake. Microbiological or radioisotope assay method may be used.
Low red cell folate levels are found in patients with megaloblastic anemia due to folate deficiency.
Figlu test (Determination of formiminoglutamic acid in urine) is an intermediary metabolic product of histidine metabolism and is normally metabolized to glutamic acid, with the help of tetrahydrofolic acid (THFA). In folic acid deficiency THFA is not available and FIGLU is found in the urine in increased amounts. The sensitivity of the test can be increased by the histidine-loading technique. This test however is not very specific.
Radioactive folic acid test is diagnostic (like schilling test in B12 deficiency).

Peripheral Blood Picture in Megaloblastic Anemia

1. Anemia with marked oval macrocytosis and elevated MCV. The higher is the MCV, the greater the incidence of megaloblastosis. MCV values above 125 fl are almost always associated with vitamin B12 or folate deficiency and a frankly megaloblastic bone marrow.
2. Neutropenia with hypersegmented neutrophils.
3. Mild, usually symptomless, thrombocytopenia.

The earliest change is the development of macrocytosis and an elevated MCV without anemia. Anemia then develops weeks, months or rarely years later and as the level of hemoglobin falls. Anisocytosis, macrocytosis and poikilocytosis become more prominent. Finally neutropenia and thrombocytopenia develop.
Neutrophil hypersegmented is present when more than 5% of neutrophils have 5 lobes or the film shows at least one six-lobed cell. Hypersegmentation is an early sign of vitamin B12 or folate deficiency, and is useful in the diagnosis of megaloblastosis with minimal or no anemia (other conditions with hypersegmentation are I.D.A, myeloproliferative syndrome and chronic renal failure).

Bone Marrow Morphology in Megaloblastic Anemia

Erythropoiesis

Megaloblastic changes occur at all stages of red cell development. The primitive cell is the promegaloblast, from which a series of maturing cell develop, namely basophilic, polychromatic and orthochromatic megaloblasts.

Megaloblasts differ from their normoblstic counterparts in the following respects.
Cell size: Megaloblasts are larger than erythroblasts, with an increase in cytoplasm and nuclear size at every stage of development.
Nucleus: The chromatin network is more open, being arranged in a fine reticular fashion to give a stippled appearance. Thus, the stippled appearance is commonly still well marked in polychromatic cells. The nucleus of the chromatin cell is commonly indented or lobulated, and one or more Howell Joly bodies may be present.
Mitosis: mitosis are more common and are some times abnormal in appearance
Maturation: Megaloblastic erythropoiesis is characterized by an increase in the proportion of more primitive cells.
Prussian blue staining of the marrow shows an increase in the number and size of iron granules in erythroid precursors. Iron in reticulum cells is increased.

Leukopoiesis

The characteristic feature is the presence of large atypical granulocytes, which occur at all stages of development but particularly at the metamyelocyte, resulting in (giant stab) forms. The giant stab cell has a large U-shaped nucleus, which may be irregular in outline. These cells result from asynchronism between the development of nucleus and the cytoplasm. They probably die within the marrow, and the hypersegmented neutrophils of the peripheral blood do not appear to be derived from them. The absolute number of developing granulocytes in the marrow is actually increaed in nucleated red cells.

Megakaryocytes

Usually are normal or slight increases. Occasionally decreased with some cells are atypical or hypersegmented nucleus.

STUDENT PERFORMANCE GUIDE

IRON DEFICIENCY ANEMIA
MEGALOBLASTIC ANEMIA

Name:
Date:

Instructions

1. Practice identifying erythrocytes from a stained blood smear.
2. Identifying erythrocytes morphology changes in shape, size inclusions and change in color. WBCs and platelets
3. Complete a written examination successfully. .

Material and Equipments

- Stained blood smear
- Microscope
- Lens paper
- Oil immersion
- Soft laboratory tissue
- Drawings and descriptions of stained blood smear

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant			
2. Assemble equipment and material			
3. Place stained smear on microscope stage and secure it with clips			
4. Bring cells into focus using low power (10x)			
5. Scan slide to find area of slide where cells are barely touching each other			
6. Place one drop of immersion oil on slide			
7. Rotate oil immersion objective carefully into position			
8. Focus with fine adjustment knob until cells can be seen clearly			
9. Raise the condenser and open the diaphragm to allow maximum light into objective			
10. Scan slide to observe RBCs changes in color, size, shape, distribution and inclusions. And WBCs and platelets			
11. Report what you see			
12. Rotate low power objective into position			
13. Remove slide from the microscope stage			
14. Clean oil objective thoroughly			
15. Clean oil from slide gently			
Comments			

Date:----------Instructor----------



10 SICKLE CELL HEMOGLOBINOPATHIES

OBJECTIVES

- Define the pathologic basis of sickle cell disorder
- Describe the type of sickle cell crisis
- State the amino acid substitution found in sickle cell disease
- Describe he solubility of hemoglobin S due to deoxygenation of erythrocyte containing hemoglobin S
- Practice sickling test and identify the sickled cells

GLOSSARY

- Sickle cell anemia: Inherited blood disorders characterized by defective hemoglobin, where there are two copies of an abnormal hemoglobin gene present (Hbss)
- Sickle cell trait: Having one copy of the gene which causes sickle cell anemia (HbAS) and one copy of the normal hemoglobin gene.

The term sickle cell disease is used generically to describe a group of genetic disorders characterized by the production of the abnormal hemoglobin S (HbS). Sickle cell anemia (SCA) is the most common type of sickle cell disease and represents the homozygous form, in which the individual inherits a double dose of the abnormal gene, which codes for hemoglobin S. This type of hemoglobin differs from normal hemoglobin by the single amino acid substitution of valine for glutamic acid in the sixth position from the NH2 terminal end of the β chain. The structural formula for sickle cell anemia (HbSS) is $\alpha 2\beta 2$.

Pathophysiology

1. When oxygenated, HbS is fully soluble. Sickling occurs when oxygen decreases at the tissue level. When oxygen is released from the Hb molecules, a conformational change occurs, which results in polymerisation of the Hb molecule and leads to the formation of tactoids or crystals, which cause the cell to become rigid.
2. The distorted and rigid sickle cells impede blood flow to tissues and organs, resulting in tissue death, organ infarction, and pain.
3. Repeated of sickle-unsickle cycles lead to loss of fragments of red cell membrane, and the cells become spherocytic and fragile. They are removal prematurely by the reticulo-endothelial system, and to a lesser extent destroyed in the circulation resulting in both extravascular and intravascular hemolysis. The bone marrow responds by increasing erythropoiesis. As a result, the marrow spaces widen and the bone cortex thins.

The amount of HbS in the red cell is clearly of great importance. The cells of a patient with sickle cell trait which contain less than 50% HbS are less likely to sickle at a particular level of deoxygenation than the cells of a patient with homozygous sickle cell disease which contain 100% HbS

Sickle Cell Trait

Patients with one normal β-globin gene and one β^s –gene are said to have sickle cell trait. This condition is by far the most common of the sickle cell variants; it is asymptomatic carrier state for HbS. HbS comprises 38-45% of the total hemoglobin, the rest being HbA, HbA2 and HbF. The cells do not contain sufficient HbS to undergo sickling at the lowest oxygen tension normally occurring in the body and the red cell lifespan is normal. In the stained blood film, no sickle cells are present and the red cells appear normal. The MCV and MCH are normal. However sickling can readily be demonstrated by the sickle test, and the hemoglobin solubility test is positive. The sickle cell trait does not cause anemia, and in general is asymptomatic. If anemia is present, other causes, e.g. iron deficiency, should be sought.

Homozygous Sickle Cell Disease

The worst of the sickle cell disease is sickle cell anemia. Like other hemoglobinopathies, it is an inherited disease. I s is transmitted in an autosomal recessive manner, occurring in persons who have inherited two β^S-globin genes. The patient receives one HbS from each parent, both of whom show sickle cell trait. The probability for each child such unions to have normal hemoglobin only, sickle cell trait or homozygous disease are 25%, 50% and 25%. In these persons, hemoglobin S accounts for more than 90% of the hemoglobin in the red cell.
In sickle cell disease, the red cells contain sufficient HbS for sickling to be produced in vivo by the reduction of oxygen tension that occurs in capillaries.
In vivo sickling is responsible for the clinical manifestations of the disease. These are chronic hemolytic anemia, organ damage and episodes of pain.

Clinical manifestations fall into two categories: those caused by the anemia and those attributable to occlusions of the microvasculature.

The diagnosis is usually made in childhood (before two years). Symptoms are infrequent in first six months (High HbF protecting the RBC from sickling). Many children died in the first 7 years. Bacterial infection is the most common cause of mortality and morbidity. (e.g. Pneumococcal meningitis). Hand foot syndrome is caused by microinfarction of the medulla of the carpal and tarsal bones. This syndrome manifested by hand and feet tender, swollen and febrile.
Spleen is palpable between six months and 8 years. Splenic sequestration syndrome developed due to sudden pooling of blood within the spleen, often with acute hypovolemia and shock. The spleen enlarges rapidly and death may occur.
Blood film: Howell-Jolly bodies and target cell found in splenectomized patients.
Repeated episodes of infarctions eventually lead to atrophy and autosplenectomy; by eight years of age, the spleen is no longer palpable and its function is permanently impaired.

In Adult all patients are anemic (many of them adapt to anemia**.**

Sickle cell crises are characteristic features of disease and are responsible for morbidity.
A.Vaso-occlusive crises :(Occlusion--Ischemia--Infarction) consist of sudden attacks of bone pain usually in the limbs, joints, back and chest or of abdominal pain.
B. Aplastic crises: occur when there is sudden cessation of marrow erythropoiesis related to infection with human parvovirus. Hemolysis continues and the red cell mass rapidly diminishes to life-threatening levels. Significant reductions are in erythrocyte count, Hb, Hct, reticulocyte count and bone marrow erythroblasts.
C. Infectious crises: Children with sickle cell anemia have an increased susceptibility to potentially life-threatening bacterial infections, including sepsis and meningitis caused by streptococcus pneumoniae and Hemophilus influenzae. The relative risk of sickle cell anemia patients compared with that of normal individuals for pneumococcal H. influenzae and all bacterial meningitis is 579:1, 116:1, and 309:1, respectively. These patients also are susceptible to bacterial pneumonia,

osteomyelitis (salmonella and staphylococcus) and urinary tract infections (Escherichia coli and klebsiella). Increased susceptibility also is seen for shiegella and Mycoplasma pneumonia. Bacterial infection is the most common reason for hospitalization of pediatric patients with sickle cell anemia and often leads to the diagnosis. Serious bacterial infections are seen in one third of children with sickle cell anemia before 4 years of age and a primary cause of death these patients.

Other Features

Conjunctival icterus is common and liver enlarged and some times is tender due to infarction. Cholelithiasis is common.
Cardiac enlargement and systolic ejection murmur/thrills.
Progressive loss of renal function occurs in many patients
Chronic leg ulcers are common.
Bone: Osteomyelitis due to salmonella and avascular necrosis of the femoral or humeral head.

Blood Picture

Anemia: Hb of 6-9 g/dl is usual but they may be lower and an occasional patient has a normal value.The anemia is due reduction of red cell life span and in some patient due to hypersplenism (red cell destruction). The anemia is usually normochromic normocytic with a normal MCV and MCH.
Blood Smear: Anisocytosis, Poikilocytosis with elongated, rounded, sharper to typical sickle cells. Oval cells are common and occasional target cells and Howell-Jolly bodies are present. Nucleated RBC may be present (polychromatic cells). Leukocytes increased with shift to left.
Reticulocyte is increased (10-20%). The ESR is low even with marked anemia as the abnormal shape of the sickle cells prevents rouleaux formation. Serum folate is subnormal and the red cell folate is low. Serum haptoglobin and hemopexin are decreased and serum bilirubin is moderately increased



FIGURE 1: PERIPHERAL BLOOD SMEAR SHOWS MARKED POIKILOCYTOSIS AND ANISOCYTOSIS WITH NUMEROUS SICKLED ERYTHROCYTES

Hemoglobin Solubility Test

The basis of these tests is the relative insolubility of reduced HbS in concentrated phosphate buffer. In practice, the hemoglobin is added to a solution of sodium dithionite, a reducing agent, in phosphate buffer. If HbS is present, the solution becomes turbid. Homozygotes and heterozygotes for the sickling gene are detected.

Currently, prenatal screening with recombinant DNA technology is done; the availability of the polymerase chain reaction has remarkably improved sensitivity of prenatal diagnosis.

Sickle Cell Preparation

The metabisulfate (reducing agent) is added to a suspension of whole red cells in saline. Cells containing any quantity of hemoglobin S – The test is simple to perform and detects even those from patients with sickle cell trait will sickle under these conditions.

Procedure

1 Mix capsule of sodium metabisulfite with 10 ml distilled water. This solution will last for 1 day only

2. Mix equal parts of fresh blood and sodium metabisulfite solution together on glass slide. Cover with slips and place on a wet sponge.

3. Observe immediately and at 15 minutes intervals for 15 minutes. Sickle cells may appear as sickle-shaped or “holy-leaf’ cells.

Comments

1. The percentage of sickled cells is unimportant in this test. It does not distinguish trait from disease.
2. There is now a commercial kit available that tests for sickle hemoglobin, based on its insolubility in certain buffers. The test does not require a microscope. A positive test is evident as turbidity of the solution (sickledex, ortho). Its convenience is in the ease of performance outside the laboratory. However, it is expensive.



Hemoglobin Electrophoresis

It is the mandatory for precise diagnosis of the sickle hemoglobinopathies.

HbS may be demonstrated by electrophoresis on cellulose acetate at PH 8.6 in a position between HbA and HbA2 or agar gel electrophoresis using citrate buffer done at PH 6.0.

TABLE 1: HB-ELECTROPHORESIS OF SICKLE HEMOGLOBINOPATHIES

Disorder	A	A2	F	S
Sickle cell trait(AS)	55-70	2-4	N	38-45%
Sickle cell disease (SS)	0	2-5	1-20	75-95%
Sickle cell Beta-Thalassemia				
$S\text{-}B^{+}$	10-30	4-8	2-10	60-85
$S\text{-}B^{0}$	0	4-8	5-30	70-90
Sickle cell Hb-C disease	0	35-50	1-5	50-65
Sickle cell Hb-D disease	0	N	1-5	95 (S+D)
S.C.trait-α thalassemia trait	65-75	N	N	20-30

DIFFERNTIAL DIAGNOSIS



The picture show Poikilocytosis of RBCs, spherocytes, and presence of immature RBCS (normoblasts) and basophilic stippling



Numerous RBCs appears as “helmet” cells such as fragment RBCs “schistocytes”. Blood smear of patient with microangiopathic hemolytic anemia (MAHA).



Peripheral blood of megaloblastic anemia patient, showing ovalo-macrocytosis of red blood cells and hypersegmented neutrophils (8 lobes

STUDENT PERFORMANCE GUIDE

SICKLE CELL ANEMIA

Name:
Date:

Instructions

1. Practice identifying sickled cells from a sickle cell preparation slide.
2. Identifying erythrocytes morphology changes “sickle shaped or holy-leaf.
3. Complete a written examination successfully. .

Material and Equipments

- Metabisulfate powder
- Suspension of whole red cells in saline
- Slid and cover slip
- Lens paper
- Microscope
- Soft laboratory tissue
- Drawings and descriptions of red blood cells

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant			
2. Assemble equipment and material			
3. Mix capsule of sodium metabisulfate with 10 ml distilled water.			
4. Mix equal parts of fresh blood and sodium metabisulfate solution together on glass slide. Cover with slips and place on a wet sponge			
5. Observe immediately and at intervals for 15 minutes. Sickle cells may appear as sickle-shaped or holy leaf cells			
6. Bring cells into focus using low power (10x)			
7. Focus with fine adjustment knob until cells can be seen clearly			
8. Raise the condenser and open the diaphragm to allow maximum light into objective			
9. Bring cells into focus using high power (40x)			
10. Report what you see			
11. Rotate high power objective into position			
12. Remove slide from the microscope stage			
13. Clean lenses thoroughly			
Comments			

Date:----------Instructor----------



ACUTE LEUKEMIA 11

OBJECTIVES

- Clinically and morphologically distinguish acute and chronic leukemias
- Characterize blasts of lymphoid and myeloid origin
- Explain the subclassification of acute myeloblastic and Lymphoblastic leukemias

GLOSSARY

- **Acute lymphocytic leukemia (ALL)** - A rapidly progressing cancer of the blood in which too many immature (not fully formed) lymphocytes, a type of white blood cell, are found in the bone marrow, blood, spleen, liver, and other organs.
- **Acute myelogenous leukemia (AML)** - A rapidly progressing cancer of the blood in which too many immature (not fully formed) granulocytes, a type of white blood cell, are found in the bone marrow and blood.
- **M:E ratio**: Myeloid:Erythroid ratio is determined by dividing the number of nonlymphoid leukocytes and their precursors counted in the marrow by the number of nucleated erythroid precursor counted .

ACUTE LEUKEMIA

Acute leukemias are stem cell disorders characterized by a neoplastic proliferation and accumulation of immature hematopoietic cells in the bone marrow.

Classification

1. Acute Myelomonocytic or Myeloblastic (Non-Lymphoid)
2. Acute Lymphocytic or Lymphoblastic

In AML, the myeloblast are peroxidase and Sudan black B positive, whereas in the entire lymphoblastic are negative. The finding of Auer rods or granules in blast cells on Romanowsky stained smear will also help identify blasts of the myeloid lineage.

FIGURE 1: DIFFERENTIATION BETWEEN AML AND ALL. REMEMBER BIG AND SMALL

AML		ALL	
Big people (Adult) Big blasts Lots of cytoplasm Lots of nucleoli (3-5) Lots of granules and Auer rods Big toxicity of treatment Big mortality rate Myeloperoxidase		Small people (children) Small blasts Little cytoplasm Few nucleoli (1-3) No granules Little toxicity of treatment Small mortality rate PAS (periodic acid schiff))	

FAB-CLASSIFICATION: French-American-British cooperative group has classified the acute leukemia into subcategories according to the morphologic and cytochemical characteristics.

FAB-ACUTE LEUKEMIA CLASSIFICATION

M0 MYELOBLASTIC LEUKEMIA MINIMALLY DIFFERENTIATED
M1 MYELOBLASTIC LEUKEMIA WITHOUT MATURATION
M2 MYELOBLASTIC LEUKEMIA WITH MATURATION
M2 baso MYELOBLASTIC WITH BASOPHIL BLASTS
M3 HYPERGRANULAR PROMYELOCYTIC LEUKEMIA
M3 variant MICRO OR HYPOGRANULAR BILOBED PROMYELOCYTE
M4 MYELOMONOCYTIC LEUKEMIA (M4 AND M4 EOS)
M5 MONCYTIC LEUKEMIA (M5a POORLY Diff AND M5b Well diff)
M6 ERYTHROLEUKEMIA
M7 ACUTE MEGAKARYOBLASTIC LEUKEMIA

L1 SMALL HOMOGENOUS
L2 LARGE HETEROGENOUS
L3 BURKITT'S CELL TYPE

ACUTE MYELOBLASTIC (NON-LYMPHOCYTIC) LEUKEMIAS (AML)

AML occur primarily in adults and in infants less than a year old, and accounts 15% of the leukemias in children.
AML is sharp increase in adults over 50 years old.

Pathophysiology

It is not known how a hemopoietic progenitor becomes leukemia but damage to the cells genetic program is though to accumulate as a result of multiple separate events.
1. Radiation: The association between radiation induced genetic damage to the hematopoietic progenitors and the development of myelodysplasia and acute leukemia is seen following nuclear disasters (e.g Hiroshima, Nagasaki, and Chernobyl)
2. Chemical drugs: Drugs and chemicals that cause bone marrow depression or aplasia are capable of producing leukemia and thus are referred to as leukemogens; some of those are chloramphenicol, phenylbutazone, arsenic-containing compounds, sulfonamides and some insecticides. Certain cytotoxic agents used in the treatment of neoplasm are likewise potentially
3. Oncogenes: Molecular studies of viruses associated with certain animal malignancies have revealed a family of viral genes known as oncogenes.
4. Proto-oncogenes: Similar viral oncogenes.
This prot-oncogene concerned with the regulation of cell growth. e.g retinoic acid receptor.
5. Genetic factors: Chromosome aberration, including aneuploidy and breakage, are demonstrated in several diseases associated with an increased incidence of ANLL. These diseases include Down's syndrome (Trisomy 21), Fanconis anemia (excessive chromosome breakage), Bloom syndrome (marked chromosomal breakage and rearrangement) and D-trisomy. Congenital leukemias are usually non-lymphocytic. Studies of cases of familial leukemia are also highly supportive of the genetic etiology of acute leukemia

6. Viruses: There is no conclusive evidence that viruses are causative agents of human leukemia. However, type CRNA viruses are recognized as being the most common class of tumor viruses associated with animal leukemia and lymphoma e.g HTLV-1 may cause T-cell leukemia/Lymphoma syndrome.

It is believed that the leukemic clone originates from a single mutant progenitor cell. The mutant cell retains the ability to proliferate, but has the capacity to differentiate and mature. The target cell in the malignant transformation may be the myeloid stem cell (CFU-S) or a more mature committed stem cell.

Hematological Findings

Anemia is normocytic normochromic, at the time of diagnosis. Occasionally, a macrocytic anemia with hypersegmented PMNs is found but the anemia does not respond to vitamin B12 or folic acid treatment. Nucleated RBC, anisocytosis, poikilocytosis are found on the blood smear. The platelet count is moderately depressed.

Hypogranular and giant forms are commonly.

The WBC count is variable, ranging from less than 1000 to >100000/μL, about 50% of the patients have a normal or decreased leukocyte count at the time of diagnosis; regardless of the WBC, diagnosis of AL is suggested by the presence of blasts on the blood smear.

Blasts usually compose from 15-95% of all nucleated WBC.

When Auer rods can be found in myeloblasts, monoblasts, and occasionally in more differentiated monocytic cells.

The monocytosis frequently precedes overleukemia.

The few mature neutrophils present frequently demonstrate signs of dysplasia; pseudopelger-Huet anomaly, hypogranulation and small nuclei with hypercondensed chromatin. Eosinophils and basophils may be mildly to markedly increase.

ESR moderately or markedly increased.

Bone marrow always indicated. Morphologic typing is according to French-American-British (FAB) classification. Bone marrow is hypercellular with sheets of blasts and normal cells. In leukemia with severe peripheral leukopenia, blasts are difficult to find in the blood but are always present in abnormal amounts in the bone marrow.

Blasts most compose 30% or more of all nonerythroid-nucleated cells in the marrow to distinguish leukemia from the myelodysplastic syndromes.

Auer rods present in blasts of 50% of AML and are never found in ALL. When Auer bodies are absent, blast morphology alone does not permit distinction of myeloblasts from lymphoblasts. Cytochemistry is necessary to define the myeloid nature of the blast cell population.

Cytochemistry, including Sudan black, and or myeloperoxidase, NASDA, NASDA-F, Acid phosphatase, Acid esterase and PAS (see table 12.2).

TABLE 2: CYTOCHEMICAL DIFFERENTIATION OF ACUTE LEUKEMIA

	Peroxidase	Sudan B B	PAS	ANAE
AML-M0	**(+)**	**(+)**	**-**	**-**
AML (M1,M2)	**+ to +++**	**+++**	**-**	**-**
AMMoL (M4)	**- to ++**	**+ to ++**	**-**	**+**
AMoL (M5)	**-/+**	**-/+**	**-**	**+++**
AML (M6)	**-**	**-**	**++**	**-**
AML (M7)	**-**	**-**	**-**	**-**
ALL	**-**	**-**	**++**	**-**



FIGURE 2: VERY LARGE, IMMATURE MYELOBLASTS WITH MANY NUCLEOLI. A DISTINCITVE FEATURE OF THESE BLASTS IS A LINEAR RED "AUER ROD"( ) COMPOSED OF CRYSTALLIZED GRANULES. THESE FINDINGS ARE TYPICAL FOR ACUTE MYELOGENOUS LEUKEMIA (AML).

Immunophenotyping

It is done on bone marrow or peripheral blood samples. The antibodies used include for ALL B lineage: CD19, CD10, CD20 and CD22. For T-lineage: CD2, CD3, CD4, CD5, CD7 and CD8. For myeloid lineage: CD13, CD33, M5 CD14 and for M6: antiglycophorin and for M7: CD 41 and CD42 and antifactor VIII.

Other Findings

Hyperurecemia and an increase in LDH

Hypercalcemia with increase bone resorption, associated with leukemia proliferation in the bone marrow.
Increase serum and urine muramidase (lysozyme) are typical finding in those leukemias with a monocytic component (M4 and M5).

Other Specific Studies

Karyotyping; gene rearrangement for some cases.
Electronmicroscopic studies for some cases

AML-M0: MYELOBLASTIC LEUKEMIA MINIMALLY DIFFERENTIATED

M0 is the most common in adult patients. Accounts for approximately 5-10% of all AML patients. WBCs show Leukocytosis in 40% and > 50% with leukocytopenia.
The diagnosis is made if less than 3% of the blasts are positive for Peroxidase or the Sudan black B reaction and if the Blasts are positive for the myeloid-associated markers CD13, 14, CD15 or CD33, CD34 and negative for B or T lineage marker (CD3, CD10, CD19 and CD5). Bone marrow aspirate was hypercellular in all patients and contained a large number of leukemic blasts. Almost no mature myeloid cells were seen. The blasts were small to medium-sized round cells with an eccentric nucleus. The nucleus often had a flattened shape and was sometimes lobulated or cleaved and contained fine chromatin with several distinct nucleoli. The cytoplasm was lightly basophilic without granules. Auer rods are not found.

AML-M1 MYELOBLASTIC LEUKEMIA WITHOUT MATURATION

It is found in all aged groups with highest incidence seen in adult and in infants less than a year old.
Leukocytosis in about 50% of patients at the time of diagnosis. The predominant cell in the peripheral blood is usually a poorly differentiated myeloblast with finely reticulated chromatin and prominent nucleoli.
Auer rods are found in the blast of 50% of the M1. If no evidence of granules or Auer rods is present, the blasts may resemble L2 lymphoblast.
The myeloperoxidase or Sudan black B stains are positive in more than 3% of the blasts indicating granulocytes differentiation.
PAS negative. Alpha-naphthyl acetate esterase and naphthol AS-D-Esterase are negative.
About 50% of the patients will have acquired clonal chromosome aberrations in the leukemic cells. CD13, 14, 15, 33 and CD34 myeloid antigens are frequently positive in M1 leukemia. The most common cytogenitic abnormalities are: t (9; 22) (q34; q11)



AML- M2 MYELOBLASTIC LEUKEMIA WITH MATURATION

The presenting symptoms for M2 AML are similar to those of the M1 type. Leukocytosis in 50% of patients. Myeloblast can usually be found in the blood smears and may be the predominant cell type. Pseudopelger–Huet and hypogranular neutrophils being most common seen in M2.
The bone marrow is hypercellular and types I and II myeloblasts make up from 30-83% of the promyelocytes to mature segmented cells. The monocytic component is less than 20%, differentiating M2 from M4. Increased basophil in some patient (M2 baso).Eosinophil may be increased.

Cytochemistry

Peroxidase and Sudan black B is positive. NaF does not inhibit esterase. PAS is negative.
Nonspecific esterase is negative.
Positive reaction with CD13 and CD15 antigens are frequently seen in cases of M2
Some of M2 have a translocation between chromosome 8 and 21 and (q22; q22)



AML M3: PROMYELOCYTIC LEUKEMIA

Occur in younger adult. Median age and survival average about 18 months. M3 is of particular interest because it results in the fusion of a truncated retinoic acid receptor alpha (RAR-alpha) gene on chromosome 17 to a transcription unit called PML (for promyelocytic leukemia) on chromosome 15. It is interesting to note that high doses of the vitamin A derivative all-trans-retinoic acid are able to overcome thus block in differentiation both in vitro and in vivo and this agent has been successfully used to induce remission in patients with AML.
The most clinical finding in initial diagnosis is bleeding.
It is believed that the release of large numbers of promyelocytic granules containing a procoagulant initiate disseminated intravascular clotting (DIC). This is the most serious complication of M3 AML. Two forms of M3 have been described the typical hypergranular type, and the hypogranular or microgranular variant.
Cytochemistry: Peroxidase and Sudan black B are positive
The PAS is negative. Nonspecific esterase is negative.
Immunological studies demonstrate positivity with CD13, CD15, CD1 and CD33 myeloid antigens.
Cytogenetic studies have revealed a high prevalence (almost 50%) of the chromosomal translocation t (15; 17 associated with both AML M3 and M3m variant



AML- M4 MYELOMONOCYTIC LEUKEMIA (Naegel, monocytic leukemia)

It is distinguished from M1, M2, and M3 by an increased proportion of leukemia monocytic cells in the bone marrow or blood or both. Gingival hyperplasia with gingival bleeding is present.
Serum and urine levels of muramidase (lysozyme) are usually elevated because of the monocytic proliferation.
The leukocyte count is usually increased monocytic cells (monoblast, promoncytes monocytes). Are increased to 5000/μL or more.
Anemia and thrombocytopenia are present in almost all cases.
The marrow differs from M1, M2 and M3 in those monocytic cells exceed 20% of the nonerythroid nucleated cells.
The sum of the myelocytic cells including myeloblasts, promyelocytes and later granulocytes is >20% and <80% of nonerythroid cells. This bone marrow picture together with a peripheral blood monocytes count of 5000/μL or more is compatible with a diagnosis of M4.
Confirmation of the monocytic component of this subgroup requires Cytochemistry. The profile includes positive reactions for sudden black B or Peroxidase and both specific and non-specific esterase. A few cases of M4 AML are characterized by increased marrow Eosinophil and classified as M4e.
Immunological studies demonstrate positivity with CD13, CD33, CD11b and CD14
Cytogenitic: inv (16) (p13; q22) and del (16)(q22)



AML-M5 MONOCYTIC LEUKEMIA (Schilling leukemia)

Common findings: weakness, bleeding and a diffuse erythematous skin rash.
There is a high frequency of extramedulary infiltration of the lungs, colon, meninges, lymphnodes, bladder and larynx.
Gingival hyperplasia (Mouth and gums).
Serum and urinary muramidase levels are often extremely high.
The one criterion for a diagnosis of M5 is that 80% or more of all nonerythroid cells in the BM are monocytic cells.
There are two distinct forms 5a (maturation index <4%) and 5b (maturation index > 4%).
M5a: Granulocyte <20% and Monocyte >80% >80% monoblast
M5b: Granulocyte <20% and Monocyte >80% <80% monoblast (Characterized by the presence of all developmental stages of monocytes; monoblast, promonocyte, monocyte)
Non-specific esterase stains and alpha-naphthyl esterase is positive. PAS is negative.
Myeloperoxidase and Sudan black are weak diffuse activity in the monoblast.
Immunological studies demonstrate positivity with CD11b and CD14
Abnormalities of the long arm of chromosome 11 associated with either chromosome 9 or 19.



AML-M6 ACUTE ERYTHROLEUKEMIA (DiGuglielmo)

M6 is a rare form of leukemia that primarily affects the peripheral cells. It is nonsexist in children. Clinical manifestations are similar other types of AML.
The most frequent presentation is bleeding.
The most dominant changes in the peripheral blood are anemia with sticking poikilocytosis and anisocytosis. Nucleated red cells demonstrate abnormal nuclear configuration. The leukocyte and platelets are usually decreased.
The diagnosis of erythroleukemia can be made when more than 50% of all nucleated bone marrow cells are erythroid and 30% or more of all remaining nonerythroid cells are type I or type II blast cells. The erythroblast is abnormal with bizarre morphologic features. Giant multilobular or multinucleated forms are common. Other features are; fragmentation, Howell-Jolly bodies, ring sideroblast, and megaloblastic changes. Dyserythropoiesis is common.
Cytochemistry: Erythroblasts are normally PAS negative. In M6, erythroblasts especially pronormoblast demonstrates coarse positivity of PAS.



AML-M7 ACUTE MEGAKARYOBLASTIC LEUKEMIA

M7 is rare. It occurs as a leukemia transformation of CGL and MDS. Anemia and pancytopenia is characteristic at initial diagnosis.
Peripheral blood shows micromegakaryocytes and undifferentiated blasts.
Bone marrow dry tap is common.
Bone marrow biopsy show increased fibroblasts and/or increased reticulin and presence of greater than 30% blast cells
Cytochemistry: Peroxidase is negative, PAS +/-, Esterase +/-and positive acid phospatase. Cytochemical positivity for α-naphthyl acetate esterase reaction and negative reaction with α-naphthyl butyrate esterase is unique to megakaryoblast. (Monocytes react positively with both esterase substrates).
The monoclonal antibodies that reacts with platelet glycoprotein Ib, IIb/IIIa and IIIb, using immunologic technique as well as CD41, CD42 and CD61 positivity**.**
Cytogenetic: Abnormalities of chromosome 21



Other Types

Hybrid leukemias: Are leukemias with both myeloid characteristics. They may be bilineal (a mixed population of cells expressing either myeloid or lymphoid features) or biphenotypic .The bilineal hybrid leukemia may occur synchronously (at same time) or metachronously (one leukemia followed by a relapse with a different type.

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

ALL is malignant disease of the lymphopoietic system that is manifested by the slow but uncontrolled growth of abnormal, poorly differentiated lymphoid cells whose DNA synthesis time is significantly longer than in normal tissue.
ALL is a primary disease of young children (peak 2-5 years). The malignant lymphocytes replace normal hematopoietic tissue in the bone marrow, spleen, liver and other organs.
The predominant cell in the bone marrow and peripheral blood can be identified as a lymphoblast.

Etiology
Unknown, but more common in patients with:
Immuno-deficiency
Genetic factor: Chromosomal anomalies (Down syndrome), Turner, Klinfiter
Ataxia telangiectasia, Schwachmann syndrome, Trisome 9, 13, 21 and monosome 7.
Leukemia in congenital disease is characterized by increased proliferation of blast cells, hyperleukocytosis and extramedullary infiltration (skin, lung)
Ionizing radiation
Exposure to electromagnetic field
Chemicals: alkaliting agents
Infections: EBV

Pathophysiology
The mutation of a single lymphoid stem cell is giving rise to a clone of malignant lymphocytes. These lymphoid cells retain the ability to proliferate in an unregulated manner but appear to be frozen in their maturation sequence.

Classification

Morphological Classification (FAB)

ALL is divided in FAB L1 (children), L2 (older children and adult), and L3 (patients with leukemia secondary to Burkitt's lymphoma. These types are defined according to two criteria (1) the occurrence of individual cytologic features and (2) the degree of heterogeneity among the leukemic cells. These features considered are cell size, chromatin, nuclear shape, nucleoli, and degree of basophilia in the cytoplasm and the presence of cytoplasmic vacuolation.

L1: HOMOGENOUS (Small cell): One population of cells within the case. Small cells predominant, nuclear shape is regular with occasional cleft. Nuclear contents are rarely visible. Cytoplasm is moderately basophilic. Best prognosis. L1 is accounts 70% of patients. The L1 type is the acute leukemia that is common in

childhood, with 74% of these cases occurring in children 15 years of age or younger.

L2: HETEROGENOUS (Large cell): Large cells with an irregular nuclear shape, cleft in the nucleus are common. One or more large nucleoli are visible. Cytoplasm varies in color and nuclear membrane irregularities. L2 accounts 27% of ALL patients. The FAB-L2 blast may be confused with the blasts of acute myeloid leukemia. Approximately 66% of these cases of ALL in patients older than 15 years are of type 2

L3: BURKITT'S LYMPHOMA TYPE: Cells are large and homogenous in size, nuclear shape is round or oval. One to three prominent nucleoli and some times to 5 nuleoli are visible. Cytoplasm is deeply basophilic with vacuoles often prominent.
Patients with L3 leukemia generally have a poor prognosis because their disease responds poorly to chemotherapy.
By immunologic markers, these are B-cell malignancies. A high mitotic index is characteristic patients with L3 leukemia generally have a poor prognosis because their disease responds poorly to chemotherapy.

Immunological Classification

This classification based on cell membrane markers:
1. **T-ALL**: Cells reacts with monoclonal antibodies against T-cell antigen (CD3, CD5 and CD2. About 50% of these patients have a mediastinal (thimic) mass
2. **B cell**: Cell reacts with anti-Ig reagent. And TdT is negative.
B-ALL usually corresponds to the morphological L3 type whereas the CD10+, null, pre-B or T types may all be L1 or L2 and are morphologically indistinguishable.
Burkitt's cell leukemia is positive for HLA-DR, CD9, CD22 and CD24
3. **Pre-B cells ALL**: These cells are characterized by the presence of HLA-DR, TdT, CD19, CD20 and CD24. CD10 (CALA) may be present.
4. **Common-ALL (Pro-B precursor**): The leukemic cells in this group are characterized by the presence of HLA-DR, CD10, CD19, CD24 and some time CD20. A polyclonal antibody to what is known as common acute lymphoblastic antigen (CALA), CD10 was produced by immunization or rabbits with sIg and erythrocyte-rosette-negative ALL cells. CD10 is present on the leukemic cells of 70% of patients with ALL. This type accounts for approximately 85% of childhood and 75% of adult ALL. Common ALL has the highest remission rate and the longest initial remission with chemotherapy.

Clinical Features

Symptoms: Fatigue, fever (infection), headache, nausea, vomiting.
Bone and joint pain related to the replacement of normal hematopoietic elements.
Pain in the extremities is produced by an infiltration of leukemic cells into the tissues.

Physical Examination

Pallor
Evidence of hemorrhage, petechiae and also GI bleeding and hematuria.
Lymphadenopathy and hepatomegaly in 75% of patients.
Leukemic meningitis and cranial nerve palsies, headache and blurred of vision (due to nerve infiltration by leukemic blasts are quite common).
Nephropathy may be present (Lysis leukocytes after therapy).

Laboratory Findings

Leukocytosis is common in 75% of patients and leukocytopenia in 25%
Peripheral blood smear: Blast cells in 50% of patients. The peripheral blood composed of 100% Lymphoblasts, Lymphocytes, and smudge cells.
Anemia is common due to:

- Decreased RBC production
- Blood loss
- Severe thrombocytopenia

Bone Marrow
BM is almost always hypercellular and heavily infiltrated with or even replaced by lymphoid cells. Fibrosis is present in 10-15%. More than 30% are lymphoblast. Auer rods are not present in lymphoblasts.

Cytochemistry
Peroxidase and Sudan black B stains are negative. PAS is Positive (coarse granular)
Acid phosphatase is positive in T-cell ALL
Chest x-ray to demonstrate mediastinal masses if present.
Bone X-ray (Skeletal survey) to detect involvement of bones
CSF examination is used for the detection of early CNS invasion.
Renal function and serum uric acid should be estimated before start of treatment.
A serous complication in ALL is infection and it is the primary cause of death in ALL. The incidence of infection is directly related to the degree of granulocytopenia.

TABLE 5: MARKERS USEFUL FOR SUBCLASSIFICATION OF ALL

Surface marker, protein on the cell membrane that can be detected with immunologic methods:

Type	TdT	CALLA	CD7	CD19	HLA-DR	sIg	Morphology
Common ALL	+	+	0	+	+	0	L1/L2
Pre B- ALL	+	+	0	+	+	0	L1/L2
B cell ALL	0	0	0	+	+	+	L3
T cell ALL	+	0	+	0	0	0	L1/L2

TdT - Terminal deoxynuceotidyl transferase
CALLA - common ALL antigen
sIg - surface immunoglobulin



FIGURE 8 : IMMATURE LYMPHOBLAST CELLS WITH LARGER NUCLEI THAT CONTAIN NUCLEOLI. SUCH LYMPHOBLASTS ARE INDICATIVE OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL).



(A) Acute Lymphoblastic leukemia (ALL-L2)



ALL-L3

STUDENT PERFORMANCE GUIDE

ACUTE LEUKEMIA

Name:
Date:

Instructions

1. Practice identifying immature leukocytes from a stained blood smear.
2. Identifying pathological blast cells and pathological changes of WBCs, RBCs, and platelets
3. Differentiate between Myeloblast and Lymphoblast
4. Complete a written examination successfully. .

Material and Equipments

- Stained blood smear
- Microscope
- Lens paper
- Oil immersion
- Soft laboratory tissue
- Drawings and descriptions of stained blood smear

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant			
2. Assemble equipment and material			
3. Place stained smear on microscope stage and secure it with clips			
4. Bring cells into focus using low power (10x)			
5. Scan slide to find area of slide where cells are barely touching each other			
6. Place one drop of immersion oil on slide			
7. Rotate oil immersion objective carefully into position			
8. Focus with fine adjustment knob until cells can be seen clearly			
9. Raise the condenser and open the diaphragm to allow maximum light into objective			
10. Scan slide to observe WBCs changes and differentiate between myeloblasts and lymphoblasts			
11. Report what you see			
12. Rotate low power objective into position			
13. Remove slide from the microscope stage			
14. Clean oil objective thoroughly			
15. Clean oil from slide gently			
Comments			

Date:----------Instructor----------



CHRONIC LEUKEMIAS

12

OBJECTIVES

- Clinically and morphologically distinguish acute and chronic leukemias
- Discuss the manifestations of a variety of chronic leukemias

GLOSSARY

Leukocytosis: increase above normal in the number of leukocytes in the blood
Leukopenia: Decrease below normal in the number of leukocytes in the blood
Granulocytes - These are leukocytes which have specific granules. The three different types of granulocytes have different types of specific granules. Granulocytes are spherical in shape, contain nuclei and include neutrophils, eosinophils, and basophils. These cells are part of the formed elements of whole blood.
Lymphocytosis: An increase in the number of lymphocytes in the blood. It may occur in chronic lymphatic leukemia and viral infections



Chronic Myeloid Leukemia



Chronic Lymphatic Leukemia

CHRONIC MYELOPROLIFERATIVE DISORDERS

Chronic myeloproliferative disorders are neoplastic diseases of bone marrow, which affect one or more of hemopoietic elements. CMPDs usually are found in patients in their fifth and sixth decades.
Cells involved in the CMPDs include mature and immature granulocytes and platelets.

1. Chronic myeloid leukemia (CML)
2. Polycythemia Vera
3. Idiopathic myelofibrosis with myeloid metaplasia
4. Essential thrombocythemia

Pathophysiology:

- Increased proliferation and myelofibrosis
- Panhyperplasia of hemopoietic cells in the BM
- Extramedullary hematopoiesis (myeloid metaplasia of liver and spleen)

This inturn lead to transformation of this syndrome to acute leukemia, myelofibrosis and myeloid metaplasia**.**

TABLE .1 DIFFERENTIAL DIAGNOSIS OF MYELOPROLIFERATIVE DISORDERS

	CML	PV	IMF	ET
Age	>30	>50	>50	>50
Sex	M>F	M>F	M>F	M>F
Cell affected	Granulocyte	Erythrocyte	Fibroblast	Platelets
Peripheral blood:				
RBC ($X10^{12}$/l)	<5.5	6.5	<5.6	<5.5 – N
WBC ($X10^{9}$/l	>30	<50	<50	<50 – N
Platlets($X10^{9}$/l	N-Increase	N-Increase	N-Increase	>600
<u>Bone marrow</u>				
Myelopoiesis	Increase +++	Increase++	I-N-D	Increase++
Erythropoiesis	N-Decrease	Increase+++	I-N-D	I-N
Megakaryopoiesis	N-Increase	Increase++	I-N-D	Increase
Splenomegally	++	+/-	+++	+++
Myelofibrosis	+/-	+/-	+++	+/-
Philadelphia	+	-	-	+/-
ANP	Decrease	Increase	N-I	N-I
I= increase, D= decrease and N= normal				

CHRONIC GRANULOCYTIC LEUKEMIA

(Chronic myelocytic leukemia, chronic myeloid leukemia, and chronic myelogenous leukemia are synonyms for chronic granulocytic leukemia)

CML is a disease predominantly of middle life. In more than 90% of patients there are bone marrow abnormalities of the chromosome (Philadelphia chromosome-Ph^1). It is a reciprocal translocation between parts of the long arms (q) of chromosome 22-G-group and C-group-chromosome 9 in nearly all instances. The resulting fusion gene (BCR-ABC) produces an altered protein believed to plat a key role in the development of CML (figure 13.1).

Etiology

Remain obscure
Epidemiological factors
1. Exposure to ionizing e.g radiologist, and in atomic bomb explosion
2. Chronic exposure to benzene

Clinical Feature

Age 50-60 years and is possible in children.
Onset insidious
Hypermetabolic alteration: loss of weight, night sweats, loss of appetite.
Splenomegaly in most patients is gross (Huge) with pain in abdomen and under left costal margin. Splenic infarction with severe pain is common.
Anemia symptoms: Pallor, dyspnoea and tachycardia.

Hemorrahage manifestations: Easy bruising, nose bleeding, menorrhagia and hematomas.
Others: Gout, visual disturbance, neurological abnormalities e.g priapism (due to obstruction to blood flow in the corpus cavernosum.

Blood Picture

Anemia is moderate with Hb 8-10 g/dl. As disease progress, the anemia becomes more severe. RBC is usually normocytic and normochromic and a small proportion of erythroblasts are occasionally present.

Leukocytes: Leukocytosis up to 500,000/μL or more. Segmented neutrophil and myelocyte constitutes the majority of cells. Neutrophil varies in size, giant and dwarf forms being common. Myelocytes are the characteristic cells and comprise 10-50% of the white cells. The vast majority are neutrophilic, although a few are eosinophilic and basophilic.

Myeloblast comprises up to 10%, but can rapidly increase in proportion when Blast cells occur. An increase in the proportion of basophils (2-10%) is a characteristic feature and can increase further as the disorder progresses towards transformation to acute leukemia**.**
The serum vitamin B12 and unsaturated vitamin B12 binding capacity are frequently increased. Uric acid is elevated. The level of serum LDH is considerably elevated in CGL

Cytochemistry
Alkaline Neutrophilic phosphatase
The absence or diminution of alkaline phosphatase in the granulocytes is characteristic but not diagnostic in CML.
Normal activity is about 10-90 %
Decreased or absent in CML (0-6%), congenital hypophosphatase, paroxysmal nocturnal hemoglobinuria, sideranemia and rheumatic disease.
Increased activity in: Osteomyelosclerosis, Polycythemia Vera, acute leukemia, Hodgkin's lymphoma, pernicious anemia, multiple myeloma, sepsis and carcinoma. Essential thrombocythemia, leukomoid reaction, sarcoidosis, and fever secondary to infection.

TABLE 2. STAGES OF CHRONIC MYELOID LEUKEMIA

A. Chronic phase Blood GP: Pathological shift to left Pseudopelger Eosinophil increased Basophil increased EP: Normoblast occur and anisocytosis Thp;Platelet mostly increased anisocytosis.mmature platelets present	Bone marrow GP: Hyperplasia shift to left Eosinophil increased Basophil increased EP: Decreased (absolute or relative) Thp: Megakaryocytes most increased, with abnormal form
B. Accelerated phase Gp: Pathological shift to left with blast <20% Basophils increased <30% Ep: Normoblasts anisocytosis, polychromasia Thp: Platelets normal or decreased with anisocytosis	Gp:P pathological shift to left with blast 15-29% Basophils increased Ep: Decreased Thp: Normal or decreased
C. Acute phase (Blast crises) Gp: Blast cells increased Ep: Anisocytos. polychromasia Normoblast Thp Decreased or absent with anisocytosis	Gp:Blast cells increased >30% Ep: Decreased Thp: Decreased
NB: in most cases, the blast cells are myeloid in type, but in 20-30% the blast cells are lymphoblastic cells.	



FIGURE 1: CHRONIC MYELOID LEUKEMIA

Bone Marrow

Marrow aspiration yields hypercellularity fragments. The cell trails are hypercellular. The cells are mainly of the myeloid series, the myelocyte being the predominant cell, although promyelocytes and myeloblasts are also increased. There is shift to left
Erythropoiesis: is normoblastic, but sometimes dyserythrocytic.
Myeloid: Erythroid ratio (M:E) is increased due to white cell hyperplasia and in the later stages there may be an actual reduction in erythropoietic tissue.
Megakaryocytes: Are often prominent and are usually smaller than normal.

Chromosome Finding

Cytogenetic studies of bone marrow and peripheral blood cells showed that, the Philadelphia chromosome is characteristically associated with the neoplastic cells in CML.

The Philadelphia chromosome usually cannot be detected in the peripheral blood when the immature cells have disappeared, but it persist in the bone marrow cells. 92% of ph^1-positive patients have the typical t(9;22), the remainder have variant translocations. Ph^1 -negative CML represents a heterogenous group of myeloproliferative or MDS and perhaps should not be called CML.

75%-80% of patients in a blast crisis of CML develop other chromosome aberrations in addition to the ph^1 chromosome. The most common abnormalities are a duplication of the ph^1 chromosome and trisomy 8.

CHRONIC LYMPHOPROLIFERATIVE DISORDERS

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

CLL is the proliferation and accumulation of lymphocytes (usually B cells) that are relatively unresponsive to antigenic stimuli. CLL is a disease predominantly of the middle and older age group with 90% of the patients being older than 50 years of age and nearly 65% older than 60. Male are affects twice as frequently as females.

Clinical Features

Common Features

1. Symmetrical lymph node enlargement in most of the patients
2. Symptoms and signs of anemia

An important complication in approximately 10% of cases is acquired hemolytic anemia. This is sometimes the first manifestation of chronic lymphatic leukemia. It should be suspected when the degree of anemia is in appropriately severe for the degree of lymph node and splenic enlargement, the degree of lymphocytosis, or when spherocytes or agglutination are present in the blood Film.

Occasional Features

3. Spleen and liver enlargement.
4. Hemorrhagic manifestation in patients with thrombocytopenia.

The causes of thrombocytopenia are like ITP. This type of thrombocytopenia is respond to corticosteroid or splenectomy.

Impaired platelet production due to hemopoietic tissue replacement by the diseases or from myelosuppressive effects of agents used for therapy of the disorder.

5. Respiratory and other infections
   Causesd by:
   - Impaired Ig production
   - Neutropenia
   - Corticosteroid administration.
6. Skin infiltration
7. Tonsillar enlargement.
8. Nervous system manifestations are due to N.S. infiltration
9. Bone or Joint pain.
10. Disturbance of vision or hearing.



FIGURE 2 : CHRONIC LYMPHATIC LEUKEMIA

Blood Picture

Hb is normal in early stages to moderate or severely depressed values in advanced CLL.

Anemia is usually normochromic and normocytic. When anemia is due to hemolysis, it usually has the typical features of autoantibody-mediated red cell destruction, with spherocytosis, a positive Coomb's test, and a reticulocytosis.

Typical Feature of CLL

Leukocytosis, with lymphocytes count is ranged from 50,000 to 200,000/μL following statement is correct about although it is occasionally greater. Sometimes leukocytes are less than 10,000. 90% or more of the leukocytes are mature lymphocytes, mostly small with a thin rim of cytoplasm. In some cases the lymphocytes are of medium size. The cells in the blood film tend to have a monotonous appearance, although some may be disrupted during the preparation of the film and are referred to as "smear' cells.

Neutrophils: Normal in early stage. When it become depressed as a consequence of:

1. Replacement of normal hemopoietic by disorder.
2. Hypersplenic effects.
3. Myelosuppression by cytotoxic therapy.

Thrombocytopenia, with counts less than 50,000/μL is common.

Serum Immunogbulin decreased in most CLL in late stages. It may fall to 0.3 to 0.4 g/dl and patient become more susceptible to all types of infection.

Bone Marrow Aspiration and Biopsy

Usually are not necessary for making the diagnosis of CLL except in those aleukemic or subleukemic cases with no nodal or splenic involvement and few or no abnormal cells in the peripheral blood.

In marrow there is increase of lymphocytes and a corresponding reduction of megakaryocytes, myeloid precursors, and erythroid precursors.

Chromosomal abnormalities are detected in more than 50% of patients with CLL and indicate a worse prognosis. The most frequently encountered is trisomy 12 (+ 12). Other cytogenetic abnormalities are 14q translocation.

In more than 90% of the cases, CLL lymphocytes express the CD5 antigen, which was formerly thought to be a T-cell antigen. Cells from most cases of B-CLL also expresses CD19, CD24, CD37 and CD21 antigen. About 60% of CLL are positive for CD23 but infrequently demonstrate positivity for CD22

TABLE 14.1: THE RAI STAGING FOR CHRONIC LYMPHOCYTIC LEUKEMIA

Stages	Characteristics	Survival
0	Peripheral blood lymphocytosis >15000/μL	>150 months
I	Lymphocytosis and lymphadenopathy	100 months
II	Hepatomegaly or splenomegaly or both	71 months
III	Anemia (<11g/dl or Hct <33%)	19 months
IV	Thrombocytopenia (platelets < 100,000/μL	19 months
Adapted from Rai KR, et al, Clinical staging of chronic Lymphocytic leukemia. Blood 1975; 46:219		

PROLYMPHOCYTIC LEUKEMIA

This is a rare form of lymphocytic leukemia in which the circulating lymphoid cells are larger and less mature in appearance than lymphocytes in chronic lymphatic leukemia.
Occur more often in elderly males and associated with splenomegaly (splenic tumour), but not particularly with lymphadenopathy.
The lymphocyte count in the peripheral blood can be greatly increased, as high as 200,000/μl and the abnormal cell population in most cases has a surface phenotype of B cell.
The prognosis for PLL is considerably poorer than for either CLL or HCL. The mean survival is reported to be less than 1 year.

HAIRY CELL LEUKEMIA

HCL is a lymphoproliferative syndrome characterised by the presence in the bone marrow, spleen and the peripheral blood of mononuclear with hairy cytoplasmic projection, which can be detected by phase contrast microscope.

Epidemiology

Incidence is 2 to 5% of leukemias. 2-3/1000000 per year
Sex: M/F 4:1, Age 40-60 years

Etiological Factors

Unknown
Ionizing, radiation and chemicals are considered as etiological factors

Clinical Pictures

Men are more often affected (4:1 to 5:1) with the median age at diagnosis being 55 years. Virtually none younger than 20 is affected. General signs are asthenia and general weakness

Tumoral syndromeincludes hepatosplenomegaly, bone infiltration and peripheral adenopathy.

Complications

1. Infections: Severe respiratory tract infections, Tb, Mycosis, Toxoplasmosis and Histoplasmosis
2. Hemorrhagic manifestation
3. Splenic rupture

Blood Picture

Pancytopenia is the most consistent laboratory observation. Anemia is normocytic normochromic. Granulocytpenia and monocytopenia are the most common cause of the leukopenia seen in HCL. Cytopenia result from infiltration of the marrow with malignant cells and fibrous tissue, and the effect is augmented by sequestration of blood cells by an enlarged spleen. Platelet is moderately decreased.

The proportion of hairy cells varies widely, but is usually in the order of 10-50%

Diagnosis by bone marrow aspiration is some time difficul (Dry Tap), but trephine biopsies of bone marrow shows characteristic appearance mild fibrous and diffuse cellular infiltrate of the hairy cells varies, but most cases belong to the B-lymphocyte lineage.

Cytochemistry

Tartrate resistance and acid phosphatase are positive

Immunophenotyping is characteristics;

CD 25 and CD 11c are positive in most cases.

Further diagnostic method is by electronic microscope.



FIGURE 3 : HAIRY CELL LEUKEMIA

STUDENT PERFORMANCE GUIDE

CHRONIC LEUKEMIA

Name:
Date:

Instructions

1. Practice identifying leukocytes from a stained blood/bone marrow smear.
2. Identifying mature and immature leukocytes and identify the pathological granulocytes monocytes and lymphocytes and differentiate between CLL and CML.
3. Complete a written examination successfully. .

Material and Equipments

- Stained blood smear
- Microscope
- Lens paper
- Oil immersion
- Soft laboratory tissue
- Drawings and descriptions of stained blood smear

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant			
2. Assemble equipment and material			
3. Place stained smear on microscope stage and secure it with clips			
4. Bring cells into focus using low power (10x)			
5. Scan slide to find area of slide where cells are barely touching each other			
6. Place one drop of immersion oil on slide			
7. Rotate oil immersion objective carefully into position			
8. Focus with fine adjustment knob until cells can be seen clearly			
9. Raise the condenser and open the diaphragm to allow maximum light into objective			
10. Scan slide to observe WBCs distribution (number) changes (CYTOPLASM, NUCLEUS, NUCLEOLI)			
11. Report what you see (draw on the worksheet)			
12. Rotate low power objective into position			
13. Remove slide from the microscope stage			
14. Clean oil objective thoroughly			
15. Clean oil from slide gently			
Comments			

Date:----------Instructor----------



COAGULATION DISORDERS TESTS *13*

OBJECTIVES

- State the purpose of the bleeding and clotting time tests
- List tests used for evaluation of platelet role in hemostasis
- List tests used for evaluation of the clotting system
- Name three components that interact to cause hemostasis
- Name and describe two methods used to determine the bleeding time and one method used to determine the clotting time and list the normal values of each
- List causes of prolonged bleeding time and clotting time
- Perform the Duke bleeding time test
- Perform the IVY bleeding time
- Perform Tourniquet test
- Perform Glass clotting time

GLOSSARY

- **Antithrombin III**- An alpha-2globulin that circulates in the plasma.
- **APTT**-Activated partial thromboplastin time.
- **Hemophilia (Also called a coagulation disorder.)** - An inherited bleeding disorder caused by low levels, or absence of, a blood protein that is essential for clotting; hemophilia A is caused by a lack of the blood clotting protein factor VIII; hemophilia B is caused by a deficiency of factor IX.
- **Platelets** - Cytoplasmic fragments of megakaryocytes (bone marrow cells). Platelets contain cytoplasmic granules; however, they lack nuclei and are part of the formed elements of blood. It is a cell found in the blood that are needed to help the blood to clot in order to control bleeding; often used in the treatment of leukemia and other forms of cancer.

INTRODUCTION

Injury to the vessel wall exposes collagen and sets it in motion, a series of events leading to hemostasis.

Hemostasis is a complex process, depending on interactions between the vessels wall, platelets, coagulation factors and fibrinolytic system. If a blood vessel endothelium is injured, 4 events take place at the same time.

1. Initially, rapid vasoconstriction reduces blood flow and promotes contact activation of platelets and coagulation factors and this produce**:**

Prostacycline that inhibits platelet aggregation in non- injured area, and factor VII.

Endothelial damage leads to:

Release of tissue thromboplastin, which activates extrinsic pathway (factor VII).

Exposure of subendothelial collagen, which lead to:

Platelet adhesion and aggregation

Activation of factor XII (Extrinsic pathway).

Activation of fibrinolysis.

2. In the second phase, platelet adheres immediately to the exposed subendothelial connective tissue, particularly collagen. The platelets are aggregates to form platelet plug**.**

Release of ADP, which increases further platelet release reaction serotonin and local vasoconstriction by releasing thromboxane A2 production and vasoconstriction and increase platelet release reaction.

Production of phospholipid (PF3), which has a local antiheparin action, so it enhances local clotting.

Finally, platelet thrombasthenin lead to formation of the firm hemostatic plug.

3. In the third phase, activation of intrinsic or extrinsic clotting systems to produce fibrin clot. Depression of fibrin stabilizes platelet plug and which lead to firm hemostatic plug.

4. Finally fibrinolysis occurs following the release of tissue plasminogen activators from the vascular wall. Fibrinolytic removal of excess hemostatic material is necessary to re-establish vascular integrity.

Causes of Hemorrhagic Diseases

1. Vascular abnormalities
2. Quantitative and qualitative platelet deficiency
3. Defective coagulation mechanism
4. Increased fibrinolysis.

TABLE 1. NOMENCLATURES OF COAGULATION FACTORS

Factors	Name	Synthesis	Function
I	Fibrinogen	Hepatocyte	Substrate
II	Prothrombin	Hepatocyte/ vitamin K	Enzyme
III	Tissue thromboplastin	EC+ other cells	Receptor/cofactor
IV	Ionized Calcium	Hepatocyte/EC/Platelets	Cofactor
V	Proaccelerin	Hepatocyte/	Cofactor
VII	Proconvertin	Hepatocyte/ vitamin K	Enzyme
VIII	Antihemophilic globulin	Sinosoides of liver	Cofactor
IX	Christmas factor	Hepatocyte/vitamin K	Enzyme
X	Staurt-Prower factor	Hepatocyte/vitamin K	Enzyme
XI	Plasma thromboplastin antecedent	Hepatocyte	Enzyme
XII	Hagman factor	Hepatocyte	Enzyme
XIII	Fibrin stabilizing factor	Hepatocyte/platelets	Transglutaminase
--	Prekalikerin Fletcher	Hepatocyte	Enzyme
--	High molecular weight Fitzgerald factor.	Hepatocyte	Cofactor



FIGURE 1 : THE COAGULATION CASCADE

FIGURE 2. EXTRINSIC PATHWAYS (TISSUE FACTOR PATHWAY)

Main component

1. Tissue factor (TF)
2. Factor VII (FVII)



FIGURE 3. INTRINSIC PATHWAY

Main component

1. Factor XI (FXI)
2. Factor IX (FIX)
3. Factor VIII (FVIII)



FIGURE 4. COMMON PATHWAY



Intrinsic tenase ***Extrinsic tenase***

Main component

1. Factor VIIIa
2. Factor IXa
3. Factor X

1. Factor VIIa
2. Factor X
3. Tissue factor



DIAGNOSIS OF BLEEDING DISORDERS

The initial or primary events that stop bleeding from a very small wound are the formation of a platelet plug, which seals the hole in the vessel wall, and arteriolar vasoconstriction. The plug is subsequently fortified by fibrin strands. The stimulus that causes the platelets to aggregate and form the primary plug is believed to exposure to subendothelial components and collagen. Aggregation is probably dependent on the von Willebrand factor and other plasma factors, such as ADP

released from lysed red cells pr platelets, a qualitative defect in platelets, thrombocytopenia, or a defect in the vascular wall can result in failure of the primary hemoststic mechanism with spontaneous bleeding or purpura. Purpura is not directly attributable to trauma and is exemplified by the type of bleeding seen in severe thrombocytopenia. Such bleeding differs from that resulting from defective fibrin formation, which is referred to as the coagulation or hemophiloid type.

Congenital bleeding disorders can characteristically be distinguished from acquired disorders by family history, age and circumstance of onset and by the presence or absence of an underlying disorder.

The formation of fibrin proceeds in a stepwise manner referred to as a cascade or waterfall. Blood clotting in vitro is initiated by contact of the blood with a foreign surface such as, grass, kaolin. The factors involved in this early contact phase are factors XII and XI, high molecular weight kininogen (HMW-k), and fletcher factor. However, even patients with severe deficiencies of these factors, with the exception of some patients with factor XI deficiency, are completely asymptomatic.

Laboratory Investigations

(A) Test for Evaluation of Platelet Role in Hemostasis

1. Platelet Count

- The normal platelet is 150000 -400000/μL
- Spontaneous bleeding occurs if count is < 40000/μL 'Thrombocytopenic purpura'.

2. Hess Test (Tourniquet Test; Capillary Fragility Test)

A blood pressure cuff is inflated around arm for 10 minutes, between systolic and diastolic pressure. Normally less than 5 petechiae appear in an area on the forearm 2.5 cm square.

An increased number indicates of thrombocytopenia or platelet dysfunction or abnormalities of small blood vessels.

Result:

1. 1+ less than 20 petechiae in an area of 2.5 cm diameter usually over the anticubital space
2. 2+ over 20 in this area with petechiae extending over the anterior surface of the forearm.
3. 3+ petechiae over whole arm and dorsum of hand
4. 4+ confluent petechiae everywhere below the cuff

3. BLEEDING TIME

Two methods for measuring the bleeding time are Ivy method and the Duke method. The IVY method, although more difficult to perform correctly, is the preferred method because it can be somewhat standardized. Both of these tests and other coagulation tests must be performed carefully and accurately by well-trained technicians. With both methods it is difficult to obtain reproducible results because of the difficulty of standardized procedure.

Bleeding time is used as a screening test for abnormalities of the primary hemostatic mechanism, particularly disorders of platelet function and von Willebrand's disease.

There is a fairly correlation between platelet count and bleeding time. If the platelets are qualitatively normal, the platelet count usually has to drop to below 80,000/mm^3 before an abnormality in the bleeding time becomes apparent. The prolongation does not become pronounced until the count falls below 40,000/ mm^3. . a prolongation is also seen in some patients with qualitative platelet abnormalities or myeloproliferative disorders. The bleeding time is prolonged in about one-third of patients with vonWillebrand's disease. Occasionally a prolonged bleeding time is the sole abnormality that can be found, despite exhaustive tests, in a patient with a life long history of bleeding.

A. Ivy Bleeding Time

1. A blood pressure cuff is applied to the arm, and inflated to 40 mmHg.
2. With a lancet 3 mm length, punctures are made along the flexor surface of the patient's forearm (2mm long and deep). Taking care to avoid any scar tissue or superficial vessels.
3. A stop-watch is started when the first drop of blood appears.
4. With three filter-paper discs, one for each puncture wound, the three bleeding points are gently blotted, without rubbing, every 30 seconds. This process is continued until all "bleeding time".

When the bleeding ceases, the time is noted and the pressure cuff is removed. The time between the first appearance of blood and the stopping of blood flow is the bleeding time. The normal bleeding time by the Ivy method is one to seven minutes. This method may also be performed using a device called a simplate which makes a more standardized incision than a lancet or blade. Ivy bleeding times may cause scar formation at incision site. The patient should be informed of this before test is begun.

B. Duke Bleeding Time

The Duke bleeding time is performed by incising the earlobe and measuring the time required for bleeding to cease. The earlobe is cleansed with alcohol and allowed to dry. A 2-3 mm deep puncture is made with a sterile lancet and timing is begun when the first drop of blood appears. The blood is blotted every 30 seconds

with filter paper and without touching the puncture site. The watch is stopped when bleeding ceases. The time elapsed is reported as the bleeding time. The normal bleeding time by Duke Method time is one to three minutes.

4. **Platelet Function Test**
Fresh citrated platelet-rich plasma is used for platelet aggregation test. A platelet aggregometer is used to examine the response of platelets to aggregating agents, including collagen, adrenalin, ADP, archidonic and ristocetin; from these studies it is possible to examine the primary and secondary aggregation responses, the release reaction and abnormalities suggesting Von willebrand's disease.
5. Bone marrow smears for number and morphology of megakaryocytes.

6. Peripheral blood smears for morphology of platelets (shape and size)

(B) Tests for Evaluation of the Clotting System
1. Whole Blood Clotting Time
A crude test for the entire coagulation mechanism.
It is the interval for a firm blood clot to form in a glass test tube.

Material:
1. 13 X 100-mm test tube (use new tube that are free of dust)
2. Water bath at 37 ^{0}C
Method:
Collect 3 ml of blood in each of 3 test tubes and place in a water bath at 37 ^{0}C. The tubes are tilted gently every 30 second until a clot is seen in one of the tubes the tubes. The stopwatch is then stopped and the clotting time recorded. The clotting times of the remaining two tubes need not be determined. If no clot is present in any of the tubes after 10 minutes, the clotting time should be recorded as abnormal. In the original Lee and White clotting test, the first tube was tilted at intervals of 30 seconds until a solid clot formed. The second and third tubes were treated similarly in sequence. The clotting time was the time required for a solid clot to form in the third tube.
Interpretation: When performed in the manner described previously, normal blood clots appear within seven minutes. If no clot has formed by 10 minutes, a defect in intrinsic coagulation is present and there is no point in determining the exact time of clotting. The test is prolonged when a severe deficiency (less than 6%) of a clotting factor (other than factor VII or XIII) or a circulating anticoagulant including heparin is present.
At the end of one hour, the degree of clot retraction and the general size of the clot is noted. It should be firm and occupy a volume approximately equal to half the total volume of the blood. If it occupies a volume more than this or if it has not retracted at all, the result is considered abnormal. However, the test is not very sensitive and a normal result does not exclude a platelet abnormality. By freeing the clot from the tube and tilting the tube, some idea of its weight can be gaued. Sometimes the clot will show signs of breaking up, indicating it is weak and defective, and on inspection the following morning it may appear to have

completely disintegrated. When the concentration of fibrinogen is low, the clot may initially be normal in size ut after retraction may be so small as to be overlooked. In the past the whole blood clotting time was the test used most often to monitor heparin therapy. However, it is cumbersome and time consuming and the same information can be obtained more conventionally by the use of the APTT.

2. Clot Retraction

Method

This may be observed in one of the clotting tubes left in the water bath for 1 hour. If at this time the clot is not retracted,gently rim and observe degree of retraction. This may be judged quantitatively by removing the clot and measuring the remaining serum.

$$\text{Normal} = >70\% \quad \frac{\text{volume of serum remaining}}{\text{Volume of blood (100-hematocrit)}} \times 100 = \%\ \text{retraction}$$

Comment:

A qualitative assessment is usually adequate.

3. Gross fibrinolysis

Method

Incubate 2 tubes with formed clots at 37C and observe for 24 hours. Fibrinolysis may be suspected if the clot decreases significantly in size or appears to be granular or fragmentd.

Comment

1. The test should be considered positive only if the clot actually dissolves.
2. Lysis in 24 hours is a phenomenon seen in several diseases. However, it is important in relation to bleding and disseminated intravascular coagulation only when noted within minutes rather than hours.

Precautions for Techniques for Measuring Clotting Factors:

1. Blood should be collected with care in plasticware, if possible. All equipment should be equally clean.
2. The ratio of blood to anticoagulant is critical. Nine parts of whole blood are added to 1 part of 3.6% Na citrate and gently mixed.
3. The sample should be cooled and plasma separated as soon as possible and in less than 4 hours.
4. Tests for most factors should be done as soon as possible and in less than 4 hours.
5. Tests should be done in glassware of constant size.

4. **Thrombin Time**

This is a test of the final conversion of fibrinogen to fibrin and bypasses the intrinsic and extrinsic systems as thrombin is added to the test system.

Diluted thrombin is added to citrated plasma in a concentration, which will clot normal plasma in 10-15 seconds. A prolongation of the time is caused by:

Deficient substrate-hypofibrinogenemia

Defective substrate-dysfibrinogenemia

Inhibitors-antithrombin action of heparin, inhibition of fibrin polymerization due to FDPs, high levels of protease inhibitors in the acute phase reaction (e.g alpha-2-macroglobulin).

5. Prothrombin Time (PT)

The PT is a test of the extrinsic pathway where citrated plasma is recalcified at the same time as tissue factor (thromboplastin) is added the clotting time recorded.

PT is used to asses the extrinsic VII and common Pathway (X, V, II,I).

The time needed for plasma to clot after addition of thromboplastin and Ca^{++}.

If phase II is normal, prolonged PT indicates deficiency of factors II, V, VII, or X.

This test is used to monitor oral anticoagulant therapy (Double the normal time).

6. Partial Thromboplastin Time (PTT).

It needs normal intrinsic (XII, XI, IX, VIII) and common (X, V, II) pathways.

The time required for plasma to clot after activation by kaolin (celite), Ca^{++}, brain extract (platelet substitute).

It is used to asses factors XII, XI, IX, VIII (phase I), when TT and PT are normal.

7. International Normalized Ratio (INR)

Differenences in commercially available thromboplastin, (tissue factor preparatations result in different sensitivities to the deficiencies of coagulation factors. Thus, on the basis of a patient PT and the normal PT, the INR is calculated:

INR = (PT of patient/PT, mean normal)

The use of INR permits doctors to obtain the appropriate level of anticoagulation independent of laboratory reagents and to follow published recommendations for intensity of anticoagulation (Normal INR is1).

8. Specific Factor Assay: for the clotting factors by immunoassay.

9. **Euglobulin Lysis Time**: Is shortened if low factor XIII and in fibrinolytic states.

10. **Clot Solubility** in 5M-urea solution: Is rapid in low factor XIII

11. **Plasma FDPs**: Are increased in case of DIC and fibrinolytic states.

(For more details Appendix 1)

TABLE 1: INTERPRETATION AND FOLLOW-UP OF SCREENING TEST

TT	PTT	PT	Platelet	Bleeding T	Problem and further investigations
Normal	Normal	Increase	Normal	Normal	?Ext. Path Look for factor VII ? Liver **? Warfarin**
Normal	Increase	Normal	Normal	Normal	? Int. Path F VIII+XI Lupus
Normal	Increase	Normal	Normal	Increase.	? von Willebrand
Normal	Increase	Increase	Normal	Normal	Defect of Appropriate Common pathway Factors **Liver/warfarin**
Increase	Increase	Increase	Normal	Normal	Fibrinogen/or heparin
Normal	Normal	Normal	Increase	Increase	Thrombocytopenia /B Marrow
Normal	Normal	Normal	Normal	Increase	Abnormal. Platelet Function

STUDENT PERFORMANCE GUIDE

BLEEDING TIME

Name:
Date:

Instructions

1. Practice performing bleeding time test (IVY)
2. Demonstrate the procedure for the bleeding time test satisfactory for the instructor. All steps must be completed as listed on the instructor's Performance Check Sheet.
3. Complete a written examination successfully. .

Material and Equipments

- Gloves
- Hand disinfection
- 70% alcohol
- Laboratory tissue
- Blood sample (in DTA)
- Blood lancet
- Filter paper
- Stopwatch
- Clean microscope slide
- Surface disinfectant
- Surface disinfectant
- Biohazard container
- Puncture-proof container for sharp objects

Procedure	s=satisfactory U= unsatisfactory		
You must	S	U	Comments
1. Wash hands with disinfectant and put on gloves			
2. Assemble equipment and materials			
3. Explain the procedure to the patient			
4. Cleanse the flexor surface of the forearm with 70% alcohol and allow to dry for wipe dry sterile gauze			
5. A blood pressure cuff is applied to the arm, and inflated to 40 mmHg.			
6. With a lancet 3 mm length, punctures are made along the flexor surface of the patient's forearm (2mm long and deep)			
7. A stop-watch is started when the first drop of blood appears.			
8. With three filter-paper discs, one for each puncture wound, the three bleeding points are gently blotted, without rubbing, every 30 seconds			
9. Stop the watch when blood is no longer absorbed onto the filter paper			

10. Report the bleeding time by calculating the time between the first appearance of blood and the stopping of blood flow			
11. Treat the puncture site by cleansing gently without disturbing the clot			
12. Clean work area with surface disinfectant			
13. Dispose of sharp objects in puncture-proof container			
14.Dispose of contaminated material in biohazard container			
15. Remove and discard gloves. Wash hands with hand disinfectant			
Comments: Student/Instructor			

Date:---------- Instructor:----------

.

REVIEW QUESTIONS

1. The normal red cell
    a. Is biconvex
    b. Has only hemoglobin within the cell membrane
    c. Has a normal MCV of 80-100 fl
    d. Is an erythroblast?

2. A normal mature erythrocyte has a life span of
    a. 8.2 hours
    b. 5 days
    c. 28 days
    d. 120 days

3. Howell-Jolly bodies are clinically seen in the following except:
    a. Hemolytic anemia
    b. Iron deficiency anemia
    c. Pernicious anemia
    d. Postsplenectomy

4. The elliptopcyte is prominent morphology in :
    a. Myeloid metaplasia
    b. Hemolytic anemia
    c. Iron deficiency anemia
    d. Sickle cell anemia

5. The blood smear of a patient with a prosthetic heart valve may show:
    a. Target cells
    b. Burr cells
    c. Schistcyte
    d. Elliptocyte

6. How would a cell that has a diameter of 9 μm and an MCV of 104 be classified?
    a. Macrocyte
    b. Microcyte
    c. Normal
    d. Either normal or slightly microcytic

7. Which type of red cell inclusion is a DNA remnant?
    a. Heinz bodies
    b. Howell-Jolly bodies
    c. Pappenheimer bodies
    d. Cabot rings

8. In apteinet with an MCHC> 36%, one would expect to observe:
   a. Target cells
   b. Spherocytes
   c. Elliptocytes
   d. All of them

9.. A microcytic cell can described as possessing:
   a. A thin rim of hemoglobin
   b. A blue-gray color
   c. A size of less than 7μm
   d. An oval shape

10. Basophilic stippling is composed of
   a. DNA
   b. Precipitated stain
   c. Denatured hemoglobin
   d. RNA

11. Which inclusion cannot be visualized on wrights stain?
   a. Basophilic stippling
   b. Pappenheimer bodies
   c. Howell-Jolly bodies
   d. Heinz bodies

12. Which morphologies would be prominent on a smear of a patient with smear liver disease?
   a. Target cells, macrocytes
   b. Microcytes, elliptocytes
   c. Schistocytes, bite cells
   d. Sickle cell, crystals

13. Which of the following is the term for erythrocytes resembling “a stock of coins” on thin sections of a peripheral blood smear?
   a. Anisocytosis
   b. Poikilocytosis
   c. Agglutination
   d. Rouleaux formation

Questions 24 through 30, match the following

14. Basophilic stippling	a. Pernicious anema
15. H-Jolly bodies	b. G6PD deficiency
16. Heinz bodies	c. Lead poisoning
17. Pappenheimer bodies	d.Iron deficiency anemia
18. Acanthocytes	e. Iron loading anemia
19. Spherocytes	f. Abetalipoproteinemia

20. Microcytes

g. Blood transfusion reaction

21. The primary site of hematopoiesis in fetus between the 10th and the 30th week of gestation is the:
    a. Spleen
    b. Bone marrow
    c. Thymus
    d. Liver

22. Active blood cell producing marrow begins to regress in the fourth year of life and replaced by:
    a. Bone
    b. Fat
    c. Fibrous tissue
    d. Collagen

23. The two cell types that produce their own growth factors are:
    a. Neutrophils and monocytes
    b. Neutrophils and lymphocytes
    c. Neutrophils and eosinophils
    d. Lymphocytes and monocytes

24. The following cells are of the myeloid cell line except
    a. Platelets
    b. T-lymphocyte
    c. Promyelocyte
    d. Monocyte

25. The most common world wide cause of Eosinophilia is :
    a. allergic disorders
    b. Parasitic infections
    c. Drug exposure
    d. Primary hematologic disorders

26. The only protozoan disease in which Eosinophilia is frequently seen is :
    a. Trypanosoma cruzi
    b. Trypanosoma gambienzi
    c. Malaria

27. Autoimmune leukopenia may be associated with:
    a. Lymphomas
    b.Felty's syndrome
    c. mononucleosis
    d. Systemic lupus erythematosus
    e. chronic active hepatitis

28. Serious risk of infection regularly accompanies WBC count of:
    a. Less than 1500/cmm
    b. Less than 3000/cmm
    c. Less than 500/cmm
    d. more than 50,000/cmm

29. Normal granulocyte function requires:
    a. Chemotaxis
    b. Destruction of organisms
    c. Phagocytosis
    d. Mobilization

30. Basophils
    a. Contain histamine
    b. contain serotonin
    c. May be increase with anaphylaxis
    d. May be increased in myeloproliferative syndrome

31. what is the primary function of iron
    a. Molecular stability
    b. Oxygen transport
    c. Cellular metabolism
    d. Cofactor

32. Which of the following influences iron absorption?
    a. Amount and type of iron in food
    b. Function of GI mucosa and pancreas
    c. Erythropoiesis needs and iron stores
    d. All of the above

33. What is the correct sequence for iron transport?
    a. Ingestion, conversion to ferrous state in stomach, reconversion to ferric state in blood stream, transport by transferring, incorporation into cells and tissues
    b. Ingestion, transport by transferring to cells and tissues, conversion to ferrous state prior to incorporation into cells and tissues.
    c. A and B are correct
    d. Non of them

34. In iron deficiency anemia there is characteristically
    a. An atrophic gastritis
    b. A low mean corpuscular volume
    c. A reduced total iron binding capacity
    d. Megaloblastic changes in the bone marrow

35. What are the two major categories of iron deficiency?
    a. Defect in globin synthesis and iron incorporation
    b. Low availability and increased loss of iron
    c. Defective RBC catabolism and recovery of iron
    d. Problems with transport and storage of iron

36. Which are characteristic laboratory findings(s) for IDA?
    a. Increased RDW
    b. Decreased MCV, MCH, MCHC
    c. Ovalocytes, elliptocytes, microcytes
    d. All of the above

37. Which laboratory test results would be most helpful in distinguishing IDA from anemia of chronic disease?
    a. Decreased MCV, MCH, marked poikilocytosis
    b. Increased MCV, MCH, MCHC, decreased RDW
    c. Increased RDW and TIBC
    d. Decreased RDW and TIBC

38. What term refers to the accumulation of excess iron in macrophages?
    a. Sideroblastic anemia
    b. Hemosiderosis
    c. Porphyria
    d. Thalassemia

39. Which of the following would not be seen in sideroblastic conditions?
    a. Increased RDW
    b. Pappenheimer bodies
    c. Ringed sideroblasts
    d. Decreased serum iron

40. What is the characteristic finding in lead poisoning?
    a. Basophilic stippling
    b. Target cells
    c. Sideroblasts
    d. Spherocytes

41. The following statements are correct about the expected effect of iron therapy except:
    a. Within the first 2 days; bone marrow shows erythroid hyperplasia.
    b. At the 3rd day, Reticulocytosis appears in peripheral blood, which peak, about the 6th day.
    c. From fourth to 30th day; gradual increase of Hb level.
    d. From 1-3 weeks gradual repletion of body iron stores.

42. The following statement concern iron deficiency anemia except
    a. stage I :is stage of depletion of iron store
    b. stage II: impaired erythropoiesis
    c. stage III: stage of anemia with marked appearing of microcytic RBCs and pathologic indices
    d. stage IV: The most significant finding is the classic microcytic hypochromic anemia

43. Abnormal hemoglobin are most often caused by
    a. Amino acid substitutions
    b. Amino acid deletion
    c. Globin chain elongation
    d. Globin chain fusion

44. Which one of the followings is not a characteristic of hemoglobinopathies?
    a. Conditions in which abnormal hemoglobins are synthesized
    b. Result from inherited abnormalities or genetic mutation
    c. All are manifested in clinically significant conditions
    d. Result in a defect instructional integrity of function of the hemoglobin molecule.

45. The most common cause of hemoglobinopathies is an abnormality in the ---- globin chain
    a. α
    b. β
    c. γ
    d. δ

46. What factors contribute to the sickling of RBCs?
    a. Increase in PH and oxygenation
    b. Decrease in PH and oxygenation and dehydration
    c. Increase in PH and decrease in oxygenation
    d. Decrease in dehydration and increase in PH and oxygenation

47. What are the therapeutic goals in the treatment of sickle cell anemia?
    a. Decrease microvascular entrapment of sickle cells or change the volume of RBCs
    b. Modify oxygen affinity or solubility of sickle hemoglobin
    c. Increase production of fetal hemoglobin
    d. All of the above

48. Laboratory values that could be found in a patient with sickle cell anemia (HbSS) disease includes all of the following except:
    a. 85% HbS on cellulose acetate electrophoresis
    b. 7% HbA2 on cellulose acetate electrophoresis
    c. Normocytic, normochromic anemia
    d. Hemoglobin 6.0 g/dl

49. Cellulose acetate hemoglobin electrophoresis is run at a (an)
    a. Alkaline PH
    b. Acid PH
    c. PH gradient
    d. Alkaline and acid PH

50. The condition (s) associated with increased levels of HbF is (are)
    a. Infancy
    b. Hemoglobinopathies
    c. Thalassemia
    d. All of the above

51. Two HbS that migrates together on cellulose acetate electrophoresis at alkaline PH are
    a. A1 and A2
    b. A1 and E
    c. S and C
    d. S and D

52. Laboratory values that could be found in a patient with sickle cell trait (HbAS) includes all of the following except:
    a.40% HbS on cellulose acetate electrophoresis
    b.4% HbA2 on cellulose acetate electrophoresis
    c.60% HbA on cellulose acetate electrophoresis
    d.Microcytic, hypochromic anemia

53. The total blast cell count in the bone marrow is important when characterizing the acute non-lymphocytic leukemia, and must be at least.
    a. 40% of the total nucleated cells in the marrow
    b. 40% of the total white cell in the marrow
    c. 30% of the total nucleated cells in the marrow
    d. 30% of the erythroid cells in the marrow

54. The technique(s) used to classify the acute nonlymphocytic leukemia is/are?
    a. Immunologic
    b. Morphologic
    c. Cytochemical
    d. All of the above

55. All of the following stains are used to identify the acute nonlymphocytic leukemia except:
    a. Peroxidase
    b. α-naphthyl butrate
    c. Sudan black stain
    d. TDT

56. Auer rods may be found in all of the following classification of acute nonlymphocytic leukemia except:

a. M0
b. M1
c. M2
d. M3

57. A cytogenitic abnormality is found in almost 50% of patients with which of the following classification of acute nonlymphocytic leukemia?

a. M2
b. M5
c. M3
d. M6

58. Which of the following laboratory findings would be least expected in a patient with acute leukemia at the time of presentation.

a. Anemia
b. Neutropenia
c. Eosinophilia
d. Leukocytosis
e. Thrombocytosis

59. Which of the following factors would adversely affect the ability to achieve a complete remission in an adult patient with ALL?

a. High white cell count at diagnosis
b. Presence of meningeal leukemia at diagnosis
c. Presence of infection at diagnosis
d. Presence of T-cell marker on lymphocyte

60. Which of the following FAB subgroups of AML would be expected to be characterized by intense nonspecific esterase activity in the cytoplasm?

a. M1
b. M2 and M6
c. M4 and M5
d. All of the above

61. Which of the following would be expected in acute monocytic leukemia (AmoL), but would occur infrequently in AML?

a. Splenomegaly
b. Hepatomegaly
c. Gangival hypertrophy
d. Sternal tenderness

62. Which of the following statements about the FAB classification of ALL is incorrect?

a. It is divided into four subgroups, L1, L2, L3, L4
b. The L1 form is the common type of childhood leukemia
c. The L3 form is morphologically identical to Burkitt's leukemia'
d. The L2 blasts may be confused with the blasts of acute myeloid leukemia

63. The primary cause of death in patients with ALL is :
    a. Strokes
    b. Infection
    c. Bleeding
    d. Liver failure

64. The major morphologic distinction between ALL and a reactive lymphocytosis such as infections mononucleosis (IM) is the:
    a. Difference in size of the blasts
    b. Difference in nuclear: Cytoplasmic ratio of the abnormal cells.
    c. Pleomorphic morphology among reactive lymphocytes in IM
    d. Morphologic evidence that red cells are being destroyed in IM

65. In the FAB classification of leukemia based on morphology, what percentage of cells may appear different from the proposed cell type of a specific classification?
    a. 1%
    b. 5%
    c. 10%
    d. 20%

66. The diagnosis of ALL in the adult must rule out:
    a. Leukemic lymphoma
    b. Blast transformation of CLL
    c. Acute myeloid leukemia
    d. All of the above

67. The FAB classification type of acute lymphoblastic leukemia seen most commonly in children:
    a. L0
    b. L1
    c. L2
    d. L3

68. TdT activity is present in
    a. Mature B cells
    b. Macrophages
    c. Myeloid cells
    d. Primitive lymphoid cells

69. The Lymphoblastic leukemia antigen found in 70% of patients with ALL is designated as CD:
    a. 2
    b. 10
    c. 19
    d. 22

70. The karyotype abnormality that carries a relatively good prognosis:
    a. t(8;14)
    b. t(9;22)
    c. Philadelphia chromosome
    d. Hyperploids

71. Accuracy to the FAB classification of acute myelocytic leukemia, which of the following would correspond to erythroleukemia or DiGuglielmo syndrome?
    a. M1
    b. M3
    c. M6
    d. M6

72. Which of the following would be least suggestive of meningeal leukemia?
    a. Unexplained tachycardia
    b. Isolated cranial nerve palsy
    c. Severe persistent headache
    d. Blurred vision

73. The best description of polycythemia vera is that it is characterized by:
    a. Increased red cell mass
    b. Leukopenia
    c. Thrombocytopenia
    d. Increased myeloblasts

74. An RBC poikilocytes that is considered to be the first sign of spent phase of polycythemia is the
    a. Dacrocyte
    b. Spherocyte
    c. Target cell
    d. Schistcyte

75.--------are the cells most responsible for the appearance of the marrow in agnogenic myeloid metaphase
    a. Neutrophils
    b. Erythrocytes
    c. Lymphocytes
    d. Fibrocytes

76. Hydoxyurea treatment may result in megaloblastic morphology because hydroxyurea is an:
    a. Alkylating agent that damages DNA
    b. Inhibitor of DNA replication
    c. Inhibitor of platelet function
    d. Inhibitor of maturation

77. Which of the following laboratory abnormalities would be least likely in a patient with PV at the time of diagnosis?

a. Leukocytosis with absolute granulocytosis
b. Normoblasts in the peripheral blood
c. Thrombocytopenia
d. Abnormal platelet function studies

78. Which criteria must be present for a diagnosis of PV that will meet the criteria of the polycythemia vera study group?

a. Any two from category A combined with any two from category B
b. One from category a and three from category B
c. Elevated red cell mass and normal arterial oxygen saturation combined with any two category B criteria
d. Non of the above

79. Which of the following is induced among the category B criteria of the polycythemia vera study group for the diagnosis of PV?

a. Thrombocytopenia
b. Leukopenia
c. Elevated serum B12 or unbound B12 binding capacity
d. Decreased leukocyte alkaline phosphatase score.

80. Which of the following would be least likely in a patient with idiopathic myelofibrosis:

a. Tear-drop RBCs on peripheral smear
b. Erythrocytosis
c. Splelenomegaly
d. Nucleated RBCs on peripheral smear.

81. Which of the following is most helpful in differentiating idiopathic myelofibrosis from myelofibrosis secondary to some other process?

a. Serum protein electrophoresis
b. Serum uric acid
c. Bone marrow biopsy
d. Urinary muramidase

82. Which of the following has been most closely associated with the development of chronic myeloid leukemia?

a. Exposure to ionizing radiation
b. Recurrent herpes virus infection
c. Chronic active hepatitis
d. Lead toxicity

83. The following statement are correct about chronic myeloid leukemia except
    a. It is the commonest form of leukemia worldwide
    b. it is associated with a median survival of <2 years
    c. Often presents asymptomatically
    d. It is more commonly derived from B cells than T cells

84. The following statements are correct about Polycythemia vera except:
    a. Occur more frequently in smokers
    b. May present as gout
    c. May transform to acute leukemia
    d. Is associated with an enlarged spleen

85. Chronic lymphocytic leukemia
    A.Often gives positive results with TRAP stain
    b. Commonly demonstrates CD5 positivity and trisomy 12
    c. May only be diagnosed by bone marrow examination
    d. All of the above.

86. Prolymphocytic leukemia
    a. It is characterized by massive lymphadenopathy and hepatosplenomegaly
    b. It is characterized by almost total bone marrow replacement by prolymphocytes.
    c. Has a comparable prognosis to CLL and HCL.
    d. All of the above

87. Hairy cell leukemia is a disease in which the abnormal cells
    a. All have a scanty amount of cytoplasm
    b. Demonstrate positivity with tatarate-resistant acid phosphatase stain
    c. Excess the CD5 surface marker
    d. All of the above

88. Which of the following could cause a patient to be stage VI in the Rai system?
    a. Bone marrow with greater than 40% lymphocytes
    b. Platelet count less than 100,000
    c. Hemoglobin less than 11g/dl
    d. Presence of splenomegaly
    e. All of the above

89. Which of the following would least likely be associated with lymphocytosis?
    a. Cytomegalovirus infection
    b. Pneumococal pneumonia
    c. Infectious mononucleosis
    d. Tuberculosis

90. Which of the following would be most useful in differentiating CLL from infectious mononucleosis?

a. Presence of immune hemolytic anemia
b. Splenomegaly
c. Cervical lymphoadenopathy
d. Lymphocyte morphology

91. Which of the following would be an indication for splenectomy in a patient with CLL?

a. Immune thrombocytopenia controlled only with large steroid.
b. Pancytopenia with increased hematopoietic marrow elements and splenomegaly.
c. Immune hemolytic anemia controlled only with high dose steroid.
d. All of the above

92. Which of the following could be expected in a patient with Hairy cell leukemia?

a. Occur primarily in infants and children
b. Splenic enlargement is uncommon
c. Fever without infections is frequently encountered
d. Granulocytosis is the most frequent WBC abnormality.

93. Which of the following statements about the cytotoxicity drug therapy of CLL is true?

a. Busulfan (Myeleran) is considered the drug of choice.
b. Vincristine (oncovin) is best ovoided because it produces thrombocytopenia.
c. Cyclophosphamide is effective only when used in combination with prednisolone
d. About 2/3 of patients respond to therapy with a single alkylating agent.

94. Which of the following is the best description of chronic lymphocytic leukemia?

a. A disease which often transforms into ALL
b. A disease in which immunologically incompetent B-cell accumulate
c. A disease which is treated with Busulfan for symptoms control
d. A disease etiologically linked to radiation exposure.

95. All are true about CLL except:

a. Is a cause of hypogammaglobulinemia?
b. Is commonly treated with intensive combination chemotherapy
c. Often presents asymptomatically
d. Is more commonly derived from B cells than T cells

96. The following statement are related to chronic lymphatic leukemia except
    a. CLL is slowly progressive, with good short-term but poor long term survival
    b. CLL may be complicated by autoimmune hemolytic anemia
    c. The Philadelphia chromosome is the sine qua non of CLL
    d. Most patients are managed supportively

97. Factor I is commonly known as
    a. Tissue factor
    b. Prothrombin
    c. Antihemeophilic factor
    d. Fibrinogen

98. The traditional intrinsic coagulation pathway includes factors
    a. X, V, IV, III, II and I
    b. XII, XI, IX, VIII, Prekallikerin and HMWK
    c. XII, X, IX, XIII, Prekallikerin and HMWK
    d. VII and tissue factors

99. A substance released from platelets that promotes their aggregation is
    a. HMWK
    b. ADP
    c. Factor V
    d. α2-atntiplasmin

100. Epistaxis is mean
    a. Nose bleed
    b. Vomiting of blood
    c. Excessive menstrual bleeding
    d. Blood in the urine

101. A normal hemostatic mechanism depends upon the normal structure and function of
    a. Tissue surrounding the blood vessels
    b. Platelets
    c. Blood vessels
    d. Plasma coagulation protein
    e. All of the above

102. The coagulation factors that are vitamin K dependent are:
    a. I, V, VIII an XIII
    b. II, VII, IX, and X
    c. XII, XI, Prekallikerin
    d. II, VII, IX and XI

103. Thrombin has many roles in hemostasis
    a. Activation of factor XIII
    b. Activation of protein C
    c. Conversion of fibrinogen to fibrin
    d. Both enhancing and inhibiting coagulation
    e. All of the above

104. Antithrombin III inhibits
    a. Factors IIa, IXa, and Xa
    b. Plasmin
    c. Factors XIA and XIIa
    d. Kallikerin
    e. All of the above

105. The Prothrombin time test
    a. It is the most frequently used test to monitor anticoagulant therapy with Vitamin K antagonists
    b. It is a good screen for the intrinsic and common pathways.
    c. It is reported as a percentage of factor activity
    d. All of the above

106. The Thrombin time test will be prolonged by all of the following except:
    a. Dysfibrinogenemia
    b. Fibrin Split Products
    c. Elevated fibrinogen levels
    d. Heparin

107. The international normalized ratio (INR) is useful for
    a. Determining coagulation reference ranges
    b. Monitoring heparin therapy
    c. Monitoring thrombotic therapy
    d. Monitoring warfarin therapy

108. The international normalized ratio (INR) is used to correct for differences in reagent preparations for
    a. Prothrombin time
    b. Partial Thromboplastin Time
    c. Activated Clotting Time
    d. Lee-White Clotting time.

109. Which of the following is NOT a vitamin K dependent factor?
    a. Factor V
    b. Factor VII
    c. Prothrombin
    d. Factor IX
    e. Factor X

110. Which vitamin K dependent clotting factor has the shortest half-life?

A. Prothrombin
B. Factor VII
C. Factor IX
D. Factor XI

111. Which of the following factor deficiencies would be expected to result in prolongation of both the Prothrombin Time (PT) and the Partial Thromboplastin Time (PTT)?

a. Factor XI
b. Factor X
c. Factor IX
d. Factor VIII
e. Factor VII

112. Which of the following factors is least likely to be depleted in disseminated intravascular coagulation (DIC)

a. Fibrinogen
b. Factor IX
c. Factor VIII
d. Factor V
e. Factor X

113-118: Correlation

113. Usual pattern of inheritance is sex-linked recessive
114. Associate with decreased factor VIII procoagulant activity
115. Associated with decreased factor VIII procoagulant activity and normal bleeding T
116. Associated with both autosomal dominant and recessive inheritance
117. Associated with decreased factor IX procoagulant activity
118. Associated with a prolonged bleeding time and defective ristocetin platelet aggregation

A. Hemophilia A
B. Hemophilia B
C. VonWillebrand
D. A and B
E. A and C

119. Withregard to anticoagulant therapy

a. Warfarin is safer than heparin in pregnancy
b. The INR is used to control heparin therapy
c. Vitamin K is used to reserve the action of warfarin
d. Vitamin C is used to reserve the action of heparin

120. All of the following about platelet are correct except:
    a. Are often multinucleated
    b. Are often increased in number
    c. Platlets increased in patients with IDA caused by chronic blood loss
    d. Are some times reduced in number in vonWillebrand disease.

121. The following are correct in DIC except
    a. Is commonly seen as in presenting feature of AML (M3)
    b. Is usually associated with reduced fibrinogen levels
    c. Is usually associated with raised platelet count
    d. Is usually associated with a prolonged APTT

122 **.** A group O woman has given birth to a group O baby. All of the following men could be the fathers except.
    a. Hamad, who is group O
    b. Shad who is group A (genotype AO)
    c. Bader, who is group AB
    d. Salem, who is group B (genotype BO)

123. The followings are correct about severe hemolytic transfusion except:
    a. Can always be prevented by invitro testing
    b. Are usually due to human failure to follow established procedure
    c. Occur relatively more often in patients previously transfused or exposed to blood.
    e. Often cause acute tubular necrosis

124. Rh negative mothers may have been sensitized to Rh-positive blood of the following except:
    a. A second trimester abortion
    b. A childhood blood transfusion
    c. Being an Rh negative child of an Rh positive mother
    d. A previous pregnancy with an Rh negative baby

125. Fresh plasma is the component of choice in the management of:
    a. Factor V deficiency
    b. Factor VII deficiency
    c. Hemophilia
    d. Factor X deficiency

126. The risk of transfusing blood containing hepatitis B surface antigen as compared to blood negative for this is:
    a. Increased
    b. Decreased
    c. Increased only in patients who have not previously transfused
    d. Identical

127. Massive transfusion of stored whole blood has been shown to be associated with:

a. Change in Acid-Base balance
b. Alteration of hemoglobin-Oxygen affinity
c. Hypocalecemia and hyperkalemia
d. Clotting deficiencies
e. All of the above

128. Platelet transfusion should be given:

a. When the platelet count is less than 20000
b. B. When the patient bleeding and the platelet count less than 20000 due to hypoplasia
c. In cases of drug purpura
d. In DIC

129. Stored plasma (4 for 21 days) is suitable for replacement of all the following except:

a. Prothrombin
b. Factor VIII
c. Factor IX
d. Factor VII

130. Blood group testing

a. Can establish maternity
b. Can exclude maternity
c. Can occasionally establish paternity
d. Can exclude paternity

131. The presence of the most immunogenic of the Rh antigens leads to the designation
of a patient as being Rh positive. Which of the following antigens is responsible?

a. C
b. D
c. E
d. e

132. Which of the following red cell abnormalities is most indicative of hemolysis?

a. Target cells
b. Acanthocytes
c. Schistocytes
d. Basophilc stippling
e. Heinz bodies

133. Two days after receiving the antimalaria drug primaquine, a 27 year-old man developed sudden intravascular hemolysis resulting in a decreased hematocrit, hemoglobinemia, and hemoglobinuria. Examination of the peripheral blood revealed erythrocytes with a membrane defect forming “bite cells”; when crystal violet stain was applied, many Heinz bodies were seen. The most likely diagnosis:

a. Hereditary spherocytosis
b. Glucose-6-phosphate dehydrogenase deficiency
c. Paroxysmal nocturnal hemoglobinuria
d. Autoimmune hemolytic anemia
e. Microangiopathic hemolytic anemia

134. Which of the following laboratory findings is least likely to be present in a patient with sickle cell anemia?

a. Normochromic anemia
b. Increased number of target cells
c. Eleveated reticulocyte count
d. Elevated erythrocyte sedimemntation rate.
e. Increased hemoglobin F

135. Megaloblasts are the result of impaired synthesis of :

a. DNA
b. RNA
c. Glutathione
d. ββchain

136. An anemic patient is found to have hypochromic, microcytic red cells. Additional tests reveal the serum iron levels, the total iron binding capacity, and the transferrin saturation to all be reduced. A bone marrow biopsy reveals the iron to be present mainly within macrophages. The most likely diagnosis is:

a. Iron deficiency
b. Thalassemia
c. Anemia of chronic disease
d. Sideroblastic anemia
e. Pernicious anemia

137. Chronic myeloid leukemia is least likely to be associated with

a. Splenomegaly
b. Basophilia
c. Translocation t (8;14)
d. Thrombocytosis
e. Low leukocyte alkaline phosphatase (LAP)

138. A 45-year-old male with an artificial heart valve is given oral Coumadin (Warfarin) to prevent the formation of thrombi on his artificial valve. Which combination of laboratory tests is most likely to be found in this individual?

	Tourniquet test	bleeding time	platelet	PTT	PT
A.	Positive	Prolonged	normal	normal	normal
b.	normal	normal	normal	prolonged	normal
c.	positive	prolonged	decrease	normal	normal
d.	normal	normal	normal	normal	prolonged

139. Intravascular hemolysis results in all the following EXCEPT:
- a. Elevated plasma hemoglobin
- b. Hemoglobinuria
- c. Jaundice
- d. Hemosiderinuria
- e. Splenomegaly

140. Typical findings in a patient with von Willebrand's disease include all the following except:
- a. Decrease levels factor VIII
- b. Normal platelet count
- c. Prolonged bleeding time
- d. Frquent hemarthrosis and spontaneous joint hemorrhage

141. Chronic granulocytic leukemia is least likely to be associated with:
- a. Thrombocytopenia
- b. Basophilia
- c. Splenomegaly
- d. Mild anemia
- e. A leukocyte count greater than 50000/μl

142. A low mean corpuscular hemoglobin concentration occurs in:
- a. IDA
- b. Pernicious anemia
- c. Anemia associated with Diphylobothrium latum
- d. Sideroblastic anemia

143. Alteration in the structure of the Hb molecule give rise to the following disease:
- a. Hemolytic disease of the newborn
- b. Sickle cell anemia
- c. Paroxysmal cold hemoglobinemia
- d. Paroxysmal nocturnal hemoglobinuria

144. Iron deficiency anemia may be associated the following except:
    a. A sensitive and painful glossitis
    b. Dysphagia
    c. Koilonychia
    d. Chlorosis

145. The following hemolytci disorders are congenital except:
    a. Thalassemia
    b. Microengiopathic haemolytic anemia
    c. Ovalocytosis
    d. G6PD deficiency

146. Which of the following biochemical changes occur in pernicious anemia;
    a. A raised serum vitamin B12
    b. A raised serum Bilirubin
    c. An increased alkaline phosphatase
    d. A decrease plasma cooper

147. The following are causes of absolute lymphocuytosis except:
    a. Loeffler syndrome
    b. Tuberculosis
    c. Pertusis
    d. CLL

148. Acute myeloblastic leukemia
    a. Is most common in young adults
    b. Is associated with presence of a large number of primitive cells in the marrow and peripheral blood.
    c. Is associated with peripheral WBC count excess of 100000/μl
    d. Marrow aspirates show decreased cellularity

149. Chronic lymphatic leukemia is associated with
    a. Marked increase in the number of lymphocytes in the peripheral blood.
    b. The early appearance of anemia
    c. An early bleeding tendency
    d. An increase in the serum globulin concentration

150. The plasma prothrombin time is increased in :
    a. In obstructive jaundice
    b. In hemophilia
    c. In Christmas disease
    d. Following splenectomy.

151. Disseminated intravascular coagulation is a complication of the following disease except:

a. Malignant disease
b Therombocythemia
c. The overadministration of thrombokinase
d. Endoteximic shock

Questions 152-156 about leukemia : Correlate between “A” and “B”

A. Acute Lymphoblastic leukemia	152. Auer rods are occasionally present in the cytoplasm of leukemic cells.
B. Acute myeloblastic leuklemia	153. Associated low leukocyte alkaline phosphatase and Philadelphia chromosome.
C. AML-M3	154. High peripheral WBC counts with numerous promyelocyte, band forms, polymorphonuclear leukocytes, and eosinophilic and basophilic precursors.
D. chronic lymphatic leukemia	
E. Chronic myeloid leukemia	155. Charcteristicall associated with a short course and diffuse intravascular coagulation.
	156. Occurs in older adults. Produces the fewest symptoms of the group listed, and is associated with longest survival.
	157. 75-80% of acute leukemia in children

158. This patients usually die from the sequelae of iron overload

a. IDA
b. Megaloblastic anemia
c. Thalassemia
d. Sickle cell anemia

159. Bleeding time is increased in

a. von Willebran disease
b. Hemophilia A
c. Hemophilia B
d. All of them

160. Bleeding time and PT are normal whereas PTT is elevated in :

a. vonWillebrand
b. Hemophilia A
c. All of them
d. Non of them

Correlate between the Diagnosison the left and the pictures on the right
Questions 161-169 :

A. AML

B. CLL

C. Prolymphocytic leukemia

D. CML

E. Hairy cell leukemia

F. Acute Lymphoblastic leukemia –ALL-L1

G. Multiple myeloma

H. Burkitt's cell leukemia ALL-L3

I. Hodgkin's disease

J. Malignant lymphoma



16



1



1©



1©



165



166



167



1©

170. Classic findings in the hemolytic anemias include all but which of the following?

a. Increeased indirect serum Bilirubin
b. Increased direct serum Bilirubin
c. Increased reticulocyte count
d. Marrow erythroid hyperplasia.

171. Which of the following anemias is not associated with a microcytic hypochromic blood picture?

a. Iron deficiency
b. Thalassemia
c. B12 deficiency
d. Anemias of chronic disease

172. Which of the following is a peripheral blood indicator of the activity of bone marrow red cell production?

a. Serum iron
b. Total Bilirubin level
c. Serum b12 level
d. Reticulocyte count

173. A negative sickle preparation, will be seen in which of the following situations?

a. Hemoglobin SS disease
b. Hemoglobin AS carrier
c. Hemoglobin SC disease.
d. Hemoglobin CC disease

174. The most immediate source of iron for red cell hemoglobin roduction is derived from which of the following?

a. Reutilization of iron from the breakdown of old red cells
b. Diet
c. Mitochondrial enzyme iron
d. Hepatocyte production

175. The proper treatment of iron deficiency involves which of the following?

a. Iron replacement and phlebotomy
b. Splenectomy and lymphadenoectomy
c. B12 and folate therapy
d. Locate and site of blood loss and administer iron supplementation

176. All but which of the following are poor prognostic factors in aplastic anemia?

a. Rticulocyte count <1%
b. Marrow cellularity >60%
c. Platelet count <20000
d. Neutrophil count <1000

177. Typical findings in the anemias of chronic disease include which of the following?

a. Elevated serum iron, elevated iron binding capacity, elevated ferritin
b. Decreased serum iron, elevated total iron binding capacity, decreased ferritin.
c. Elevated serum iron decreased total iron binding capacity.
d. Decreased serum iron, decreased total iron binding capacity, elevated ferritin.

178. The peripheral blood smear is frequently diagnostic of the cause of the anemia in all of the following except:

a. Malaria
b. Acute blood loss
c. Hereditary ovalocytosis
d. Sickle cell disease

179. In pernicious anemia the patients are B12 deficient because:

a. Their diet is low in B12
b. They are bleeding
c. They are lacking effective intrinsic factor in the stomach
d. They have a hemoglobinopathy

180. Folate deficiency can be caused by all of the following except:

a. Splenetomy
b. Pregnancy
c. Malabsorption
d. Poor dietary intake

181. How long a patient with B12 deficiency secondary to gastrectomy, iliotomy, or pernicious anemia require monthly B12 replacement therapy?

a. one year
b. Three months
c. Life long.
d. Three years

182. Spherocytes on the peripheral blood smear would be expected in all of the following except:

a. Hereditary spherocytosis
b. Methyldopa-induced haemolytic anemia
c. Iron deficiency anemia
d. Coomb’s positive autoimmune hemolysis.

183. Which of the following would not help to differentiate a patient with B-thalassemia minr from a patient with a mild iron deficiency anemia?

a. Bone marrow iron stain
b. Hemoglobin level
c. Serum ferritin
d. Serum iron and iron binding capacity

184. In a patient with a severe pancytopenia and an aplastic bone marrow, which of the following would be an important initial step?

a. Iron therapy IV
b. Discontinue any drug or toxin exposures
c. B12 injection IM
D. Splenectomy

185. An elevation erythrocyte sedimentation rate (ESR) is expected in all of the following disorders except:

a. Multiple myeloma
b. Anemia
c. Rheumatoid arthritis
d. Sickle cell anemia

186. Elevated hemoglobin may occur with the following except:

a. High altitude
b. Severe burns
c. Polycythemia
d. Cirrhosis

187. The following are stages of ESR except:

a. In the initial 10 minutes, there is little sedimentation as rouleaux form
b. For about 40 minutes, setting occurs at a constant rate.
c. Sedimentation slows in the final 10 minutes as cells pack at the bottom of the tube.
d. All of the above
e. A and B

188. ESR is of clinical significance in:

a. Helpful in disgnosis of pneumonia
b. Play role in prognosis of myocardial infarction
c. Helpful in following diagnosis of osteomyelitis
d. Elevated ESR has higher incidence of progression and death in Toxoplasmosis

189. Dectreased hematocrit in the following except:
a. Polycythemia
b. Hypothyroidism
c. Leukemia
d. Prologed blood loss

190. The following are correct except:
a. The faster the speed of spreading, the longer the thiner film.
b. The greater the volume of blood, the shorter and thicker the film.
c. The stronger the pressure of spreading, the longer and thiner the film
d. The more obtuse the anle between the slide and the spreader, the shorter and thicker the film

Questions 191-196 : Correlate the pictutres and the statements



1
1
a
cellular hemoglobin. It is common in sickle cell anemia
b. Seen also in patient with with myelofibrosis
c. Produced in blood smear which dried slowly
d. Increase in patients with uremia and gatric carcinoma
e. May be seen in megaloblastic anemia ans postsplenectomy
f. May be seen in DIC and heart valve surgery

197. The normal range for the white cell count is
a. 1000 to 3000 /μl
b. 10,000 to 15,000/μl
c. 5,000 to 10,000 /μl
d. 4,000 to 6,000/μl

198. In performing a white cell count, which of the following solutions may be employed as a diluting fluid:
a. Gower's solution
b. Drabkin's solution
c. 2% acetic acid solution
d. 5% nitric acid solution

199. In a counting chamber with improved Neubauer ruling, the central square millimetre is subdivided into:
a. 100 small squares
b. 16 small squares
c. 400 small squares
d. 80 small squares

200. Drabkin's solution contains:
a. Calcium chloride
b. Sulfuric acid
c. Copper sulphate
d. Cyanide

201. In the cyanomethemoglobin method for determining Hb, the diluent is:
a. 1% hydrochloric acid
b. Normal saline solution
c. Amonium hydrochloride
d. Drabkin's solution

202. Hemoglobin is measured in a cyanomethemoglobin in a spectrophotometer at a wavelength of:
a. 540 millimicrons
b. 360 millimicrons
c. 450 millimicrons
d. 720 millimicrons

203. In a differential white cell count, the following cell would have the following normal range:
a. Neutrophil segment cell
b. Eosinophil segment cell
c. Baophil segment cell
d. Lymphocyte
e. Monocyte

204. Shift to left means:
a. Irreversible coagulation
b. Terminal leukemia
c. Increase in monocytes
d. Increase in immature cells

205. Which Of the following is not considered an erythrocyte inclusion?
a. Howell-Jolly bodies
b. Basophilic stippling
c. Cabot rings
d. Heinz bodies
e. Auer bodies

206. Which of the following could not be considered as a source of error in the sedimentation rate:
a. Excessive anticoagulant
b. Partially clotted blood
c. Use of cold unmixed blood
d. Air bubles in blood column
e. Use of freshly drawn blood

207. A high hematocrit reading is characteristically seen in:
a. anemia b. Leukemia
c. Infectious mononucleuosis d. Cancer
e. Polycythemia vera

208. To determine the MCH, you divide the :
a. Hct by the RBC in millions b. Hct by the Hb in grams
c. RBC by the Hct d. RBC by the Hb in grams
e. Hb in grams X 10 by the RBC in millions

209. Which of the following is a method for testing capillary contractility:
a. Lee and Wkite method b. Wintrobe method
c. Ivy method d. Quick method

210. The reticulocyte count following acuye hemorrhage is at its peak in:
a. 1 hour
b. 1 to 3 days c. 10-12 hours
d. 5 to 7 days e. 12 to 14 days

211. Which of the following terms is defined as average values?
a. Mean b. Mode
c. Median

212. The closeness of a test value to the actual value is termed:
a. Accuracy b. Precision
c. Reproducibility d. Standard deviation

ANSWERS

1. C	43. A	85. B	127. E	170. B
2. D	44. C	86. B	128. B	171. C
3. B	45. B	87. B	129. B	172. D
4. C	46. B	88. E	130. BD	173. D
5. C	47. D	89. B	131. B	174. A
6. A	48. B	90. D	132. C	175. D
7. A	49. A	91. D	133. B	176. B
8. B	50. D	92. C	134. D	177. D
9. C	51. D	93. D	135. A	178. B
10. D	52. D	94. B	136. C	179. C
11. D	53. C	95. B	137. C	180. A
12. A	54. D	96. C	138. D	181. C
13. D	55. D	97. D	139. E	182. C
14. C	56. A	98. B	140. D	183. B
15. A	57. B	99. B	141. A	184. B
16. B	58. E	100. A	142. A	185. D
17. E	59. C	101. E	143. B	186. D
18. F	60. C	102. B	144. A	187. D
19. G	61. C	103. E	145. B	188. C
20. D	62. A	104. E	146. B	189. A
21. D	63. B	105. A	147. A	190. B
22. B	64. C	106. C	148. B	191. B
23. D	65. C	107. D	149. A	192. C
24. B	66. D	108. A	150. A	193. D
25. B	67. B	109. A	151. C	194. A
26. C	68. D	110. B	152. B	195. E
27. ABCDE	69. B	111. B	153. E	196. F
28. C	70. D	112. B	154. E	197. C
29. ABCD	71. C	113. D	155. C	198. C
30. ACD	72. A	114. E	156. D	199. C
31. B	73. A	115. A	157. A	200. D
32. D	74. A	116. C	158. C	201. D
33. A	75. D	117. B	159. A	202. A
34. B	76. B	118. C	160. B	203. C
35. B	77. C	119. C	161. E	204. D
36. A	78. C	120. A	162. C	205. E
37. C	79. C	121. C	163. B	206. E
38. B	80. B	122. C	164. A	207. E
39. D	81. C	123. A	165. G	208. E
40. A	82. A	124. D	166. I	209. C
41. D	83. A	125. A	167. J	210. D
42. C	84. A	126. D	168. D	211. A
			169. H	212. A

BIBLIOGRAPHY

For Further reading

Atul Mehata & Victor Hoffbrand: Hematology at a glance 1st edition, 2000

Ayalew Tefferi: Primary Hematology. Human Press. 2001

Barbara A. Brown: Hematology: Principles and Procedures. Sixth edition 1993

Barnard D.L, Mcverry B.A: Clinical Hematology; 1989

Bernard M. Babior: Hematology; A pathophysiological Approach. Third edition 1994

Charles E. Seiverd: Hematology for Medical Technologist ;5th edition ,1983

Delamore J.A, Liu Yin J.A: Haematological Aspects of Systemic Disease 1990

Denise M, Harmening: Clinical Hematology and Fundamentals of Hemostasis. Third edition. 1997.

Fred J. Schiffman: Hematologic pathophysiology; 1998

Harold R. Schumacher: Acute Leukemia; Approach to diagnosis; 1990

Hoffbrand A.V & Pettit J.E: Essential Hematology; 4th edition, 2000, Blackwell Science.Oxford

Hughes-Jones N.C: Lecture Notes on Hematology. Third edition 1979

Lanzkowski; Pediatric Hematology and Oncology, 1995

Lee G.R., ForsterJ., Lukens J.N, Parakevas F& Rodgers G. (eds) 1998 , ***Wintrobe's clinical Hematology*** (10th). Lippincott.

Mary Louise Turgeon: Clinical Hematology "Theory and Procedures. Third edition, 1999

Mehat A.B :Self Assessment Color Review of Hematology, Manson Publishing, London .1995

Norma J. Walters etal: Basic Medical Laboratory Techniques 2nd edition. 1990. Delmar Publishers Inc.

Penington David, Rush B., and Castaldi P.: G.G deGruchy Clinical Hematology in Medical Practice.

Reinhold Munker, Erhard Hiller and Ronald Paquette: Modern Hematology; Biology and Clinical Management. 1st edition Human Press. 2000

Robert S. Hillmand Kenneth A. Ault: Hematology in clinical practice: A guide to diagnosis and management. Second edition, 1998

Rodak F. Bernadette: Diagnostic Hematology; 1995

Samuel Gross, Stuart Roath: Hematology; A problem-oriented approach; 1996

Simsons: Hematology: A combined theoretical and technical approach 1989.

Steine-Martin E. Anne, Lotspeich-Steininger Cheryl A., Koopke Jhon A: Clinical Hematology; principles, procedures, correlations 2nd edition. Lippincot 1998

Stephen H. Robinson and Paul R. Reich: Hematology; Pathophysiology Basis for Clinical Practice: Third edition 1993

William C. Maslow, etal: Practical Diagnosis of Hematological Diseases; 1980

William G. Hocking: Practical Hematology; 1983